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CERVICAL CANCER 
Cervical cancer is the third most common cancer and fourth leading cause of 
cancer death in women worldwide, with an estimated occurrence of 530,000 new 
cases and approximately 266 000 deaths per year (2012) [1]. Since the introduction 
of population-based screening programs in the mid ‘70s a decline in incidence of 
cervical cancers has been observed in developed countries. In developing countries 
without population-based screening programs the age-standardized incidence rate 
(ASR) per 100,000 women per year is highest, accounting for 15.7 incidences and 
8.3 of related deaths worldwide (estimations for 2012). The highest incidence rate 
was observed in Africa with an ASR of 27.6 new cases per 100,000 women per 
year, followed by America (14.9), Asia (12.7), Europe (11.4) and Oceania showed 
the lowest incidence rate with 10.2 new cases per 100,000 women per year. 
The cervix consists of the endocervix (inner part), which is covered by columnar 
epithelium and the ectocervix (outer part) consisting of squamous epithelium. The 
area between both epithelia is called squamocolumnar junction (SCJ). With aging 
from puberty onwards the columnar epithelium at the SCJ is replaced by 
metaplastic, squamous epithelium and the SCJ moves inwards to the endocervix. 
The area between new and old SCJ is called transformation zone. This metaplastic 
tissue has been considered to be most susceptible to cancer development as a 
result of a persistent infection with a high-risk human papillomavirus (HPV). 
Approximately 80% of cervical cancers are squamous cell carcinomas (SCC) and 15-
20% of cervical cancers are adenocarcinomas (AdCA) [2].  
SCC develop through a series of well-defined precursor lesions, named cervical 
intraepithelial neoplasia (CIN) (Figure 1). CIN lesions are classified according to the 
degree of atypia of the epithelium, graded from CIN1, in which up to one third of 
the epithelium is dysplastic to CIN3, showing atypia from two thirds to the full 
thickness of the epithelium. CIN1 and a subset of CIN2, mainly result from a 
productive HPV infection in which new viral particles are produced. These lesions 
are also referred to as low-grade CIN and are likely to regress often following virus 
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clearance [2]. High-grade CIN lesions consist of CIN2 and CIN3, and harbor a so-
called transforming HPV infection. High-grade CIN can develop rapidly, within 3 
years, following HPV-infections, whereas progression to cervical cancer may take 
another 10 to 30 years [3-5].  
 
Figure 1: Schematic view of cervical carcinogenesis. A Traditional concept of the development of 
squamous cell carcinoma (SCC) and B adenocarcinoma (AdCA). Infection of the transformation zone 
(TZ) by high-risk HPV (hrHPV) can result in low-grade (CIN1) and high-grade (CIN2/3) lesions. CIN2/3 
lesions can either develop from progression of a CIN1 or develop rapidly without a preceding CIN1 
lesion. Precursor lesions of AdCA are less well defined, but adenocarcinoma in situ (ACIS) represents a 
precursor lesion. Occasionally CIN2/3 and ACIS progress to SCC or AdCA, respectively. CIN1 and CIN2/3 
can regress following virus clearance. C Shows an alternative concept of cervical carcinogenesis. 
Whereas infections by hrHPV of the basal cells in the TZ mainly result in low-grade lesions (CIN), can 
infections of a discrete population of cuboidal cells (squamocolumnar junction cells (SCJ)) result in high-
grade lesions that are more likely to progress to cancer. Figure and legend adapted from promotie 
Snellenberg. 
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Why the region of the transformation zone is most susceptible for neoplasm 
development is still under debate. Previously, it was thought that persistent HPV 
infections in metaplastic squamous epithelium of the transformation zone are 
most prone to neoplastic changes. Recently, a discrete population of cuboidal cells 
(n=~40) of embryonic origin has been identified in the SCJ, referred to as SCJ cells 
[6]. Given the fact that most high-grade CIN lesions and cervical cancers express 
markers specific for these SCJ cells, it is suggested that particularly CIN lesions 
arising from HPV infections in these cells are susceptible to neoplastic progression 
and cancer development, whereas CIN lesions resulting from infection of non-SCJ 
cells are less likely to progress (Figure 1).  
HUMAN PAPILLOMAVIRUS (HPV) 
HPVs are small, non-enveloped, double-stranded DNA viruses that establish 
productive infections only within the stratified epithelium of the skin, the 
anogenital tract, or the upper aerodigestive tract (Figure 2A). A new HPV type is 
defined if there is more than 10% difference in DNA sequence compared to a 
previously classified type. An HPV type variant is defined by less than two percent 
variation from the reference viral prototype in the nucleotide sequence of coding 
regions and less than five percent in the non-coding regions [7, 8]. More than 150 
types have been identified to date [7, 9]. Based on their sequence similarity HPVs 
are grouped into genera (alpha-, beta-, gamma-, mu- and nu-papillomaviruses) 
(Figure 3). Generally, types of the same genera share the same characteristics, 
such as tissue tropism and oncogenic potential. For example, beta-
papillomaviruses usually infect the skin, and HPVs from the alpha genus tend to 
infect the mucosa. The mucosal HPV types of the alpha genus are further 
subdivided into low-risk (mainly causing genital warts) and (probable/possible) 
hrHPV based on their association with cervical cancer (Table 1). By the World 
Health Organization (WHO) twelve HPV types (i.e. HPV16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58 and 59) are classified as high-risk (category 1), and another one 
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(HPV68) as probable high-risk (category 2A). Of several other HPV types (ie. HPV 
26, 30, 34, 53, 66, 67, 69, 70, 73, 82, 85 and 97) epidemiological data has not 
confirmed their cancer-causing risk and based on their evolutionary sequence 
similarity with high-risk HPVs, they are therefore classified as possible hrHPVs 
(category2B) [10]. 
Of the hrHPV types of the alpha genus, HPV16 and 18 are thought to be the most 
oncogenic types and account for about 55% and 15% of the invasive cervical 
cancers worldwide, respectively (Table 1) [1]. Longitudinal studies have revealed 
that the risk to develop CIN3 or worse (≥CIN3) differs between hrHPV types. 
Whereas infections with the hrHPV types 16, 18, 31, 33, 35, 45, 52 and 58 
comprise the highest long-term (>5 years) ≥CIN3 risk, other hrHPV types embrace 
an almost negligible long-term risk [11-13]. Of the types with the highest long-term 
≥CIN3 risk, HPV16, 18, 31 and 33 are able to develop CIN3 relatively fast, i.e. even 
within a short period of 18 months and therefore have the highest short-term risk 
[14]. Some studies suggest that the high ≥CIN3 risk of some types is related to the 
fact that infections with these types (HPV16, 18, 31 and 33) are more likely to 
persist than infections with other hrHPV types [11, 12, 15]. Further type-specific 
differences in cancer risk, however, suggest that persistence alone is not the only 
determinant for cancer risk of the various hrHPV types, but also differential 
oncogenic properties are thought to account for differences in cancer risk.  
Next to differences in ≥CIN3 risk and viral persistence between HPV types, some 
types tend to have a preferred cell tropism. The most prominent example provides 
HPV18, which is more frequently found in AdCA (~36 %) compared to SCC (~11 %) 
and is relatively infrequent in CIN3 (~7%) [1].  
Though HPV types of the same genus generally share the same characteristics, 
there still exist differences in cancer risk [11, 14], viral persistence [15] and tissue 
tropism [16] between types belonging to the same genus. Even variants of the 
same type have been suggested to confer differences in cancer risk, suggesting 
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that there must exist fundamental differences in the sequences responsible for the 
various characteristics [17-19]. 
 
Figure 2: Schematic representation of HPV16 virus and its genomic organization. A The genome 
organization of HPV16 is typical for the high-risk alpha papillomaviruses. It comprises a long control 
region (LCR), 6 early viral genes (E1, E2, E4, E5, E6 and E7) and 2 late viral genes (L1 and L2). The LCR 
contains binding sites for cellular transcription factors (e.g. Sp1) as well as for E1 and E2 that control 
viral replication and early viral gene expression. HPV16 has two promoter elements (P97 and P670) that 
regulate the expression of spliced mRNA products. The figure and legend is adapted from 
http://www.nobelprize.org/ and Doorbar et al. [20]. B The E6 and E7 open reading frames run from 
nucleotide 83–559 and 562–858, respectively. Splicing events within the pre-mRNA lead to transcripts 
termed E6* I, II and III. Figure and legend adapted from Liu et al. [21]. 
B 
A 
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Figure 3: Phylogenetic tree of papillomaviruses. Adapted from Doorbar et al. [16].  
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Viral life cycle 
HPV is thought to infect the basal cells of the epithelium presumably at sites of 
injury (Figure 4A). Following infection, the viral life cycle and thereby the 
expression of the viral genes is tightly linked to the differentiation program of the 
infected epithelium and viral proteins are produced as the infected cell migrates 
upwards towards the epithelial surface (reviewed by [20]). This type of infection is 
referred to as productive infection.  
The viral genome contains eight open reading frames (ORFs), and can be divided 
into two functional parts; the early viral genes (E1, E2, E4-E7), and the late viral 
genes (L1-L2), the latter encoding the structural capsid proteins required for virus 
assembly. A large non-coding part referred to as the long control region (LCR) 
contains promoter and enhancer elements necessary for the replication and 
transcription of the viral DNA (Figure 2A) [16]. 
E1 and E2 are involved in the replication of the viral DNA and its maintenance as 
episomes [22]. E2 recruits E1, a helicase essential for the initiation and elongation 
of viral DNA replication, to the origin of replication in the LCR. The use of this viral 
helicase is suggested to uncouple the viral DNA replication from the host cell 
replication machinery during genome establishment and amplification [23]. E2 
facilitates the correct segregation of the replicated viral DNA by tethering the viral 
episomes to the cellular chromatin during cell division [24]. Furthermore, E2 is a 
DNA-binding protein that recognizes a palindromic motif [5’ACCGN4CGGT3’] in the 
LCR, where N4 represents a 4bp central spacer that can be any sequence. Thereby, 
E2 acts as transcription factor that regulates the viral early promoter and controls 
the expression of E6 and E7 [25].  
Expression of E6 and E7 drives infected cells into S-phase allowing replication of 
viral episomes without inducing apoptosis. Prevention of apoptosis is 
accomplished by E6-mediated degradation of p53 and induction of cell cycle 
progression results from an interaction of E7 with pocket protein family members 
pRB, p130 and p107. E6 and E7 are expressed from a bicistronic mRNA, that are 
General Introduction 
21 
subject to alternative splicing, which results in several truncated versions of E6 
named E6* (I-IV) (Figure 2B). To date, splicing within the E6/E7 region has only 
been described for hrHPVs and the function of the various splice variants is not 
completely understood [26]. Though E6* has been found to function 
independently of E6 in the transformation process [27, 28], it is still controversial 
whether splicing of E6 enhances the translation efficiency of E7 [29-33].  
E4 and E5 become upregulated in the upper differentiated layers and enhance the 
release of viral particles [34]. E4 is involved in the late stages of viral life cycle and 
E5 may function during both early and late phases.  
In the more differentiated strata, E2 represses expression of E6 and E7 and 
expression of the late viral genes L1 and L2 become activated to provide the viral 
capsid. Finally, epithelial cells are exfoliated and thousands of newborn viruses are 
shed.  
TRANSFORMING INFECTIONS 
A transforming infection, as observed in a subset of CIN2 and CIN3 lesions (i.e. 
transforming CIN lesions), results from a deregulated or shifted expression of the 
viral genes E6 and E7 from primarily differentiating cells to basal proliferating cells 
of the epithelium. This triggers uncontrolled replication of cellular DNA and 
genomic instability, which ultimately may result in malignant transformation 
(Figure 4B). To date, it is not quite understood how this molecular switch in E6/E7 
expression occurs. A possible mechanism might be the integration of the viral 
genome in the host cells genome (reviewed in [35]). Integration mostly occurs in 
the E2 region, thereby disrupting E2 mediated E6 and E7 repression [36].  
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However, not all carcinomas contain integrated viral DNA, suggesting other 
mechanisms to contribute to the deregulated expression of E6 and E7. One such 
mechanism is methylation of the viral DNA, which has been demonstrated to 
increase with severity of disease (reviewed in [35] + [37]). The LCR of hrHPV 
contains four E2 binding sites (E2BS) which can become methylated, thereby 
interfering with E2 binding, resulting in a loss of repression of E6 and E7 
transcription (Figure 2A).  
 
Figure 4: HrHPV life cycle. A Productive Infection by human papillomaviruses (HPV) is thought to occur 
via microtrauma that allows the infectious virions to access the basal layer of the epithelium. In the 
infected basal cells, the viral genome is maintained as a low copy number episome. As these cells 
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divide, they produce daughter cells that are pushed outwards towards the epithelial surface. In the 
lower layers E6 and E7 are expressed to drive cells through the cell cycle and are stimulated to divide 
(cycling cells marked with red nuclei). In the mid layers, proteins necessary for genome amplification 
become elevated in these cells, allowing genome amplification to occur. These cells express the viral E4 
protein and are typically in the S or G2 phases of the cell cycle (E4 presence marked in green, with red 
nuclei indicating replication competence). In the upper epithelial layers, the cells leave the cell cycle. In 
a subset of E4-positive cells, L2 and L1 proteins are made, allowing packaging of the amplified viral 
genomes. HPV may also be able to infect the columnar cells and infection of these cells may be 
associated with different patterns of disease progression and with the development of 
adenocarcinoma. B Only a minority of the HPV infections progress to cervical intraepithelial neoplasia 
(CIN) stage 1 to 3. During progression from CIN1 to CIN3, normal regulation of the papillomavirus life 
cycle is lost. CIN1 generally resemble productive lesions and express virus coat proteins at the epithelial 
surface. In CIN2/3 lesions, transforming infections, the order of life cycle events is unchanged, but the 
extent of E6 and E7 expression is increased. Figures and legend adapted from Doorbar et al. [20] and 
[16]. 
A third mechanism that may contribute to E2-mediated repression of the LCR is 
recruitment by E2 of transcription factors to the LCR [38]. Deregulated 
transcription factor binding and/or activity would thereby alter E2 mediated E6 
and E7 repression.  
Alternatively, infection of so-called SCJ-cells may render deregulation of the LCR 
superfluous to induce E6 and E7 overexpression (see Discussion). 
Though the long-term (over)expression of E6 and E7 in proliferating epithelial cells 
is a widely accepted necessary determinant for the development of cervical 
cancer, it does not explain HPV type specific differences in cancer risk and 
persistence. 
HPV TYPE SPECIFIC FUNCTIONS OF E6 AND E7  
E6 and E7 are known to interfere with various cellular pathways regulating cell 
proliferation (via HDAC, pRB, p107, p130 and cyclins), apoptosis (via caspase 8, 
BAX, BAK, p53, p600 and p48), replicative lifespan (via hTERT, Myc and NFX1-123) 
and genomic stability (via ATM, ATR and y-tubulin) [39, 40]. To date, an increasing 
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number of interaction partners and functions of E6 and E7 are discovered and 
besides common interaction partners, also specific interaction partners per risk-
classification or HPV type have been discerned. More detailed information on E6 
and E7 interactions and functions are given in two recent reviews by Vande Pol 
and Klingelhutz, respectively [41, 42]. In this paragraph we will focus on the virus-
host interactions that are most relevant for this thesis. Of these the association of 
E6 with the ubiquitin ligase E6AP, thereby marking p53 for proteolytic degradation, 
represents one of the most critical interactions in terms of transformation [43, 44]. 
Interestingly, E6 protein of various hrHPV types display differential p53 
degradation efficiencies, with HPV58 being most potent and HPV66 having the 
least degradation efficiency [45]. E6 can also bind directly to p53 to block its 
function as a transcriptional activator [46]. The abrogation of p53 function allows 
cells with DNA damage and genetic alterations to survive, resulting in genomic 
instability and cellular transformation [39]. 
Another function of E6 is to activate the transcription of human telomerase 
reverse transcriptase (hTERT), the catalytic subunit of the telomere lengthening 
enzyme telomerase [47-50]. Somatic cells have very little or no telomerase activity 
and telomeres shorten with normal cell division. This leads to replicative 
senescence or aging. A hallmark of cancer cells is their unlimited replicative 
capacity [51]. Recently, for several HPV types the ability to activate hTERT 
transcription has been shown and was found associated with their oncogenic risk 
[52]. E7, on the other hand, can promote telomere maintenance through the 
alternative lengthening of telomeres (ALT) pathway involving homologues 
recombination of telomere sister chromatids [53].  
The best known activity of E7 is the ability to associate with and degrade pRB and 
family members (p107 and p130) [54]. PRB and family members negatively 
regulate entry into S-phase of the cell cycle by inactivation of members of the E2F 
family of transcription factors. Degradation of pRB by E7 in HPV infected cells 
results in the release of active E2F, which promotes S-phase entry and DNA 
General Introduction 
25 
replication [55, 56]. The efficiency of pRB degradation and promotion of 
proliferation correlate with the HPV risk-classification [57]. Furthermore, E7 can 
induce transcriptional activity of histone demethylases KDM6A and KDM6B, 
resulting in epigenetic reprogramming and an upregulation of p16
ink4a
 [58, 59]. 
Another activity represents the direct association of HPV16 E7 with histone 
deacetylases (HDACs) and DNA methyltransferase 1 (DNMT1) thereby affecting 
chromatin remodeling and promoter accessibility [60]. DNA methyltransferases 
are responsible for methylation of cytosines, which in CpG-rich promoter 
sequences may lead to gene silencing and contribute to transformation. DNMT1 is 
thought to be the major methyltransferase [61], involved in maintenance of 
methylation marks during DNA replication. In addition to E7, HPV16 E6 also 
mediates DNMT1 upregulation via p53 [62].  
Both E6 and E7 of high-risk HPV types independently induce genomic instability in 
normal cells by induction of abnormal centrosome numbers and an accumulation 
of DNA damage [63, 64]. E6 initiates abnormal centrosome numbers through 
multinucleation [65, 66]. HrHPV E7, on the other hand, provokes centrosome 
amplification by inducing multiple rounds of centrosome synthesis in a single S 
phase through the formation of multiple immature centrioles [67]. Although 
abnormal mitosis and a certain degree of DNA damage in cells is usually lethal, E6 
and E7 oncoproteins act synergistically to allow cells with DNA breaks and 
abnormal centrosomes to survive, which in turn leads to genomic instability and 
neoplastic progression [64, 65]. 
IN VITRO MODELS FOR HPV-INDUCED 
TRANSFORMATION 
Cloning of HPV16 and HPV18, the two most common HPV types detected in 
cervical cancer, by Dürst et al (1983) [68] and Boshart et al. [69] have formed the 
basis for research on the molecular understanding of cervical cancer development. 
Almost three decades ago the transforming properties of hrHPV16 and 18 were 
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recognized for their capacity to induce immortalization of primary human 
keratinocytes [70-73] and in vitro studies have shown that E6 and E7 were 
sufficient to immortalize primary keratinocytes [71, 72]. Furthermore, hrHPV was 
able to immortalize epithelial cells of various origins such as prostate [74, 75], oral 
cavity [76], tonsil [77], bronchus [78], oesophagus [79], foreskin [71] and cervix 
[80]. Thereafter, it has been shown that a fully tumorigenic phenotype can be 
obtained following immortalization and anchorage independent growth [80, 81]. 
This sequential progression will be shortly outlined in the following paragraphs. 
Extended growth and immortalization 
Somatic cells, like primary human keratinocytes, have a finite lifespan ranging from 
50 to 100 population doublings until they reach a non-proliferative stage, called 
replicative senescence [82]. Senescent cells have a large and flattened 
morphology, are still viable, but are incapable to proliferate [83]. Senescence is 
caused by telomere erosion occurring through every cell division (reviewed in 
[84]). It is a result of the inability of the DNA polymerase to completely replicate 
chromosome ends. Critically shortened chromosome ends are recognized as DNA 
damage, upon which the machinery for growth arrest is activated.  
Bypass of senescence by hrHPV E6 and E7 is accomplished by inactivation of p53 
and pRB. This results in an extended, though still limited, lifespan. Through further 
cell division, chromosome ends finally reach a critical point of shortening that 
result in a state of extensive chromosomal instability and massive cell death, called 
crisis. As described above E6 and E7 also disturb chromosome duplication and 
segregation during mitosis and induce chromosomal instability (reviewed by [85]), 
driving additional genetic and epigenetic changes. Some of these (epi)genetic 
alterations may give a growth advantage and eventually (few) immortal clones 
may emerge that are characterized by activation of the telomere lengthening 
enzyme telomerase and the concomitant or delayed arrest of telomere shortening 
[86, 87]. Immortalization of primary keratinocytes by HPV16 and 18 is associated 
General Introduction 
27 
with specific chromosomal changes, including losses at chromosomes 3p, 6q, 10p, 
11p, 11q, 13q and/or 18q and gains at chromosomes 5, 7q, 8q, 9q and 20q 
(summarized in [88]). Additionally, HPV16 and 18-induced immortalization is 
associated with DNA methylation of candidate tumor suppressor genes, such as 
MAL, miR124-2, FAM19A4 and PRDM14 [89-93]. 
HPV-induced immortalization of keratinocytes has been associated with reduced 
differentiation when grown on organotypic raft cultures [80, 94-96] or 
transplanted beneath a skin muscle flap in athymic mice [97, 98].  
The immortalization capacities of HPV16 and HPV18, the most common HPV types 
in cervical cancer, have previously been extensively studied by several groups. 
However, only a limited number of studies draw some attention to other HPV 
types. Next to HPV16 and 18, immortalization of primary keratinocytes has been 
demonstrated for HPV31, 33, 53, 56, 58, 66 and 82, but not for low-risk HPV6, 11 
and 61 [99-101].  
Anchorage independent growth and tumorigenesis 
Upon further passaging, the immortalized cells may become anchorage 
independent, characterized by the ability to form colonies when grown in soft-
agarose [81]. Compared to HPV16, HPV18 is shown to induce anchorage 
independence both earlier and more efficiently [80, 81, 102]. In another study on 
HPV33-immortalized keratinocytes, only a small subset (2 of 10) of the HPV33-
immortalized cell lines was able to form colonies in soft-agar [103]. Further 
passaging of anchorage independent cells can lead to the acquisition of a 
tumorigenic phenotype characterized by tumor formation when transplanted into 
nude mice [81]. Acquisition of this transformation characteristic has almost 
exclusively been reported for HPV18 [79, 81, 102, 104-106]. Only one study 
described the capacity of HPV33-immortalized cells to form tumors in nude mice 
[107]. HPV16-immortalized keratinocytes can become tumorigenic when 
cotransfected with oncogenes [108, 109]. 
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OUTLINE OF THE THESIS 
Whereas non-cervical HPV-induced cancers, like head and neck and vulvar cancers, 
are mainly associated with HPV16, 25 (possible/probable) hrHPV types have been 
linked to cervical cancer. For most common HPV types the carcinogenic behavior 
can be assessed based on epidemiologic data on cervical cancers. Some types, 
however, have a low prevalence and are only rarely found in cervical cancers. The 
precise carcinogenicity of these types as well as the mechanisms by which these 
types induce cervical neoplasia is, therefore, difficult to examine. The main focus 
of this thesis is the analysis of the immortalization capacities of various high-risk as 
well as probable/possible high-risk HPV types and to unravel the accompanying 
host cell alterations. 
Since deregulated expression of E6 and E7 is the main risk determinant and 
responsible for malignant transformation, we first investigated the potential role 
of E2 binding site methylation during cervical carcinogenesis. In Chapter 2 we 
developed a novel DNA methylation detection method, based on methylation 
independent PCR (MIP) in combination with the Luminex® xMAP™ system, to 
determine the frequency of E2BS methylation in the LCR of HPV16-positive cervical 
tissue specimens. Methylation frequencies increased proportional to cervical 
disease and were significantly increased in SCC versus precursor lesions.  
In Chapter 3 nine high-risk and two probable/possible hrHPV E6 and E7 open 
reading frames were analyzed for their potential to immortalize primary human 
foreskin keratinocytes. Differential immortalization capacities were obtained, 
characterized by the absence versus presence of an intervening crisis period, in the 
total of 29 cell lines generated. The differences in immortalization capacities could 
be attributed to an early onset of hTERT expression and higher p53 degradation 
efficiency for the more competent types. 
The differential growth behaviors suggest that additive epigenetic or genetic 
events in host cell genes, or timing of these events may vary between the various 
HPV-immortalized cell lines. Epigenetic events associated with HPV-induced 
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cervical carcinogenesis include promoter methylation of various host cell genes. In 
Chapter 4, we investigated the cell lines described in Chapter 3 for the onset of 
DNA methylation of fourteen host genes, during the course of immortalization. 
Hereto, both pre-immortal cells and three stages of immortal cells were analyzed 
by quantitative methylation specific PCR (qMSP) for the 14 target genes. The onset 
of methylation was found to occur in early passages and both methylation levels 
and the number of genes targeted by methylation increased with passaging. 
However, for the far majority of genes, the onset and level of methylation was not 
related to the growth behavior of the cell lines in culture.  
In Chapter 5 pre-immortal and immortal passages of the above described cell lines 
were analyzed for chromosomal abnormalities by array comparative genomic 
hybridization. In all cell lines DNA copy number aberrations (CNA) increased from 
the mortal to the immortal stage. However, upon HPV-induced immortalization, 
the number of chromosomal aberrations was inversely related to the viral 
immortalization capacity. This suggests that hrHPV types with reduced 
immortalization capacity in vitro, reflected by a crisis period, require more genetic 
host cell aberrations to facilitate immortalization than types that can immortalize 
without crisis.  
Chapter 6 summarizes and discusses the results obtained in chapters 2 to 5 and 
gives a future perspective based on our observations.  
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ABSTRACT 
Cervical carcinogenesis is driven by deregulated E6/E7 expression in dividing cells. 
A potential deregulating mechanism is methylation of E2 binding sites in the viral 
long control region, thereby prohibiting HPVE2-mediated transcription regulation. 
Here the frequency of HPV16E2BS methylation in cervical lesions (SCC, n=29; CIN3, 
n=17) and scrapes (controls, n=17; CIN3, n=21) was investigated. Three E2BSs were 
amplified using methylation independent PCR followed by specific detection of 
methylated CpGs using the Luminex® xMAP™ system. The frequency of E2BS1, 
E2BS3 and E2BS4 methylation was significantly higher in SCC compared to CIN3, i.e. 
93% vs. 21% (pb0.01), 90% vs. 47% (pb0.01) and 69% vs. 5% (pb0.01), respectively 
and ranged from 6 to 15% in controls. In scrapings of women with CIN3 
methylation ranged from 24 to 33%. In conclusion, we showed that the MIP–
Luminex system is a highly sensitive method for methylation analysis. HPV16 E2BSs 
methylation appeared highly frequent in SCC, with particularly E2BS3 methylation 
occurring proportional to severity of cervical disease. 
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INTRODUCTION 
Infection with high-risk human papillomaviruses (hrHPVs) is a necessary cause of 
cervical cancer. The major hrHPV type associated with cervical cancer is HPV16, 
accounting for 50% of cervical cancers [1, 2]. Viral replication and virion production 
are coupled to the differentiation program of the infected squamous epithelium 
and relies entirely on the host cell machinery [3]. Upon differentiation viral 
transcription, including that of the viral oncogenes E6 and E7, increases and virus 
assembly occurs in the squamous epithelia undergoing terminal differentiation. 
Since differentiated cells have already lost the ability to divide, expression of E6 
and E7 in differentiated layers does not result in cellular transformation. However, 
increased expression of E6 and E7 in dividing cells can cause oncogenic 
transformation, for which interaction of E6 and E7 with the tumour suppressor 
gene products p53 and pRb, respectively, is essential [2, 4-6].  
Expression of E6 and E7 is regulated by the long control region (LCR) to which 
cellular transcription factors like Activator Protein 1 (AP1) and specificity factor 1 
(Sp1) can bind, as well as the viral protein E2 [7]. The LCR contains four E2 binding 
sites (E2BS) characterized by the specific sequence 5’-ACCN6GGT-3’ (Figure 1) [8]. 
Binding of E2 to the proximal E2BS sites hampers binding of host cell transcription 
factors to adjacent DNA sequences, such as the TFIID and Sp1 binding sites 
overlapping E2BS3 and E2BS4, and thereby represses transcription initiation [9]. 
Vice versa, displacement of E2 at either one or both E2BSs results in binding of 
TFIID to the TATA box or Sp1 to the Sp1 binding site leading to transcription 
activation [9, 10]. On the other hand binding of E2 to E2BS1 increases viral early 
gene expression [11-13], resulting from a stimulation of the function of the 
transcription factor YY1 binding the YY1-binding site upstream of E2BS1 [14], which 
at this site functions as an activator [15]. The interaction of E2 with E2BS1 is found 
to be the most stable interaction compared to binding of E2 to the other binding 
sites, with E2BS2 being the least stable [16]. When E2 concentrations are low, E2 
binds preferably to E2BS1, leading to E6/E7 expression. As the E2 concentrations 
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increase, the other E2 binding sites will also be bound by E2, resulting in E6/E7 
repression [12]. Hence, the observed change in E2 expression during cervical 
carcinogenesis, with E2 expression being high in low grade cervical intraepithelial 
neoplasias (CIN1) and decreased in high grade CIN and carcinoma in situ [17-19], 
may at least in part explain the increased E6/E7 expression in high grade lesions.  
Accordingly, it has been suggested that deregulated expression of E6/E7 in dividing 
cells, which is believed to initiate the transformation process may, amongst others, 
results from loss of E2 repression. This is substantiated by in vitro studies showing a 
growth repression of cervical cancer cells associated with reduced E6/E7 expression 
upon E2 overexpression [20, 21]. A widely established mode of E2 downregulation 
is by viral DNA integration into the host cell DNA [22]. When integrated, the HPV 
genome is often disrupted within or just upstream of the E2 open reading frame, 
thereby either affecting the continuity of that gene or uncoupling it from its 
promoter sequence [2]. However, not all cervical lesions associated with a 
transforming infection harbour integrated DNA. Recently, it has been reported that 
only 19% of HPV16 positive CIN3 lesions and 55% of HPV16 positive cervical 
carcinomas contain integrated viral DNA [23]. Moreover, previous studies often 
showed presence of an intact E2 open reading frame in cervical cancers, despite 
absence of E6 and E7 repression [24, 25].  
 
 
Figure 1: Schematic representation of the HPV16 LCR. Binding sites of transcription factors (specificity 
factor 1 (Sp1), Ying Yang 1 (YY1), Transcription Factor I (TFI), Nuclear Factor (NFI), Activator Protein 1 
(AP1), Transcription Factor IID (TFIID); boxes and circles) are shown. The LCR contains four E2BSs, with 
CpG dinucleotides located at nts 7455, 7461 (E2BS1; ACCGAATTCGGT), 7862 (E2BS2; ACCGTTTTGGGT), 
37, 43 (E2BS3; ACCGAAATCGGT), 52 and 58 (E2BS4; ACCGAAACCGGT)  
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This implies that other mechanisms are responsible for the deregulation of E6/E7 in 
at least part of the cervical precancers and cancers. One such a mechanism may 
involve DNA methylation, which is a well-known and critical regulator of 
transcription [26]. Each E2BS contains one or two CpG dinucleotides, which are 
potential targets for DNA methylation. In vitro studies have shown that methylation 
of the CpG dinucleotides in the E2BS consensus sequence inhibits binding of E2 
[27], and that when E2BSs are methylated E2-mediated transcription regulation is 
inhibited [28]. Moreover, the inhibition of E2 binding upon E2BS methylation also 
affects E1 binding to the origin of viral replication, as its affinity is drastically 
decreased in the absence of E2 [29-32]. This implies that E2BS methylation 
decreases viral replication, thereby contributing to the switch from a productive to 
a transforming infection.  
Several studies have demonstrated that the HPV genome becomes subject to DNA 
methylation during cervical carcinogenesis, though present data on site specific 
methylation are inconclusive. Whereas in some studies the LCR and E6 sequences 
of HPV16 were commonly found to be unmethylated independent of the stage of 
neoplastic progression, the L1 region was densely methylated in cancers [33-35]. 
However, in other studies, methylation of the LCR was frequently observed in 
primary cervical carcinomas, especially at the E2BSs [36, 37].  
Most studies in which the methylation status of HPV16 was examined made use of 
methylation-dependent enzyme cleavage or bisulfite sequencing [28, 34-36, 38, 
39]. However, the sensitivity of these techniques may be insufficient to detect low-
abundance methylated DNA. Microsphere-based suspension array technologies, 
such as the Luminex® xMAP™ system, offer a new platform for high-throughput 
detection of DNA methylation. The Luminex system includes polystyrene 
microspheres that are internally labeled with two distinct fluorochromes, which 
can be mixed in various proportions yielding about 100 distinguishable beads [40]. 
In the past, bead-based assays have been used predominantly for quantitative 
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measurements of multiplexed protein–ligand interactions or high-throughput 
nucleic acid detection through DNA hybridization [41, 42].  
Here we describe the development of an E2BS methylation detection method 
based on the Luminex® xMAP™ system. With this method we determined the 
frequency of HPV16 E2BS methylation in HPV16 positive CIN3 lesions, cervical 
cancers and scrapes of women with CIN3 compared to HPV16 positive normal 
cervical samples.  
 
RESULTS 
Development of a bead-based detection assay for the analysis of DNA 
methylation at the E2BS of HPV16 
To determine the methylation status of the E2BS of HPV16 we developed 
methylation-independent PCRs (MIPs) followed by a bead-based detection assay 
using the Luminex® xMAP™ system, as is outlined in Figure 2. In short, DNAs were 
first treated with sodium bisulfite, which converts unmethylated cytosines to 
uracils while leaving methylated cytosines unaffected. This was followed by a MIP 
amplification with a pair of primers of which one was biotinylated at its 5’-
terminus. The amplified products were denatured and hybridized to probes 
coupled to microspheres, which are either completely complementary to the 
methylated CpGs (M-probes) or unmethylated CpGs (U-probes). Next, streptavidin-
phycoerythrin (SAPE) conjugates were added to bind the hybridized PCR products 
via streptavidin-biotin binding. Finally, the methylation status was determined 
based on the fluorescence signal of phycoerythrin (PE) coupled to each 
microsphere-specific dye.  
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Figure 2: Principle of detecting methylation with the Luminex® xMAP™ system. Genomic DNA is treated 
with sodium bisulfite converting unmethylated cytosines into uracils, while leaving methylated cytosines 
unaffected. Using MIP, PCR products are generated reflecting the same degree of methylation as 
present in the template ( : methylated CpG; : unmethylated CpG). One of the primers is biotinylated   
( ) at the 5’-terminus. Microspheres are coupled to probes specific for fully unmethylated (U-probe) or 
fully methylated (M-probe) E2BS. Multiplexed hybridization reactions are performed, followed by 
incubation with SAPE to capture labeled PCR products via streptavidin-biotin binding. The methylation 
status is determined based on the fluorescence signal of PE (PCR-product) coupled to each microsphere-
specific dye (probe). 
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For amplification of the E2BS two primer sets were designed, one for E2BS1, and 
one for E2BS3 and E2BS4 together (see Table 2). Since pilot experiments revealed 
that the Luminex® xMAP™ system needs at least two nucleotide differences to  
reliably discriminate between the methylated and unmethylated status (data not 
shown) and E2BS2 contains only one CpG (ACCGTTTTGGGT), E2BS2 was excluded 
from analysis. The two MIPs (E2BS1 and E2BS3-4) were validated on DNAs isolated 
from HPV-negative primary foreskin keratinocytes (EKs) and the HPV16 positive 
cervical cancer cell lines CaSki and SiHa. MIP products were formed for CaSki and 
SiHa, while no product was seen using EKs (Figure 3A). Upon sequencing analysis all 
three binding sites were found to be methylated in CaSki cells, while no 
methylation was detected in SiHa cells (Figure 3B). The difference in methylation 
between these two cell lines most likely relates to the number of copies present, 
since CaSki cells contain approximately 400-600 of HPV16, while SiHa cells only 
contain 1-2 copies [34, 43, 44]. Van Tine et al. [45] reported that only one or a few 
of the HPV16 copies in CaSki cells showed active transcription, whereas the 
remaining copies are silenced by methylation. Due to the extreme 
overrepresentation of methylated HPV16 DNA in CaSki cells, the few copies of 
unmethylated viral DNA remained undetectable upon bisulfite sequencing analysis.  
To accurately determine the analytical sensitivity of the MIP-Luminex detection 
system we used cloned MIP products of CaSki and SiHa, the sequences of which 
were confirmed by sequencing analysis, as positive and negative controls, 
respectively, for the detection of E2BS methylation in further experiments.  
Using these cloned MIP products all probes, i.e. a M-probe and an U-probe for 
E2BS1, E2BS3, and E2BS4, were found to be highly specific and to accurately 
discriminate between methylated and unmethylated DNA (Table 1). High median 
fluorescence intensities (MFI) were observed with all three methylation positive M-
probes using CaSki derived MIP products, whereas MFIs for the unmethylated U-
probe were negligible. The opposite was seen for SiHa-derived MIP products. 
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To determine the limit of detection (LOD) of the MIP-Luminex system, CaSki 
miniprep DNA was spiked with SiHa miniprep DNA in order to obtain a dilution 
series of 2.5 x 10
6
 copies (100%) to 0 copies (0%) of methylated E2BSs in 
unmethylated background DNA and analyzed in triplicate. The LODs were defined 
as a MFI above the mean background MFI (0%) plus three times the standard 
deviation. For E2BS1 and E2BS3 the LOD was 0.5% (1.25 x 10
4
 copies), and for 
E2BS4 this was 1% (2.50 x 10
4
 copies) (Figure 4). Bisulfite sequencing analysis of the 
same dilution series revealed a LOD for detecting methylated DNA of 10% (data not 
shown), which is in line with previous reports [46]. This indicates that the MIP-
Luminex system has at least a 10 times higher sensitivity for the detection of 
methylated DNA compared to bisulfite sequencing. 
 
 
Figure 3: Methylation status of E2BS in SiHa and CaSki. A PCR products for E2BS1 and E2BS3-4 were 
formed in CaSki and SiHa. HPV negative primary keratinocytes (EK) show no E2BS1 and BS34 PCR 
product. The ACTB gene was included as a control for bisulfite treatment. B Bisulfite sequencing 
revealed methylation in CaSki, but no methylation in SiHa at all CpGs of all three E2BS; CpG/TpG’s of 
each E2BS are circled in red. 
 
A 
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Table 1: Summary of the obtained MFI values from the minipreps. 
Sample SQ E2BS1U E2BS1M E2BS3U E2BS3M E2BS4U E2BS4M 
             MIP-Luminex results 
CaSki M 18 2018 45 5699 25 3656 
SiHa U 1617 7 3669 21 3026 19 
Blank - 9 6 6.5 5 9 10 
 
Methylation of BS1, BS3 and BS4 in cervical tissue specimens and scrapings 
Using the MIP-Luminex system, methylation of the E2BSs was examined in 19 CIN3 
lesions and 29 cervical SCCs containing HPV16. Seventeen scrapings of HPV16 
positive women with normal cytology without evidence of cervical (pre)malignant 
disease up to the next screening round after 5 years served as disease negative 
controls, as HPV16 positive normal cervical biopsies were insufficiently available. 
For E2BS1, methylation positivity rates of 21% in CIN3 and 93% in SCC were found. 
For E2BS3 methylation rates were 47% in CIN3 and 90% in SCC and for E2BS4, these 
percentages were 5% and 69%, respectively. The E2BS methylation frequencies for 
E2BS1, E2BS3 and E2BS4 in scrapings with normal cytology were 12%, 6% and 18%, 
respectively (Figure 5A). The methylation frequencies for E2BS1, E2BS3 and E2BS4 
were significantly higher in cervical SCC specimens, both when compared to 
controls (p<0.01) and CIN3 (p<0.01). Only for E2BS3 the methylation frequency was 
found to be significantly higher in CIN3 compared to controls (p<0.01). When 
combining the methylation results of the three binding sites, all (100%) SCC showed 
methylation of at least one E2BS, compared to 58% of CIN3 lesions (p<0.01) and 
24% of controls (p<0.01). Additionally, the methylation levels of E2BS1, E2BS3 and 
E2BS4 were significantly higher in SCC compared to CIN3 and normal scrapings 
(p<0.01) (Figure 5C-E). Only for E2BS3 the methylation levels were significantly 
higher in CIN3 compared to normal scrapings (p<0.01).  
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Figure 4: Limit of detection of the MIP-Luminex system. Results of methylated E2BS1, E2BS3 and E2BS4 
using serially diluted CaSki miniprep DNA in a background of SiHa minprep DNA. For E2BS1 and E2BS3 as 
low as 0.5% methylated DNA and for E2BS4 as low as 1% methylated DNA can be detected. 
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Figure 5: Summary of E2BS MIP-Luminex results in cervical tissue specimens and scrapings. DNA 
methylation is depicted in black; white boxes indicate unmethylated DNA. A The upper section 
represents cytomorphologically normal scrapings of HPV16 positive women without CIN lesions during 
5-year follow-up. The two lower sections represent cervical tissue specimens of HPV16 positive women 
with CIN3 or SCC. B This section represents scrapings classified as moderate dyskaryosis or worse of 
HPV16 positive women who developed CIN3 within 18 months of follow-up. C-E Association between 
E2BS methylation, disease stage, and histotype. Scatter plots of the levels of E2BS1 (C), E2BS3 (D), and 
E2BS4 (E) methylation. On the y-axes levels of methylated E2BS are presented; on the x-axes the 
samples are grouped for each disease stage and histotype. The grey dotted line indicates the cut off 
value.  
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Next we determined whether E2BS methylation could also be detected in cervical 
scrapings of women with underlying CIN3. For this purpose, 21 cervical scrapings of 
HPV16 positive women with CIN3 were tested for E2BS methylation (Figure 5B). 
MIP-Luminex analysis for E2BS1, E2BS3 and E2BS4 methylation showed 
methylation positivity of 33%, 29% and 24%, respectively. When combining the 
results, 48% of scrapings were found to be methylation positive for at least one 
E2BS, which is comparable to any methylation as detected in CIN3 biopsies, i.e. 
58%. This finding also implies that the use of normal cytology samples as controls 
for both tissue specimens and scrapings is unlikely to have a major impact on the 
results obtained. For E2BS3 and E2BS4 significant differences in methylation levels 
between normal and CIN3 scrapings were found (p<0.05), which was not seen for 
E2BS1 (Figure 5C-E).  
 
Confirmation of MIP-Luminex results of the E2BS by bisulfite sequencing 
To confirm the results acquired with the MIP-Luminex, five CIN3 and six SCC tissue 
specimens were selected for further bisulfite sequencing analysis (Figure 6). The 
results of bisulfite sequencing of the cervical tissue specimens were identical to 
MIP-Luminex results for E2BS1 and E2BS4. In all except two of the CIN3 specimens, 
E2BS3 methylation revealed identical results by MIP-Luminex analysis and bisulfite 
sequencing. The two exceptions were methylation positive by MIP-Luminex 
analysis but negative by bisulfite sequencing, most likely reflecting the differences 
in LOD between the two techniques. The MIP-Luminex positive, but sequencing 
negative CIN3 specimens had M values of 38 and 78 MFI (methylation fraction 
(MF): 2% and 7%), whereas the SCC, which were positive using both techniques, 
varied from 1111 to 4601 MFI (MF: 48 – 76%). This indicates that these CIN3 tissue 
specimens could easily be missed using bisulfite sequencing. 
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Figure 6: For comparison, the MIP-Luminex (LU) and bisulfite sequencing (SQ) results are presented for 
E2BS methylation in CaSki, SiHa, CIN3 and SCC specimens. Black boxes indicate the sample was 
methylated and white boxes indicate the sample was unmethylated.  
 
DISCUSSION 
Analysis of DNA methylation at three E2BS of HPV16 using the newly developed 
MIP-Luminex system in cervical tissue biopsies revealed an increase in methylation 
at E2BS1 and E2BS3 with severity of cervical disease, i.e. 21% and 47% in CIN3 
lesions and 93% and 90% in SCC, respectively. The methylation frequency of E2BS3 
was significantly lower in normal cytology controls, in which 6% of samples tested 
positive. Methylation at E2BS4 was low in both normal cytology controls and CIN3 
(5-18%), but increased in SCC (69%). When scoring for methylation at any E2BS, 
100% of SCCs and 58% of CIN3 lesions were found to be positive, compared to 18% 
of controls.  
The methylation frequencies detected in this study are higher compared to those 
reported in previous studies using bisulfite sequencing or pyrosequencing [33, 34]. 
These observations as well as the discrepancies between published data on HPV 
DNA methylation may at least in part be related to differences in techniques used. 
As suggested by Sun et. al. [33], methylated molecules might be overrepresented 
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when using bisulfite treatment followed by cloning and sequencing. In this case the 
actual methylation pattern might not be correctly reflected, since only a limited 
number of clones are sequenced. In other studies methylation-sensitive enzyme 
restriction cleavage was used [35, 36], which is prone to false positives, due to 
incomplete digestion or false negatives, due to low abundance DNA methylation 
[47]. With the use of MIP, as applied in the current study, the PCR products 
analyzed reflect the same degree of methylation as present in the template. 
Moreover, the specific detection of methylated and unmethylated CpGs by the 
Luminex® xMAP™ system appeared to be highly specific and sensitive, with a limit 
of detection of 0,5-1% for E2BS1/E2BS3 and E2BS4, respectively (Figure 4).  
Present findings, showing methylation of all three investigated HPV16 E2BS in CaSki 
cells and complete absence of methylation in SiHa cells, is in concordance with 
previous reports [33, 34, 48-50], and most likely relates to the difference in viral 
copy numbers between the two cell lines. Methylation of the 400-600 copies in 
CaSki cells ensures tight expression regulation of E6 and E7 [34, 45, 50]. In these 
cells it was shown that active viral RNA transcription occurs only at a single-copy or 
low copy-number site on a derivative of chromosome 14, whereas all other loci 
were inactive. Transcription from the silent (i.e. methylated) viral DNA copies was 
activated upon growth in the presence of a DNA methylation inhibitor in a subset 
of cells [45], suggestive of additional mechanisms regulating gene silencing. In 
contrast in SiHa cells, containing only 1-2 copies of HPV16 per cell, viral DNA is 
found to be integrated within the host cell DNA by interruption of its E2 gene [51]. 
Hence interference with E2 binding by E2BS methylation is redundant in SiHa cells. 
From this it may be inferred that also in cervical high grade lesions and carcinomas 
which often harbour multiple viral copies [52-54], viral transcripts are originating 
from a single or a few copies only and the remaining copies being silenced by 
methylation.  
In the clinical specimens tested in this study, E2BS1 and E2BS3 revealed the highest 
methylation rate compared to E2BS4. A recent study by Vinokurova et al. [55] has 
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demonstrated that methylation of E2BS1 results in an increased activity of the p97 
promoter in the presence of E2, which intriguingly was associated with binding of a 
yet uncharacterized protein complex. In close proximity to E2BS3, the second most 
frequently methylated E2BS in SCC, resides a Sp1 binding site and the TATA box 
(Figure 1). Whereas in the absence of methylation E2 compete with the 
transcription factors Sp1 and TFIID for binding to the promoter [9, 10], inhibition of 
E2 binding by E2BS methylation [27] induces TFIID and Sp1-mediated transcription 
activation. Earlier studies have shown that methylation of CpG dinucleotides has 
little or no effect on the binding of the transcription factors Sp1 (near E2BS3) and 
YY1 (near E2BS1) [56, 57]. However, we cannot rule out the possibility that binding 
of these transcription sites might be blocked indirectly, either by conformational 
changes or by interacting with methyl-CpG-binding proteins [58, 59]. Taken, 
together, current data indicate that methylation of E2BS1 as well as E2BS3 and 
E2BS4 results in an increased expression of E6/E7. 
In this study, the methylation status of E2BS2 was not examined, due to technical 
limitations. Previous work done by Kim et al. [28] reported the highest methylation 
rate of E2BS2 compared to the other three E2BSs in an cervical epithelial cell line 
that was isolated from an HPV16-infected patient. In contrast, in a study on clinical 
specimens the CpG residue in E2BS2 appeared unmethylated in nearly all CIN and 
cervical cancer specimens [60]. Although we were unable to study methylation at 
E2BS2 using the presently used system, this might be accomplished by the 
incorporation of a locked nucleic acid (LNA) at the CpG site in the probe sequence. 
Incorporation of LNAs in oligonucleotides has been shown to improve nucleotide 
discrimination [61].  
Previous studies have proposed that testing for HPV DNA methylation may serve as 
a disease marker for progressive cervical disease [33, 35, 38, 39]. Present findings 
indicate that also the specific detection of E2BS methylation may be of diagnostic 
value. Although all SCC showed E2BS methylation at any E2BS, only a subset of 
CIN3 lesions was methylation positive. Hence, E2BS methylation analysis may serve 
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as a complementary marker to host methylation markers, such CADM1 and MAL 
[62-64], to improve the early detection of high grade cervical disease. In this 
respect, E2BS3 methylation seems to be the most promising marker, since only 6% 
of the normal samples were methylated compared to 47% of CIN3 biopsies. 
In this study we showed that the MIP-Luminex system is a highly sensitive and 
reliable method for the detection of HPV16 E2BS methylation. Hence, this system 
may in the future be extended further by inclusion of other CpG sites within the 
HPV-methylome, such as methylation within the L1 regions which appears highly 
predictive for high-grade disease [33]. 
In conclusion, we showed that the MIP-Luminex system is a highly sensitive and 
reliable method for the detection of methylation of E2BS. Methylation of HPV16 
E2BS appeared highly frequent in SCCs, indicating that it is a rather late event in 
cervical carcinogenesis. Particularly methylation of E2BS3 which is most frequent in 
CIN3 lesions and occurs proportional to severity of cervical disease may have 
diagnostic potential. 
 
MATERIALS AND METHODS 
Cell cultures 
Primary human foreskin keratinocytes (EKs) and the cervical cancer cell lines CaSki 
and SiHa were cultured as described previously [65].  
 
Cervical samples 
This study followed the ethical guidelines of the Institutional Review Board of the 
VU University Medical Center. Formalin-fixed, paraffin-embedded (FFPE) samples 
were collected from patients with CIN3 (n=19) and cervical SCC (n=29), which were 
HPV 16 positive as determined by the method described below. The mean age of all 
women included in this study was 43 years (range 26-74). Per histological group the 
women had the following mean ages: 37 years (range 26-74) in the CIN3 group and 
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42 years (range 30-74) in the SCC group. All specimens were collected during the 
course of routine clinical practice of women who underwent biopsy or surgery and 
were stored within the tissue bank of the Department of Pathology at the VU 
University Medical Center. A series of seven consecutive tissue sections were cut 
from each specimen. The first and last sections (4 µm) were stained with 
hematoxylin and eosin for histological diagnosis by an expert pathologist. Five in 
between sections (10 µm) were used
 
for DNA isolation and methylation analysis. 
Cervical scrapings were obtained from the population-based cervical screening trial 
POBASCAM [66]. We included 17 cervical scrapings of HPV16 positive women with 
normal cytology without evidence of CIN disease up to the next screening round 
(after 5 years) and 21 abnormal scrapings of HPV16 positive women with CIN3. The 
median age of HPV16 positive women with normal cytology was 34 years (range 
18-46), and that of the women with abnormal cytology was 35 years (range 24-56). 
 
DNA extraction, HPV typing and bisulfite modification  
FFPE tissue sections, cervical scrapings and cell cultures were incubated in 
proteinase K solution (0.1 mg/ml) for 48 hours at 56°C at 600 rpm. DNA was 
isolated using the High Pure PCR Template Preparation kit (Roche Diagnostics, 
Almere, The Netherlands) according
 
to the manufacturer's recommendations. 
Genomic DNA from cell cultures was isolated with UltraPure™ 
Phenol:Chloroform:Isoamyl Alcohol (Invitrogen, Breda, The Netherlands). 
HPV detection and genotyping was performed using the GP5+/6+-PCR with an 
enzyme immunoassay (EIA) readout followed by reverse-line-blot analysis of EIA 
positive cases [67].  
For E2BS analyses DNAs were subjected to bisulfite treatment with the EZ DNA 
Methylation Kit™ (Zymo Research, Orange, CA, USA) according
 
to the 
manufacturer's recommendations.  
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Methylation-Independent-Specific PCR (MIP) 
Primers used for MIP of E2BS1 and E2BS3-4 are listed in Table 2. In the PCR 
reaction, 50 ng of bisulfite treated genomic DNA was amplified with FastStart Taq 
PCR buffer (Roche Diagnostics) supplemented with 2 mM MgCl2, 500 nM of each 
primer, each dNTP at 200 μM, and 0.75 U of FastStart Taq DNA polymerase in a 
total volume of 30 l. Amplification reaction was carried out in a GeneAmp® PCR 
system 9800 (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) using 
the following conditions: 96°C for 5 min, followed by 45 cycles of 95°C for 30s, 45°C 
or 50°C, for BS1 or BS3-4, respectively, for 30s and 72°C for 45s, with a final 
extension of 72°C for 4min. MIP products were analyzed by electrophoresis on 2% 
agarose gels. 
 
Cloning of PCR products 
MIP-products of SiHa and CaSki were cloned into pCR®-Blunt II-TOPO vector. 
(Invitrogen, Breda, The Netherlands). Multiple colonies of each construct were 
grown in selection medium at 37°C overnight and plasmids were isolated with 
GeneJET
TM
 Plasmid Miniprep Kit (Fermentas, St. Leon-Rot, Germany) according to 
the manufacturer’s recommendations. The insert of each miniprep was verified by 
sequencing analysis.  
 
Bisulfite sequencing 
To remove unincorporated primers and dNTPs, 2 ul ExoSAP-IT reagent (1:1; USB, 
High Wycombe, United Kingdom) was added to each MIP product. The mixture was 
incubated at 37°C for 15 min, followed by 15 min at 80°C to inactivate the enzymes. 
Samples were sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit on 
an ABI Prism 3130-Avant Genetic Analyzer (Applied Biosystems) according to 
manufacturer’s recommendations. After 30 cycles of amplification, excess dye 
terminator was removed with the BigDye XTerminator® Purification Kit (Applied 
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Biosystems). Sequences were analyzed using Chromas Lite 
(http://www.technelysium.com.au/chromas_lite.html). 
 
Table 2: Primer and probe sequences. For luminex the reverse primers were tagged 
with biotin at their 5'-end. 
MIP/Luminex 
Target Sense (5’-3’) Antisense (5’-3’) bp Bead 
nr. 
E2BS1* GTTAGCGGTTATTTTGTAGT 
& 
GTTAGTGGTTATTTTGTAGT 
CCATAATTACTAACATAAAAC 94  
E2BS3-4 ATAATTTATGTATAAAATTAAGGG TACAACTCTATACATAACTAT 156  
ACTB TGGTGATGGAGGAGGTTTAGTAAGT AACCAATAAAACCTACTCCTCCCTTAA 133  
Probes 
BS1 M TAATCGAATTCGGTTGTATGT   45 
BS1 U TAATTGAATTTGGTTGTATGTTT   44 
BS3 M CGTAATCGAAATCGGTTGAA   24 
BS3 U GGTGTAATTGAAATTGGTTGA   23 
BS4 M GAATCGAAATCGGTTAGTATA   89 
BS4 U TTGAATTGAAATTGGTTAGTATA   49 
*) The forward primer for the BS1 region contains a CpG dinucleotide, therefore two primers were 
designed for this region, one containing a CG in its sequence, while the other contains a TG  
 
Labeling of microspheres with probes 
Two probes were designed for each E2BS for Luminex detection (Table 2). 
Carboxylated microspheres (2.5·10
6
; Biorad, Veenendaal, The Netherlands) were 
pelleted in a microcentrifuge for two minutes at 13,000 rpm and supernatant was 
carefully removed. The microspheres were dissolved in 25 μl MES buffer (0.1 M, pH 
4.5; Sigma-Aldrich, Zwijndrecht, The Netherlands), 4 µl of amino-substituted 
capture probe (100 μM) and 2 μl of a freshly made solution of 100 mg/ml 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC) (Pierce Thermo 
Scientific, Rockford, IL, USA). The mixture of microspheres, capture probes and 
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EDAC was vortexed briefly and incubated at room temperature for 30 minutes at 
300 rpm in the dark. After 15 minutes the reaction was mixed by brief vortexing. A 
second incubation step was done adding 2 µl EDAC (100 mg/ml). After the coupling 
reaction, 500 μl of 0.02% Tween 20 (Sigma-Aldrich) was added to the microspheres, 
followed by centrifugation for 2 minutes at 13,000 rpm. The supernatant was 
carefully removed and the coupled microspheres were washed in 500 μl of 0.1% 
SDS (Sigma-Aldrich) by vortex and centrifuged for 2 minutes at 13,000 rpm. Finally, 
the supernatant was removed and the capture-probe conjugated microspheres 
were resuspended in 100 μl of TE-buffer (10 mM TrisHCl, 1 mM EDTA, pH8) and 
stored at 4°C in dark. 
 
Hybridization protocol 
To 10 µl of biotinylated DNA target (MIP product), 0.33 µl of conjugated 
microspheres, 33 µl hybridization buffer (0.15 M TMAC, 75 mM TrisHCl, 6 mM 
EDTA, 1.5 g/l Sarkosyl, pH8) and 7 µl TE-buffer were added. Hybridization reactions 
were carried out with an initial step of 95°C for 3 minutes, followed by 30 minutes 
at 45°C with shaking speed of 500 rpm. Each sample was transferred into 
filterplates (multiscreen HTS; Millipore, Bedford, MA, USA) containing 200 µl 
blocking buffer (0.02% Tween 20). Vacuum filtration was performed for sample 
collection, followed by an additional washing step with blocking buffer. To each 
sample 75 µl SAPE (Moss, 1:600) was added and incubated for 15 minutes at 45°C 
with a shaking speed of 500 rpm. Samples were washed three times with blocking 
buffer and resuspended in 100 µl of blocking buffer. For each experiment, 100 
events of each subset of microspheres were analyzed on the Luminex® xMAP™ 
system (xMAP technology, Austin, TX) to obtain a median fluorescence intensity 
value (MFI) that was representative of the whole population of each set of beads. 
The M fluorescence signal intensity from hybridization with the M-probe and the U 
signal intensity from hybridization with the U-probe were used to calculate the 
methylation fraction (MF) with the following formula: 
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%100(%) 


UM
M
MF  
The 99% confidence interval of the 17 scrapings with normal cytology was used as 
cut-off value to calculate the percentage of methylation-positive samples.  
 
Statistical analysis  
Statistical analysis was performed using SPSS (version 14.0). Associations between 
methylation frequencies and levels versus histotypes were analyzed using a 
2
-test 
and Mann-Whitney U-test, respectively. A two-sided p-value of <0.05 was 
considered statistically significant.  
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ABSTRACT 
Epidemiological studies identified 12 high-risk HPV (hrHPV) types and 8 
probably/possibly hrHPV types which display different cancer risks. Functional 
studies on transforming properties of hrHPV are mainly limited to HPV16 and -18, 
which induce immortalization of human foreskin keratinocytes (HFKs) by successive 
bypass of two proliferative lifespan barriers, senescence and crisis. Here, we 
systematically compared the in vitro immortalization capacities as well as 
influences on p53, pRb, hTERT, growth behavior, and differentiation capacity of 
nine hrHPV types (HPV16, 18, 31, 33, 35, 45, 51, 52, 59), and two probably hrHPV 
types (HPV66 and 70). By retroviral transduction the respective E6/E7 coding 
sequences were expressed in HFKs of two to three independent donors. Reduced 
p53 levels and low-level hTERT expression in early-passage cells, as seen in HPV16-, 
31-, 33-, 35-, and to a lesser extent HPV18-transduced HFKs, was associated with 
continuous growth and an increased immortalization capacity. Less frequent 
immortalization by HPV45 and -51 and immortalization by HPV66 and 70 was 
preceded by an intervening period of strongly reduced growth (crisis) without prior 
increase in hTERT expression. Immortalization by HPV59 was also preceded by a 
period crisis, despite the onset of low hTERT expression at early passage. HPV52 
triggered an extended lifespan, but failed to induce immortality. Variations in p53 
and pRb levels were not correlated to differences in alternative E6/E7 mRNA 
splicing in all hrHPV-transduced HFKs. On collagen rafts, transductants showed 
disturbed differentiation reminiscent of precancerous lesions. In conclusion, the in 
vitro oncogenic capacity differs between the established hrHPV types and both 
some established and probably hrHPV types display weak or moderate 
immortalization potential. 
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INTRODUCTION  
Cervical cancer, the third most common cancer among women worldwide, is 
caused by a persistent infection with certain types of human papillomavirus (HPV) 
[1, 2]. Most HPV infections are transient and are cleared within 1 to 2 years. 
However, a fraction of infections eventually give rise to either squamous cell 
carcinoma (SCC) or adenocarcinoma (AdCA) of the cervix. SCCs develop from so 
called cervical intraepithelial neoplasia (CIN) precursor lesions. Low-grade CIN 
lesions (CIN1) mostly reflect a productive infection in which viral replication and 
virion production are linked to the differentiation program of the epithelium. High-
grade CIN lesions (CIN2/3) mainly represent transforming infections and are 
characterized by a deregulated expression of the early viral genes E6 and E7 in the 
proliferating basal cells of the epithelium [3, 4].  
HPV types belonging to the alpha (α) genus can infect the cervical mucosa [5], and 
are classified into low-risk (lrHPV) and high-risk (hrHPV) HPV based on their 
association with malignancy [6]. Infections with lrHPV types, e.g. HPV type 6 (HPV6) 
and HPV11, are associated with benign warts or low-grade lesions, whereas 
infections with hrHPV can give rise to high-grade CIN lesions and carcinoma. 
According to epidemiological and biological criteria, 12 HPV types have now been 
consistently classified as high-risk (i.e. HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 
and -59 (International Agency for Research on Cancer {IARC} group 1)). Another 8 
types have been classified as probably or possibly high-risk (i.e. HPV26, 53, 66, 67, 
68, 70, 73 and 82: IARC group 2A/B) [7]. Due to the rare detection of these latter 
types in cervical cancers there is very limited to no evidence of their 
carcinogenicity. 
Longitudinal studies have revealed that even established hrHPV types confer 
different risks of CIN3. Infections with the hrHPV types 16, 18, 31, 33, 35, 45, 52 
and 58 comprise the highest long-term (>5 years) risk of CIN3 or higher lesions, 
whereas most of the other hrHPV types present an almost negligible long-term risk 
[8-10]. Furthermore, a large, randomized, controlled prospective trial conducted in 
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the Netherlands has revealed that amongst hrHPV-positive women with normal 
cytology or borderline to moderate dyskaryosis, those infected with hrHPV types 
16, 18, 31, and 33 have an increased 18-month risk of CIN3 or cancer [8]. Apart 
from type-specific differences in viral persistence [9], these and other data also 
point to the existence of differential oncogenic properties of the various high-risk 
types. 
Although some non-HPV16 and -18 types recently received some attention [11-14], 
functional studies on transforming properties of hrHPV are mainly limited to HPV16 
and HPV18. Others and we have previously demonstrated that HPV16 and HPV18 
can induce immortalization of primary human foreskin keratinocytes (HFKs) by 
successive bypass of two proliferative lifespan barriers, i.e. senescence and crisis 
(reviewed in [15]). Bypass of senescence relies primarily on the expression of the 
virus-encoded oncoproteins E6 and E7, which act synergistically by deregulating 
apoptosis and cell cycle of the infected cell, respectively. E6 inactivates the tumor 
suppressor gene p53, resulting in loss of p53-mediated apoptosis, as well as a 
number of other targets, such as BAK, Dlg, Magi-1 and hScrib [16]. The 
retinoblastoma protein (pRb) and family members (e.g. p107, p130) are inactivated 
by the viral oncogene E7 (reviewed in reference [17]). Upon bypass of senescence, 
cells enter an extended though still limited life span. Subsequent immortalization 
may depend on the HPV type and/or, in part, also upon culture conditions and may 
be infrequent and preceded by an evident second proliferative life span barrier, 
crisis, resulting from extremely eroded chromosome ends [18, 19]. In most 
instances, immortalization is characterized by activation of the telomere 
lengthening enzyme telomerase, resulting from upregulated expression of the 
telomerase catalytic subunit hTERT [20, 21].  
E6 and E7 are expressed from a bicistronic mRNA and, in the case of hrHPV, are 
subject to alternative splicing, leading to several truncated versions of E6 named 
E6*I to E6*IV) and E7 [22-24]. Whether splicing of E6 enhances the translation 
efficiency of E7 is still controversial. Whereas in some studies an increase in the 
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efficiency of E7 translation was reported [25-27] in other studies E7 is translated 
equally efficient from spliced and unspliced transcripts [28, 29]. Nevertheless, E6* 
has been found to function independently of E6 in the transformation process [30, 
31].  
To date, a limited number of comparative in vitro studies on the oncogenic capacity 
of high-risk and probably high-risk HPV types have been described, most of which 
lack a comprehensive comparison of multiple molecular and growth characteristics 
in combination with genetic background dependency.  
This study aimed to analyze the in vitro immortalization capacity of the E6/E7 genes 
of 11 (probably) hrHPV types. HFKs isolated from independent donors were 
transduced with the E6/E7 open reading frame of hrHPV16, 18, 31, 33, 35, 45, 51, 
52, 59 and the probably hrHPV types 66 and 70. Low risk HPV11 and empty vector 
were included as negative controls. We closely monitored stably transduced HFKs 
for their p53, pRb and p16
INK4A
 status; their growth behavior in culture; and 
immortalization by analyzing hTERT expression and telomerase activation and their 
differentiation potential on organotypic raft cultures.  
RESULTS 
Generation of HPV E6/E7-transduced HFKs 
To analyze the in vitro immortalization capacity of the hrHPV types 16, 18, 31, 33, 
35, 45, 51, 52 and 59, and the probably hrHPV types 66 and 70, HFKs were 
transduced with recombinant retroviruses containing the E6/E7 open reading 
frames of the respective HPV types. HPV16, 18, 31, 33, 35, 45 and 66 were cloned 
from full-length HPV-plasmids which contained the prototype, as was confirmed by 
sequencing analysis. HPV52 was also amplified from a full-length HPV plasmid and 
contained a sequence variation in E6 (K93R). This HPV52 variant has frequently 
been detected in cervical cancers in Asia [32, 33]. HPV51 and HPV59 E6/E7 were 
cloned from cervical scrapes and HPV70 was cloned from a tumor sample. 
Sequencing analysis revealed non-silent sequence variations in HPV51 E7 (S66L), 
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HPV59 E7 (L19G, L20F, H95R) and HPV70 E6 (N100D) relative to the GenBank 
prototype sequences [34, 35]. LrHPV11 and the empty vector (LZRS) were included 
as negative controls. To control for genetic-background-dependent variations, HFKs 
isolated from at least two independent individuals were transduced. Cells isolated 
from the first donor, referred to as donor I, were transduced with all constructs. 
Cells from the second donor, donor II, were transduced with all constructs, except 
for HPV33, due to technical problems. A third donor (donor III) was transduced 
with HPV16, 33, 35, 45, 51, 52, 59 and 70. 
At various passages throughout culturing presence of the correct HPV type was 
confirmed by type-specific DNA PCR analysis (data not shown). Moreover, analysis 
of viral DNA quantities in all transductants, using a qPCR for the vector backbone, 
revealed relatively minor variations between cell lines, which were generally not 
donor related and most likely reflect neomycin selection (data not shown).  
 
p53 and pRb status  
To examine whether the E6 and E7 oncogenes of the different HPV types display 
differential abilities to degrade p53 and pRb and to reactivate p16
INK4A
, we first 
verified transgene expression by RT-PCR using HPV type-specific E6 and E7 primer 
sets. Both E6 and E7 were expressed in the various transductants of all three 
donors (Figure 1A). Quantitative RT-PCR analysis for E7 verified comparable levels 
of viral oncogene expression between donors (Figure 1B). Only in case of HPV35 
was a relative low expression seen in donor I. HPV70E7 expression could not be 
examined using this method. 
Western blot results showing p53, pRb, and p16
INK4A
 expression levels at early 
passage (~passage 8, 30 to 40 population doublings [PDs]) are shown in Figure 1C. 
Although some slight variations between the different donors were evident, 
(probably) hrHPV-transduced cells showed generally decreased p53 levels to 
various degrees in comparison to untransduced and LZRS- and HPV11-transduced 
HFKs. In donor I, the lowest p53 levels were observed in HPV16, 31, 33 and 59 
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transductants, similar to donor III, in which p53 was markedly reduced in HPV16-, -
33- and -59-transduced HFKs (Figure 1C). In donor II less variation was evident, and 
all HPV16-, 18-, 31-, 33-, 45-, 51-, 59-, 66- and 70-transduced HFKs showed 
decreased p53 levels.  
pRb protein expression was also decreased to various degrees in all (probably) 
hrHPV transductants compared to controls (Figure 1C). In some cell lines, an 
inverse correlation was seen between p53 and pRb degradation. The relatively low 
E7 expression in HPV35 transductants of donor I compared to donor II and III was 
not linked to a reduced pRb degradation. The reduced pRb expression in donor I 
transduced with HPV11 and untransduced cells of donor II may reflect the onset of 
senescence in these cells.  
To further validate HPV biological activity, we investigated p16
INK4A 
protein levels. 
HrHPVE7 expression induces increased p16
INK4A
 expression, being either or both 
pRb-dependent and -independent [36, 37]. p16
INK4A
 protein levels were strongly 
increased in all (probably) hrHPV-transduced HFKs (Figure 1C). Elevated p16
INK4A
 
expression was also observed in HPV11 transductants from donor I and 
untransduced cells from donor II that had reduced pRb expression.  
 
Splicing of the HPVE6 mRNA 
Next, we aimed to determine whether variations in p53, pRb and p16
INK4A
 levels 
were related to differences in alternative splicing of the hrHPVE6/E7 transcripts in 
favor of either more full-length E6 template or full-length E7 template. RT-PCR was 
performed on DNAse-treated RNA samples using primers located upstream and 
downstream of the predicted donor-acceptor splice sites (Figure 1D). In accordance 
with previous reports [12, 23], only a single band encoding full-length E6/E7 was 
observed in HPV11-transduced HFKs. The most prominent product seen in HPV16-, 
18-, 31-, 33-, 35-, 45-, 51-, 52-, and 70-transduced HFKs represented an E6*I splice 
variant, that was confirmed by sequencing. In HPV16-, 18-, 31-, 59- and 66-
transduced HFKs, also a full-length E6/E7 transcript was observed, which was most 
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prominent in all HPV59 transductants and HPV66-transduced cells from donor I. 
Only in case of HPV16 was an E6*II splice variant seen.  
The presence of spliced E6*I transcripts in all (probably) hrHPV-transduced cell 
lines suggests that the observed variations in p53 and pRb degradation were not 
(entirely) due to alternative splicing of the E6/E7 transcripts.  
 
 
Figure 1: Functional expression of the viral oncogenes E6 and E7 in the various transductants. A E6 and 
E7 mRNA expression assessed by type-specific RT-PCR. RT-negative PCR (-), without reverse 
transcriptase, served as a negative control, and snRNP expression analysis was included as a 
housekeeping control. B Relative E7 mRNA expression determined by qRT-PCR. HPV51 donor III and 
HPV70 transductants could not be analyzed. mRNA expression was corrected for the houskeeping gene 
snRNP and is shown relative to donor I. C Steady state protein levels of p53, pRb and p16INK4A in 
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preimmortal HFKs transduced with empty vector (LZRS), HPV11, 16, 18, 31, 33, 35, 45, 51, 52, 59, 66 and 
70 as determined by Western blotting. β-Actin expression served as a loading control. C E6/E7 mRNA 
products. Full-length transcipts are indicated by arrowheads, and spliced E6 mRNAs are indicated by 
asterisks (*, E6*I; **, E6*II). SnRNP served as housekeeping control. mRNA and protein products of 
donor I are shown as representative.  
 
Cell culture growth characteristics 
To determine how the above-described characteristics correlated with 
immortalization, cells were closely monitored during culture for their potential to 
bypass the two proliferative lifespan barriers, i.e. senescence, which leads to an 
extended lifespan, and crisis, resulting in immortalization (Figure 2A, B). 
Based on their culture characteristics, distinct groups could be discerned. The first 
group comprised untransduced and LZRS- and HPV11-transduced HFKs, which did 
not overcome senescence. In more detail, untransduced HFKs of donor I, II and III 
entered senescence and eventually died after 38 population doublings (PDs), 30 
PDs and 33 PDs, respectively (Figure 2A, B). Cells transduced with empty vector 
(LZRS) senesced and died after 37, 39 and 40 PDs, respectively, and HPV11-
transduced cells died after 43 PDs and 35 PDs for donor I and II, respectively. 
Morphologically, all untransduced HFKs and HFKs transduced with LZRS and HPV11 
contained large, flattened cells, a senescence-related phenotype, upon 
approaching the last population doublings. Senescence was confirmed by staining 
for senescence-associated beta-galactosidase (SA-β-gal) (Figure 2C).  
The second group consisted of HFKs transduced with HPV16, 18, 31, 33 and 35, 
which showed no signs of senescence or crisis throughout culturing and 
proliferated continuously in all three donors. Interestingly, these HPV types 
demonstrated the highest p53 degradation efficiencies. HPV18-transduced cells, 
which showed somewhat less efficient degradation of p53, encountered a slight 
growth reduction for 61 days between 54-76 PDs in donor I and for 70 days 
between 58-69 PDs in donor II. During this period, a mixture of senescent cells and 
proliferating cells was observed.  
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HPV45-, 51-, 59-, 66- and 70-transduced cells comprised the third group. Although 
these types revealed an abnormal growth pattern, their transductants endured a 
strong and long crisis period prior to immortalization. In HPV45-transduced HFKs 
from donor I, senescent cells were seen after 101 PDs and after 189 days of crisis, 
islands of small proliferating cells emerged. In donor II and III, crisis was entered at 
97 PDs and 60 PDs, and the cells eventually died. In HPV51-transduced HFKs, 
senescent-like cells appeared after 104 PDs, 62 PDs and 70 PDs in donor I, II, III, 
respectively. Whereas cells started to proliferate after 52 days in donor I, HPV51 
transductants of donor II and III eventually died. The HPV59-transduced HFKs 
revealed senescent cells at 48 PDs and 72 PDs and escaped crisis after 64 and 202 
days in donor II and donor III, respectively. In donor I, senescence was entered at 
20 PDs, and the cells eventually died. In both HPV66-transduced donors, a strong 
crisis period was observed. The crisis period in donor I started at 53 PDs and ended 
after 130 days. Donor II transduced with HPV66 entered crisis after 87 PDs, which 
lasted 112 days. A similar growth pattern was observed in HFKs transduced with 
HPV70. Those from donors I and II ceased to proliferate after 81 PDs and 78 PDs 
and escaped crisis after 67 and 94 days, respectively. HPV70-transduced HFKs from 
donor III entered crisis at 71PDs, which lasted longer (255 days) and from which a 
single colony of immortal cells emerged. Crisis-like cells showed a senescent 
morphology, as verified by staining for senescence-associated beta-galactosidase.  
The fourth group includes all HPV52-transduced HFKs with an extended life span 
that was followed by a long crisis period and eventual cell death. HPV52-
transduced HFKs from donors I and II entered a strong crisis period after 62 PDs 
and 81 PDs, respectively. HPV52-transduced cells from donor III entered 
senescence after 32 PDs and none of the HPV52-transduced HFK bypassed crisis. 
Even upon repeated thawing and culturing of early-passage transductants, no 
outgrowth of immortal cells was seen.  
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Immortalization 
To find support for the fact that all HPV16-, 31-, 33-, 35-, 66-, 70-transduced HFKs, 
as well as one donor of HPV45 and 51 and two donors of HPV59-transduced HFKs 
that escaped from crisis, were indeed immortal, hTERT mRNA expression and 
telomerase activation were analyzed (Figure 3). qRT-PCR analysis revealed no 
hTERT expression in untransduced HFKs and HFKs transduced with LZRS and 
HPV11. In cells without intervening crisis period (HPV16-, 31-, 33-transduced cells), 
but also HPV59-transduced cells (with a crisis period), generally low levels of hTERT 
mRNA were detected at early passage (<44 PDs). These levels progressively 
increased at 62 to 137 and >150 PDs, respectively. In other transductants with an 
intervening crisis period (with exception of HPV52-transduced cells from donor I), 
i.e. HPV45, 51, 52, 66 and 70, as well as in HPV18 transductants, no hTERT 
expression was observed at early passage (<44 PDs). hTERT expression, however, 
became apparent as soon as proliferating cells escaped from crisis (depending on 
the donor, 70-100 PDs) and was increased further at >150 PDs. All immortalized cell 
cultures showing elevated hTERT mRNA expression tested positive for telomerase 
activation (Figure 3, bottom). Weak telomerase activity was seen in early-passage 
cells of HPV51 donors II and III, HPV52 donor III and HPV59 donor I, all of which did 
not become immortal. 
 
Raft-cultures of the transductants display dysplastic changes  
Since immortalization of HFKs by full-length HPV16 and HPV18 has previously been 
associated with disturbed differentiation in organotypic raft cultures [38], the 
differentiation capacity of HPV16, 18, 31, 33, 35 45, 59, 66 and 70 transductants 
was assessed at approximately equal passages (90 to 161 PDs) (Figure 4). Raft 
cultures of untransduced HFKs closely resembled normal epithelium, showing 
distinct basal/parabasal, spinous, granular, and cornified layers. 
Immunohistochemical staining for Ki-67 revealed that proliferating cells were 
restricted to the basal/ parabasal layer of the epithelium. The spinous and granular 
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layers of the un-transduced cells stained positive for the differentiation marker 
cytokeratin 10 (CK10).  
Organotypic raft-cultures of HPV16 (104 PDs), 18 (90 PDs), 31 (103 PDs), 35 (140 
PDs) and 66 (97 PDs) containing HFKs from donor I, HPV16 (132 PDs), 31 (101 PDs), 
35 (147 PDs), 59 (92 PDs), 66 (106 PDs) and 70 (103 PDs) containing HFKs from 
donor II and HPV16 (117 PDs), 33 (112 PDs) and 35 (161 PDs) containing HFKs from 
donor III revealed disturbed differentiation, and no clearly distinct epithelial layers 
were seen, which was reminiscent of severe dysplasia. Only HPV33 (108 PDs), 45 
(90 PDs) and 70 (97 PDs) transduced cells from donor I, HPV18 (105 PDs) 
transduced cells from donor II and HPV59 (93 PDs) -transduced cells of donor III 
showed abnormal differentiation resembling mild dysplasia. The dysplastic 
histology of all hrHPV-transduced cells was characterized by the presence of basal-
like cells in almost all strata of the epithelium, as indicated by the presence of Ki-67 
positive cells in upper cell layers and the absence of CK10 staining. Only the HPV70 
(97 PDs) transductant from donor I, the HPV18 (105 PDs) and 35 (147 PDs) 
transductants from donor II and the HPV35 (161 PDs) and 59 (93 PDs) 
transductants from donor III stained (weakly) positive for CK10. Unfortunately, the 
HPV70-immortalized HFKs of donor III repeatedly failed to grow on organotypic 
rafts. 
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Figure 2: Growth characteristics of HPV-transduced HFKs and controls. HFKs were derived from 
independent individuals and are depicted in red (donor I), blue (donor II) and green (donor III). A HFKs 
and HFKs transduced with empty vector (LZRS) and HPV11 entered senescence and died. HPV52-
transduced HFKs had an extended life span and died. A crisis period with reduced growth was observed 
in HPV45-, -51-, -59-, -66-, and -70-transduced cells prior to immortalization. HPV16-, -18-, -31-, -33-, 
and -35-transduced HFKs grew continuously in culture. B Maximal numbers of population doublings per 
individual transductant. The arrows pointing up indicate continuous growth. C Representative 
photographs of HPV-transduced cells and controls (donor I) stained for senescence-associated _-
galactosidase. Over 90% of primary cells and cells transduced with LZRS and HPV11 stained blue. Only 
single hrHPV E6/E7-transduced keratinocytes stained blue. The same magnification (x10) was used for 
all photomicrographs. 
 
 
 
Figure 3: Top Relative hTERT mRNA expression levels as determined by quantitative reverse 
transcriptase PCR in cells at a preimmortal stage (16 to 44 PDs), at 62 to 116 PDs (precrisis in the case of 
HPV45 and postcrisis in the cases of HPV51, -66, and -70 transductants), and at an immortal stage (157 
to 301 PDs). Shown is a representative experiment performed in duplicate on donor I. The error bars 
indicate standard deviations. Bottom Telomerase activity as determined using the TeloTAGGG 
Telomerase PCR ELISAPlus kit (Roche, Mannheim, Germany). +, telomerase positive; +/-, weakly 
telomerase positive; -, telomerase negative; NA, not applicable. 
 
Immortalization Capacities 
85 
 
Chapter 3 
86 
Figure 4: Organotypic raft cultures of untransduced and HPV16-, 18-, 31-, 33-, 35-, 45-, 66-, and 70-
transduced HFKs. A H&E (hematoxylin and eosin) staining showing raft culture morphology. B and C 
Immunohistochemical staining on sections of the same cultures as in panel A were performed for the 
proliferation marker Ki-67 (B) and the differentiation marker CK10 (C). Raft cultures were performed in 
duplicate, and one raft per HPV type from donor I is shown as representative. 
 
DISCUSSION 
In the present study, we systematically compared the viral oncogenic E6/E7 regions 
of 9 hrHPV types (HPV16, 18, 31, 33, 35, 45, 51, 52 and 59) and 2 probably hrHPV 
types (HPV66 and 70) for their effects on known E6 and E7 targets, such as p53, 
pRb, p16
INK4A
, and hTERT [17], as well as their immortalization capacities. Almost all 
(probably) hrHPV types, with exception of HPV52 (alpha 9), were able to induce 
immortalization of HFKs, albeit with different efficiencies, as is schematically 
represented in Figure 5. E6/E7 of the closely related types HPV16, 31, 33 and 35 of 
the alpha 9 genus and, to a lesser extent, HPV18 (alpha 7 genus) displayed the 
highest growth-promoting activities early during the transformation process, with 
no signs of senescence or crisis throughout culture. This was generally 
accompanied by a prominent E6 activity exemplified by relatively low p53 levels 
compared to other types and early onset of hTERT expression. HFKs transduced 
with HPV45, 59 and 70 (alpha 7), HPV51 (alpha 5), and HPV66 (alpha 6) 
encountered a long crisis period prior to immortalization. These types, with the 
exception of HPV59, showed no hTERT expression in preimmortal transductants. 
Growth characteristics were not related to the relatively small differences seen in 
transgene DNA copy numbers and expression levels. Overall, our Western blot 
results are in line with earlier reports showing p53 and pRb degradation by 
(probably) hrHPV types, but not by HPV11 [11-13, 39]. Similar to other in vitro 
studies [11, 12], the p53 degradation capacity varied among the hrHPV types. 
However, type differences are not fully consistent across the different studies, 
most likely reflecting different model systems and assays used. In a comparative 
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study by Hiller et al. [11] using in vitro-translated E6, almost equal degradation 
efficiencies of p53 were found for HPV16, 18, 33, 35, 39, 45, 51, 52, 53, 56, 58, 66, 
70 and 82. Using a more quantitative approach, HPV58 and 59 E6 proteins were 
found to be the most potent types, and HPV56 and 66 showed least p53 
degradation activity [12]. HPV16, 18, 31, 33 and 35 had slightly lower p53 
degradation capability compared to HPV45, 51, 52, 59 and 70 [12]. The 
discrepancies with present study may, at least in part, be explained by E6 being 
expressed from a bicistronic E6/E7 mRNA, which is subject to alternative splicing, 
potentially affecting E6 activity. HPV18 E6*I has been demonstrated to counteract 
full-length E6 in p53 degradation [30]. In the study by Mesplede et al. [12] using 
HPV E6-transfected cells, splicing was observed in HPV16, 18, 31, 33, 35, 51, 66 and 
70 E6, but not in HPV45, 52 and 59 E6-transfected cells. In all our (probably) hrHPV 
transduced cell lines E6*I expression was detected. Full-length E6 was most 
prominent in HPV66 from donor I and all three HPV59 transductants, which was 
associated with more p53 degradation in HPV59-, but not in HPV66-transduced 
HFKs. These data suggest that differences in alternative splicing do not fully 
account for the variations in p53/pRb degradation and immortalization capacities. 
The latter most likely depend on potential type-dependent interactions with other 
cellular targets, as well [40].  
E6-mediated activation of telomerase via hTERT promoter activation, as originally 
demonstrated for HPV16 [41-43], has recently also been demonstrated for other 
HPV types using luciferase assays and was found to be HPV type dependent. With 
respect to the types studied by us, HPV16, 33, 35, 51 and 52 E6 proteins showed 
the highest hTERT promoter activation capacities, followed by HPV18 and 31. 
HPV11, 66 and 70 E6 proteins displayed no elevated hTERT activation, and HPV45 
and 59 were not tested [44]. In our study, hTERT expression was primarily found to 
be directly upregulated, albeit at a still relatively low level, in cell lines in which no 
intervening crisis period was observed, i.e. upon HPV16, 31, 33, 35 transduction, as 
well as upon HPV59 transduction. This implies that upon stable transduction and in 
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the presence of naturally occurring splice products, the E6 proteins of HPV16, 31, 
33, 35 and 59 can induce low levels of hTERT transcription themselves, whereas the 
E6 proteins of HPV45, 51, 52, 66 and 70 may lack this ability. The major discrepancy 
between our results and the study by Van Doorslaer and Burk [44] concerns HPV51 
and 52, which may be related to E6*I expression being dominant in present study. 
The fact that in all cell lines hTERT expression levels increased upon passaging 
indicates that, besides HPV, additional events contribute to telomerase activation 
and immortalization, in line with previous observations [45-47]. Recent studies 
indicate that telomerase-independent functions of hTERT also contribute to HPV-
induced immortalization of HFKs; among others, they involve bypass of senescence 
by regulation of a gene set similar to that regulated by hrHPV E6 [48]. How the 
increasing hTERT expression levels with passaging correlate to its telomeric and 
nontelomeric functions is currently unclear.  
Whereas HPV16, 18, 31, 33, and 35 induced immortalization in all donors, 
immortalization by HPV45 was infrequent. Although this observation was surprising 
given its relatively high prevalence in cervical cancer worldwide [7], one may 
speculate that HPV45 is more effective in the induction of subsequent 
transformation events, such as anchorage independent growth and colony 
formation, as was shown for HPV18 compared to HPV16 [49]. 
Infrequent induction of immortalization by HPV51, on the other hand, is in line with 
epidemiological data showing a strong decrease in prevalence with progression of 
cervical disease [50].  
HPV52 invariably induced an extended life span but failed to induce immortality. 
The E6 K93R variant in our construct is present in 98% of the HPV52-positive 
cervical cancers in Japan [32, 33, 50] and has been significantly associated with an 
increased CIN2/3 risk, suggesting that it represents a carcinogenic variant [51]. Yet, 
the findings that p53 expression levels were unaltered and immortalization was 
unsuccessful in our hands indicate that this highly common variant is not as 
oncogenic as other hrHPV types, at least in a Caucasian genetic background.  
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HPV59, which is less prevalent in invasive cervical cancers [7], showed a better 
immortalization capacity. Despite three sequence variants in E7, the observed pRb 
degradation and p16
INK4A
 upregulation indicates E7 activity. We cannot rule out the 
possibility that these variants render HPV59 more carcinogenic, as was shown for 
the Asian-American HPV16 E6 variant AAE6 (amino acid changes Q14H/H78Y/L83V) 
compared to the prototype [52, 53].  
 
 
 
Figure 5: Schematic representation of the immortalization characteristics of untransduced and empty-
vector (LZRS)- and HPV11-, 16-, 18-, 31-, 33-, 45-, 51-, 52-, 59-, 66-, and 70-transduced HFKs. Control 
transductants (HFKs, LZRS, and HPV11) were unable to degrade p53, showed no hTERT expression, 
entered senescence (M1), and died. Immortalization of HFKs transduced with HPV16, -31, -33, and -35 
and, to a lesser extent, HPV18 was reached without an intervening crisis period (M2).Those cells 
generally showed strong p53 degradation and early onset of hTERT expression. HPV45-, 51-, 59-, 66-, 
and 70-transduced HFKs became immortal following a strong crisis period and, with the exception of 
HPV59, generally showed less efficient p53 degradation. hTERT expression was evident following escape 
from crisis. HPV52-transduced cells without obvious p53 degradation remained hTERT negative and had 
an extended life span but failed to induce immortalization. 
 
All donors transduced with hrHPV66 and HPV70 encountered a long crisis period, 
followed by the escape of single colonies of telomerase-positive cells. These 
findings are in accordance with earlier studies showing successful immortalization 
of primary keratinocytes by full-length HPV66 and HPV70 E6/E7 [11, 14]. This study 
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is, however, the first to systematically demonstrate that these probably hrHPV 
types display a reduced immortalization capacity compared to the established 
hrHPV types 16, 18, 31, 33 and 35. Unfortunately, no proper comparison to the 
various published studies can be made, given the fact that besides varying culture 
conditions, most studies lack a comparative analysis between multiple HPV types 
and/or used a single keratinocyte isolate. 
The reduced immortalization capacity of the hrHPV types 45, 51, 52 and 59 and the 
probably hrHPV types 66 and 70, may in part explain their rare detection in CIN3 
lesions [15, 18], though the overall prevalence and potentially more efficient 
clearance by the immune system can also be important determinants. Diverse 
mechanisms of interference with immune surveillance and immune escape of HPV-
induced lesions are described, such as interference with interferon response, 
downregulation of MHC class I, TAP-1 and control of Langerhans cell density [54-
56]. However, the potential existence of type-dependent mechanisms of immune 
escape and the role of tumor microenvironment are still largely unexplored. 
Furthermore, we cannot rule out the possibility that the oncogenicity of HPV45, 51, 
52 and 59 is epithelium dependent, although no such cell-type dependency was 
demonstrated for HPV11, 16, 18 and 31 [49]. 
The finding that HPV 16, 18, 31, 33 and 35 displayed the highest immortalization 
efficiency in a donor-independent manner corresponds to epidemiological studies 
in which HPV16, 18, 31, and 33 revealed the highest 18-months risk to develop into 
a CIN3 or higher lesions and an increased prevalence in cervical cancers [7, 8, 50]. 
The reduced immortalization efficiency of other types, like HPV45, 51, 52, 59, 66 
and 70, reflected by a long crisis period and donor-dependent outgrowth of 
immortal cells, underlines the value of comparative analysis in multiple donors. 
Most studies so far have made use of a single HFK donor.  
Shortly after immortalization, all hrHPV-transduced keratinocytes showed 
disturbed differentiation on organotypic raft cultures, and most were histologically 
classified as severe dysplasia, reminiscent of high-grade CIN, indicating that 
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histomorphology is type independent, whereas molecular phenotypes may be 
type-dependent [57].  
These in vitro models not only enable a systematic comparison of the 
immortalization and transformation capacities of (probably) hrHPV types, but will 
also aid our understanding the type-dependent molecular mechanisms of 
transformation.  
MATERIALS AND METHODS 
Generation of retroviral constructs 
The E6 and E7 open reading frames of HPV11, 16, 18, 31, 33, 35, 45, 51, 52, 59, 66 
and 70 were amplified using Phusion High-Fidelity DNA polymerase (Finnzymes, 
Espoo, Finland). PCR-products containing a XhoI and NotI restriction site and a 
Kozak sequence were first cloned into pCR-Blunt II-TOPO vector (Invitrogen/Life 
Technologies, Carlsbad, USA). The E6/E7 fragments were subsequently inserted 
into the XhoI and NotI restriction sites of the retroviral vector LZRS-MS-IRES-
NEO/pBR (LZRS) (kindly provided by Dr. J. Collard, NKI, Amsterdam). All 
intermediate HPVE6/E7 pCR-Blunt II-Topo and LZRS constructs generated were 
confirmed by DNA sequence analysis and compared to the GenBank database 
(http://www.ncbi.nlm.nih.gov/Genbank/index.html). Sequencing analysis of the 
E6/E7 genes revealed no mutations for HPV11 (Accession FR872717), HPV16 
(Accession K02718), HPV18 (Accession F202155), HPV31 (Accession J04353), HPV33 
(Accession M12732), HPV35 (Accession M74117), HPV45 (Accession X74479). In 
HPV51E7 (Accession M62877) one mutation (S66L) and two silent mutations (T79T 
and L91L) were observed. HPV52 (Accession X74481) contains one silent (L83L) and 
one mutation in the E6 (K93R) and two silent mutations in the E7 (L67L and Q83Q) 
and HPV59 (Accession X77858) has two silent mutations (S89S and D116D) in the 
E6 and three mutations in the E7 (L19G, L20F and H95R). Two silent mutations 
(L43L and Thr146Thr) were observed in HPV66E6 (Accession M75123) and one 
mutation (N100D) in HPV70E6 (Accession U21941). HPV E6/E7 containing LZRS 
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constructs were transfected into the 293T-based Phoenix amphotropic packaging 
cell line, and after selection with puromycin, recombinant helper-retroviruses were 
retrieved as described before [58]. 
 
Retroviral transduction and cell culture 
All cells were grown at 37°C and 5% CO2. HFKs were isolated from foreskins of 
three independent donors as described previously [21]. After two initial passages, 
HFKs were transduced with amphotropic retroviruses expressing the HPV E6/E7 
oncogenes using 15μg/ml Polybrene (Life Technologies, Breda, The Netherlands). 
Geneticin selection (80μg/ml; Life Technologies) was performed 48 hours after 
transduction. Primary HFKs and transductants were cultured in defined 
keratinocyte serum-free medium (SFM) (Life Technologies) containing 5ng/ml 
epidermal growth factor (EGF) and 50ng/ml bovine pituitary extract, 100 U/mL 
penicillin, 100 μg/mL streptomycin, and 2 mmol/L L-glutamine (Life Technologies) 
and grown to subconfluence until passage. The splitting dates and dilutions were 
recorded to generate growth curves and proliferation characteristics. Exponentially 
growing cells were harvested every few passages and cell pellets were stored at -
80°C. DNA was isolated by proteinase K digestion followed by UltraPure
TM
 
Phenol:Chloroform:Isoamyl Alcohol (Life Technologies) extraction [59]. Total RNA 
was isolated using TRIzol Reagent (Life Technologies) according to the 
manufacturer’s instructions.  
SiHa cells were obtained from the American Type Culture Collection (Manassas, VA) 
and were grown in Dulbecco's modified Eagle Medium (DMEM) (Life Technologies) 
supplemented with 10% fetal calf serum, 100 U/mL penicillin, 100 μg/mL 
streptomycin, and 2 mmol/L L-glutamine (all from Life Technologies).  
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HPV DNA and RNA analysis  
Throughout culturing, DNA was isolated of all transductants to verify the presence 
of the correct HPV type using HPV type-specific E7 primers. Using a quantitative 
PCR (qPCR) for the viral backbone targeting the LZRS sequence and beta-globine as 
a reference, the quantities of ectopic DNA were measured.  
For E6 and E7 expression analysis, 500ng of total RNA was treated with RQ1 RNase-
free DNase (Promega, Madison, WI, USA) and used for cDNA synthesis with specific 
reverse primers. For each sample a reaction without reverse transcriptase (RT-) was 
run in parallel to control for DNA contamination. A quantitative RT-PCR for E7 was 
performed using a newly developed quantitative HPV detection method, which 
allowed the analysis of all HPV types under study, except for HPV70 (A. T. 
Hesselink, J. Berkhof, M. L. van der Salm, A. P. van Splunter, T. H. Geelen, F. J. van 
Kemenade, M. G. B. Bleeker, and D. A. M. Heideman, unpublished data). As a 
reference, we performed a qRT-PCR for snRNP, as described previously [60]. 
 
hTERT expression analysis and telomerase activity 
For hTERT mRNA expression analysis, 500ng of total RNA was treated with RQ1 
RNase-free DNase (Promega), and qRT-PCR was performed as described before 
[61].  
Telomerase activity was measured using the TeloTAGGG Telomerase PCR ELISA
Plus
 
kit (Roche, Mannheim, Germany) according to the manufacturer’s protocol.  
 
Beta galactosidase staining 
Senescent cells were detected by staining for acidic β-galactosidase [62]. Cells were 
fixed in 3% formaldehyde in phosphate-buffered saline (PBS), washed with PBS and 
stained with 40mM citric acid-sodium phosphate buffer (pH6), 5mM potassium 
ferricyanide, 5mM potassium ferrocyanide, 150mM sodium chloride, 2mM 
magnesium chloride, 1mg/ml X-gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside) at 37°C in the absence of CO2.  
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Protein extraction and Western blotting 
Total cellular protein extracts were derived from exponentially growing cells as 
described previously [63]. Fifteen micrograms of protein lysates were 
electrophoresed on a SDS-PAGE gel and transferred to a nitrocellulose membrane. 
Antibodies anti-p53 (clone D07, Dako, Glostrup, Denmark, 1:1000), anti-pRb (clone 
4H1, Cell Signaling Technology, Beverly, MA, USA, 1:1000), β-actin (Cell Signaling 
Technology, 1:1000) and anti-p16
INK4A
 (G175-1239, BD Pharmingen
TM
, 1:1000) were 
incubated in 3% dry milk in PBS containing 0.05% Tween 20 at 4°C overnight. For 
detection, membranes were incubated with the appropriate horseradish 
peroxidise-conjugated secondary rabbit-anti-mouse (p0260, Dako, 1:1000) and 
swine-anti-rabbit (p0217, Dako, 1:1000) antibody for 1hour, and protein levels 
were visualized with enhanced chemiluminescence (ECL) (GE Healthcare, 
Buckingham, United Kingdom). 
 
Organotypic raft cultures system and immunohistochemistochemical 
staining 
Organotypic raft cultures of untransduced HFKs and HPV E6/E7-transduced cells 
were performed as described previously [38]. For all cultures duplicate raft cultures 
were performed. Briefly, mouse fibroblast (J2 3T3) cells were seeded in a dermal 
equivalent. The raft culture medium contained DMEM-Ham’s F-12 (3:1), 10% fetal 
calf serum (Life Technologies), hydrocortisone (0,4 μg/ml), 0,1 nM cholera toxin, 
transferrin (5μg/ml), insulin (5 μg/ml) (all from Sigma) and human epidermal 
growth factor (0,5 ng/ml) (Life Technologies). The rafts were harvested after 9 
days, fixed in 10% saline-buffered formalin, paraffin embedded, and subjected to 
immunohistochemical staining.  
Immunohistochemical staining was performed on 4-μm sections, which were 
deparaffinized and rehydrated. Following antigen retrieval with citrate buffer (pH6, 
800 W, 10 min) slides were incubated for 30 min in 3% H2O2 in methanol and 
incubated overnight with MIB/Ki-67 (M7240, Dako, 1:40) and cytokeratin 10 (NCL-
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CK10, Novo Castra Laboratories, 1:200). For detection, the Envision horseradisch 
peroxidase system (Dako) was used. Sections were counterstained with 
haematoxylin. 
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ABSTRACT  
High-risk human papillomavirus (hrHPV)-induced immortalization and malignant 
transformation is accompanied by DNA methylation of host genes. To determine 
when methylation is established during cell immortalization and whether it is 
hrHPV type dependent, DNA methylation was studied in a large panel of HPVE6/E7-
immortalized keratinocyte cell lines. These cell lines displayed different growth 
behaviors, i.e., continuous growth versus crisis period prior to immortalization, 
reflecting differential immortalization capacities of the seven HPV types (HPV16, 
18, 31, 33, 45, 66 and 70) studied. In this study, cells were monitored for 
hypermethylation of 14 host genes (APC, CADM1, CYGB, FAM19A4, hTERT, miR124-
1, miR124-2, miR124-3, MAL, PHACTR3, PRDM14, RASSF1A, ROBO3, and SFRP2) at 
4 different stages during immortalization.  
A significant increase in overall methylation levels was seen with progression 
through each stage of immortalization. At stage 1 (pre-immortalization) a 
significant increase in methylation of hTERT and miR124-2 and PRDM14 was 
already apparent, which continued over time. Methylation of ROBO3 was 
significantly increased at stage 2 (early immortal), followed by CYGB (stage 3) and 
FAM19A4, MAL, PHACTR3 and SFRP2 (stage 4). Methylation patterns were mostly 
growth behavior independent. Yet, hTERT methylation levels were significantly 
increased in cells that just escaped from crisis. Bisulfite sequencing of hTERT 
confirmed increased methylation in immortal cells compared to controls, with the 
transcription core and known repressor sites remaining largely unmethylated.  
In conclusion, HPV-induced immortalization is associated with a sequential and 
progressive increase in promoter methylation of a subset of genes, which is mostly 
independent of the viral immortalization capacity. 
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INTRODUCTION 
Infection with high-risk human papillomavirus (hrHPV) is the major cause of cervical 
cancer, as well as a subset of other anogenital cancers and head and neck cancers 
[1, 2]. According to their prevalence in cervical cancer, twelve HPV types (HPV16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) are classified as high-risk and eight 
(HPV26, 53, 66, 67, 68, 70, 73 and 82) as probable or possible high-risk [1]. 
Cervical cancer develops via morphologically recognizable precancerous lesions, 
also known as cervical intraepithelial neoplasia (CIN). Cervical carcinomas and their 
closest precursor lesions, i.e. high-grade or transforming CINs, are characterized by 
elevated expression of the viral oncogenes E6 and E7 in proliferating cells [3]. E6 
and E7 are known to dysregulate apoptosis, cell cycle control and the replicative 
lifespan by interfering amongst others with activities of p53, pRB and hTERT [4, 5]. 
This is further accompanied by the induction of genomic instability and epigenetic 
changes [4]. Epigenetic alterations include both histone modifications and DNA 
methylation, which control the chromatin status and affect gene transcription [6]. 
We and others have previously shown that various established and 
probable/possible hrHPV types display differential properties in terms of 
immortalization of primary human foreskin keratinocytes (HFK) [7-9]. In our 
studies, the E6/E7 genes of HPV16, 18, 31 and 33 consistently triggered a 
continuous growth without apparent growth arrest (crisis). Transduction of HFK by 
E6/E7 of HPV45, 66 and 70, on the other hand, resulted initially in an extended 
lifespan, but only after a long period of growth reduction or crisis some immortal 
clones emerged. In case of HPV45 only HFKs of one out of three donors ultimately 
became immortal. In all cultures, immortalization was characterized by upregulated 
expression of hTERT, the catalytic subunit of telomerase, and by activation of 
telomerase. The differential growth behaviors suggest that immortalization 
induced by HPV16, 18, 31 and 33 either requires less additive epigenetic or genetic 
events, or that the timing of these events is different, i.e. before normally a crisis 
period would become manifest. Candidate epigenetic events associated with HPV-
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induced cervical carcinogenesis include promoter methylation of various host cell 
genes, often resulting in silencing of the respective genes. Frequently methylated 
genes in cervical cancer include APC, CADM1, CYGB, FAM19A4, hTERT, miR124-1, 
miR124-2, miR124-3, MAL, PHACTR3, PRDM14, RASSF1A, ROBO3, and SFRP2 (for 
reviews see refs. [3, 10-12]). A subset of the above mentioned genes (such as APC, 
CADM1, FAM19A4, hTERT, MAL, miR124-1, miR124-2, miR124-3, PHACTR3 and 
PRDM14) have previously been tested in HPV16- and 18-immortalized HFK cell lines 
to determine the onset and order of DNA methylation alterations during HPV16 
and 18-induced transformation [13-18]. A progressive increase in methylation 
levels with passaging of these cell lines was seen and methylation levels were 
generally higher in cervical cancer cell lines than in in vitro HPV16- or 18-
immortalized HFKs. Furthermore, for CADM1, hTERT, MAL, miR124, PRDM14 and 
SFRP2 a functional role of methylation-mediated gene silencing in HPV-induced 
transformation could be demonstrated [15-20]. Whereas promoter 
hypermethylation of most of the above mentioned genes has been linked to gene 
silencing, hypermethylation of hTERT has been found to positively correlate to 
gene expression and activation [18, 21-24]. This phenomenon may be attributed to 
methylation-mediated inhibition of the transcriptional repressor CTCF, which can 
bind to the hTERT gene in the first and second exon [25]. Since upregulated hTERT 
mRNA expression is critical to telomerase activation and HPV-induced 
immortalization [26], hTERT methylation may represent an important regulatory 
mechanism of HPV-induced immortalization. 
It is currently unknown to what extent the changes in methylation are related to 
the different stages of transformation induced by HPV types other than HPV16 and 
18, and whether altered DNA methylation during immortalization is related to the 
oncogenic capacity of the different HPV types.  
Since cells from various passages of HPV16-, 18-, 31-, 33-, 45-, 66- and 70-
transduced keratinocytes have been harvested and stored, this offers unique 
possibilities to relate gene promoter hypermethylation to the immortalization 
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capacities of these HPV types in a longitudinal manner. Here, we analyzed the 
methylation status of 14 host cell genes, i.e. APC, CADM1, CYGB, FAM19A4, hTERT, 
miR124-1, miR124-2, miR124-3, MAL, PHACTR3, PRDM14, RASSF1A, ROBO3, and 
SFRP2, at various passages pre- and post-immortalization. This included a more in 
depth methylation analysis of individual CpGs within the hTERT regulatory 
sequences.  
 
RESULTS 
Promoter methylation increases during HPV-induced immortalization 
Previously, we have shown that E6/E7 of HPV16, 18, 31, 33, 45, 66 and 70 have 
differential capacities to immortalize primary HFKs [8]. HPV16-, 18-, 31- and 33-
transduced HFKs showed a continuous growth, whereas immortalization of HFKs by 
HPV45, 66 and 70 was preceded by a long period of crisis. Accordingly, the latter 
types are considered less oncogenic in terms of in vitro immortalization.  
To determine whether methylation of particular genes during the immortalization 
process is related to the observed variations in growth behavior, methylation was 
analyzed at four different stages of two or three HPV-transduced HFK donors 
(donor I-III) per HPV type. These involved the following stages: (1) passage 14-20, 
pre-immortal cells in their extended life span; (2) passage 25-30, early passage 
immortal, telomerase positive cells; (3) passage 40-46, intermediate passage 
immortal, telomerase positive cells and (4) passage 73-80, late passage immortal, 
telomerase positive cells. Cultures were considered immortal in case of growth 
beyond a state where HFKs transduced by E6/E7 of HPV45, 66 and 70 were in crisis. 
All immortal cultures were characterized by prolonged growth, elevated hTERT 
mRNA expression and telomerase activity [8]. For stage 1, 17 cell cultures were 
analyzed, including those of HPV45 transduced HFKs of donor II and III, which did 
not reach stage 2. For stage 2 to 4, 15 cell lines were examined. Early passages of 
untransduced HFKs (n=6), HFKs transduced with empty vector (LZRS; n=3) and HFK 
of donor I transduced with low-risk HPV11, that did not become immortal, were 
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used as negative controls [8]. The cancer cell lines, SiHa, CaSki and A549 served as 
positive controls [13, 15-18, 27, 28].  
Promoter methylation of 14 genes that are frequently methylated in (cervical) 
cancer [13, 15-18, 27], i.e. APC, CADM1, CYGB, FAM19A4, hTERT, miR124-1, 
miR124-2, miR124-3, MAL, PHACTR3, PRDM14, RASSF1A, ROBO3, and SFRP2, was 
determined by qMSP. For hTERT, two qMSPs, referred to as hTERT M1 and hTERT 
M2 that target the promoter region and first intron/second exon, respectively, 
were tested, given their putative association with methylation-mediated hTERT 
activation [18, 21-25].  
The promoter regions of APC, miR124-1, miR124-3 and RASSF1A did not show any 
hypermethylation in the HPV-immortalized cell lines, whereas methylation levels 
were high in (cervical) cancer cell lines. For the remaining ten genes, CADM1, CYGB, 
FAM19A4, hTERT, miR124-2, MAL, PHACTR3, PRDM14, ROBO3, and SFRP2, 
increased promoter methylation was detected in the HPV-immortalized cells at 
least at one stage of transformation. 
When comparing the averaged methylation level of all 14 genes a significant 
increase was seen with progression through each stage of transformation (p<0.01 
at each stage) (Figure 1A). Moreover, methylation levels at stage 1 were 
significantly increased compared to controls (p<0.01) and the highest methylation 
levels were detected in cancer cells (Figure 1A). 
The methylation levels per individual gene at stage 1 to 4 are shown in Figure 1B-L. 
At stage 1 a significant increase in methylation of hTERT M1 and M2, miR124-2 and 
PRDM14 compared to controls was already apparent (Figure 1E, F, H and J, 
respectively). Moreover, methylation of all three genes showed a progressive 
increase over time. Methylation of ROBO3 was significantly increased at stage 2 
compared to stage 1 (Figure 1K) and methylation of CYGB was significantly 
increased at stage 3 compared to stage 1 (Figure 1C). FAM19A4, MAL, PHACTR3 
and SFRP2 was significantly increased at stage 4 (Figure 1D, G, and I, respectively). 
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For CADM1 a slight increase in methylation was seen with passaging, which did not 
reach significance in this relatively small sample set. 
 
 
 
Figure 1: Progressive increase in DNA methylation levels. A Box-plot of average methylation level of all 
14 genes (APC, CADM1, CYGB, FAM19A4, hTERT, miR124-1, miR124-2, miR124-3, MAL, PHACTR3, 
PRDM14, RASSF1A, ROBO3 and SFRP2) per stage. B-L Boxplots of the methylation levels of the individual 
gene per stage. Only genes that became methylated in at least one stage are shown (CADM1 (B), CYGB 
(C), FAM19A4 (D), hTERT M1 (E), hTERT M2 (F), MAL (G), miR124-2 (H), PHACTR3 (I), PRDM14 (J), ROBO3 
(K) and SFRP2 (L)). * p<0,05, ** p<0,01 
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Progressive increase in levels of DNA methylation is mostly growth behavior 
independent  
In order to determine whether the progressive increase in DNA methylation levels 
is related to the growth behavior of the cells, the average methylation level of all 
14 genes at the individual stages were compared between cell lines that grew 
continuously (i.e. HPV16-, 18-, 31- and 33-immortalized cells) and cell lines that 
encountered a crisis period prior to immortalization (i.e.HPV45-, 66- and 70-
immortalized cells). As shown in Figure 2A a borderline significant difference 
between both groups is seen at stage 2 (p=0,059), which is just after 
immortalization. No clear differences were seen at stage 1, 3 and 4. Further 
comparison of individual gene methylation levels at stage 2 between cells with and 
without growth crisis, revealed that methylation of hTERT at the M2 region and 
methylation of PHACTR3 were both significantly increased in cells that underwent a 
crisis compared to those that grew continuously (Figure 2B,C).  
 
Increased hTERT methylation in HPV-immortalized cell lines 
As described above, methylation of hTERT represented one of the earliest 
methylation events in the majority of HPV-transduced HFKs and methylation at the 
M2 region was significantly increased in cells that just escaped crisis (i.e at stage 2 
in HPV45-, 66- and 70- immortalized cells) compared to cell that grew continuously 
(i.e. HPV16-, 18-, 31- and 33-immortalized cells). This difference leveled out at 
stage 3 and 4. The M2 region was included as it is located next to a CTCF binding 
site implicated in negative hTERT transcription regulation. Methylation of CTCF 
binding sequences has been shown to inhibit CTCF binding, thereby contributing to 
hTERT upregulation and telomerase activation [21, 22, 25]. To determine in more 
detail which transcription factor binding sites in hTERT are targeted by DNA 
methylation in the HPV-immortalized cells, cells (stage 3) were subjected to 
bisulfite sequencing on 4 overlapping regions of the hTERT promoter and gene: -
476 to -185 bp (region S1), -209 to +96 bp (region S2), +90 to +338 bp (region S3) 
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and +319 to +600 bp (region S4) (top Figure 3). The methylation patterns in hTERT-
positive HPV-immortalized cells were compared to HFKs and HPV11-transduced 
HFKs which we previously showed to be hTERT mRNA negative [8], and hTERT 
mRNA positive SiHa cervical cancer cells, in which the hTERT promoter is known to 
be highly methylated [18].  
 
 
 
Figure 2: Progressive increase in levels of DNA methylation is mostly growth behaviour independent. A 
Boxplot of the average methylation level of all 14 genes (APC, CADM1, CYGB, FAM19A4, hTERT (M1 and 
M2), MAL, miR124-1, miR124-2, miR124-3, PHACTR3, PRDM14, RASSF1A, ROBO3 and SFRP2) per stage 
divided between cell lines that grew continuously in culture (white: HPV16, 18, 31 and 33) and cell lines 
that encounter a crisis period prior immortalization (grey: HPV45, 66 and 70). Significantly differential 
methylation between cell lines without and with a crisis period prior immortalization was observed for 
PHACTR3 (B) and hTERT M2 (C) at stage 2. * p<0,05, ** p<0,01 
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Figure 3: Bisulfite sequencing results of the hTERT CpG island. Overview of the CpG methylation results 
of individual cloned PCR products of untransduced HFKs, HPV11- and stage 3 HPV16-, 18-, 31-, 33-, 45-, 
66- and 70-transduced HFKs of donor I of four regions: S1 spanning -476 to -185 bp, S2 spanning -209 to 
+96 bp, S3 spanning +90 to +338 bp and S4 spanning +319 to 600 bp relative to the ATG. Numbers refer 
to the respective CpG and their position relative to the ATG. The position of known and putative 
transcription factor binding sites are plotted on top of the corresponding CpG. Regions analyzed by 
qMSP (M1 and M2) are plotted on top of de appropriate CpG in green. 
 
As shown in Figure 3 and Table 1, an increase in methylated CpGs in hrHPV-
immortalized cells compared to controls is particularly evident for region S1. 
Methylation in this region ranged from 7% to 22% in HPV-immortalized cells 
compared to 3% in HFKs and 0% in HPV11-transduced HFKs. In regions S2 and S3 
relatively few CpGs were methylated in both HPV-immortalized cells and controls. 
Only in SiHa cells these regions are heavily methylated. More pronounced 
differences were observed in region S4, which is within the gene body. In HPV18-, 
31-, 33-, 45-, 66- and 70-, but not in HPV16-immortalized cells, methylation in S4 
was higher than in HFKs and HPV11-HFKs. The 3’ part of region S4 was densely 
methylated in all cells analyzed. No major differences were evident between less 
oncogenic HPV types (HPV45, 66, and 70), compared to cells immortalized by the 
more transforming HPV types 16, 18, 31 and 33. However, amongst the different 
cell lines least methylation was seen in the HPV16-immortalized cells in all four 
regions.  
With respect to the specific transcription factor binding sites previously associated 
with hTERT regulation in HPV-containing cells, i.e. the X-box motif, E-box motif and 
CTCF binding sites [25, 29-32], minor differences between individual cell lines were 
observed. The X-box motif in promoter region S1 showed increased methylation in 
HPV18-, 31-, 33-, 45-, 66- and 70-immortalized cells compared to the controls. 
However, in HPV16-immortalized cells this site was largely unmethylated. The two 
E-boxes (c-myc binding sites) were mostly unmethylated, except for a few 
methylated CpGs in the distal site in HPV18-, and 45-immortalized cells.  
Chapter 4 
114 
Both CTCF-sites, located within the gene body in region S2 and S4, were mostly 
unmethylated, whereas CpGs flanking the CTCF site in S4 were methylated more 
frequently.  
In conclusion, compared to HFK control and HPV11-containing cells, most HPV-
immortalized cells showed increased hTERT methylation (with slight differences 
between the HPV types). Importantly, the bisulfite sequencing results correspond 
with the methylation levels determined by qMSP (Figure 1). More methylation was 
observed in the S3/S4 region where qMSP M2 is located compared to region S1 
containing the qMSP M1 region. Moreover, in contrast to qMSP analysis showing 
significantly increased hTERT M2 methylation at stage 2 in cells that underwent a 
crisis period, both bisulfite sequencing and qMSP showed no relation to growth 
behavior at stage 3.  
 
Table 1: Percentage of hTERT methylation in primary human keratinocytes (HFK), 
HPV E6/E7 containing HFKs and SiHa cells. 
 % methylation (total number of clones analyzed) 
 S1 
(-476/-185 bp) 
S2 
(-209/+96 bp) 
S3 
(+90/+338 bp) 
S4 
(+319/+600 bp) 
Cell lines     
HFK 3 (8) 2 (9) 2 (8) 15 (10) 
+HPV11 0 (10) 2 (10) 1 (9) 15 (10) 
+HPV16 7 (10) 1 (7) 0 (10) 5 (10) 
+HPV18 15 (10) 4 (10) 6 (10) 37 (9) 
+HPV31 22 (7) 0 (6) 14 (8) 32 (10) 
+HPV33 10 (8) 1 (5) 8 (8) 28 (10) 
+HPV45 9 (10) 4 (7) 7 (10) 19 (10) 
+HPV66 13 (14) 5 (6) 4 (10) 18 (8) 
+HPV70 7 (10) 0 (10) 1 (10) 25 (10) 
SiHa 82 (10) 38 (13) 26 (9) 92 (11) 
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DISCUSSION 
The efficiency of keratinocyte immortalization by HPV is HPV type dependent and 
may result from differential necessities of supplementary (epi)genetic host cell 
alterations [8]. Longitudinal analysis of multiple HPV16-, 18-, 31-, 33-, 45-, 66- and 
70-immortalized keratinocyte cell lines revealed a sequential and progressive 
increase in host gene promoter methylation with passaging. These genes include 
both (candidate) tumor suppressor genes that are known to become silenced by 
DNA methylation in the context of hrHPV, such as CADM1, MAL, miR124, PRDM14 
and SFRP2 [15-17, 19, 20], and hTERT, of which methylation has been associated 
with gene activation [18, 21-25].  
Methylation of hTERT, miR124-2 and PRDM14 represented the earliest methylation 
events, methylation levels of which were already significantly increased at the pre-
immortal stage (stage 1) compared to controls. Subsequently, at stage 2 a 
significant increase in ROBO3 methylation was seen. Methylation levels of all four 
genes progressively increased with passaging. Their rather early onset of 
methylation is in line with previous results on cervical biopsies, showing 
methylation in a substantial subset of precursor lesions (CIN3) and increasing 
frequencies and levels of methylation in cervical carcinomas [13, 15, 18, 33].  
Methylation of CYGB was identified as a successive event detectable from stage 3 
onwards. To the best of our knowledge, this is the first report showing that HPV-
mediated transformation is associated with CYGB methylation. In support of this, 
our preliminary data on cervical biopsies also revealed frequent CYGB methylation 
in cervical carcinomas and precursor lesions (unpublished results). CYGB 
methylation has been described in lung-, oral-, breast-, ovarian- and head and neck 
cancer [28, 34-37].  
A significant increase in DNA methylation levels of FAM19A4, MAL, PHACTR3 and 
SFRP2 was seen upon progression from stage 3 to stage 4. CADM1 methylation 
levels showed a slight increase with passaging, and were particularly high in cancer 
cell lines. Methylation of these genes has previously also been described in a 
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(major) subset of CIN3 lesions and cervical carcinomas, in line with the cell lines 
representing a premalignant phenotype [13, 16, 17, 38]. An earlier onset of MAL 
methylation compared to CADM1 methylation has been described previously [16, 
17, 39].  
A number of genes remained unmethylated, such as APC, miR124-1, miR124-3 and 
RASSF1A. Given the fact that these genes are methylated in cervical carcinomas 
[15, 40-44], methylation-mediated silencing of these genes may occur at later 
stages of transformation and/or may be cell type dependent. In fact, methylation 
of miR124-1 and miR124-3 was highly frequent in SCC and only occasionally 
detected in CIN3 lesions [15]. Cell type dependence may particularly account for 
APC and RASSF1A methylation, which appeared more often in adenocarcinomas 
than in squamous cell carcinomas [14, 40-42, 45]. Our in vitro models are based on 
squamous epithelial cells.  
Comparison of cells that grew continuously (HPV16-, 18-, 31- and 33-transduced 
HFKs) and cells that underwent a crisis period (HPV45-, 66- and 70-transduced 
HFKs), revealed a nearly significant (p<0.059) increase in methylation levels in cells 
that just escaped from crisis at stage 2. This difference was mainly attributable to 
significantly increased hTERT methylation. This suggests that methylation of hTERT 
is particularly advantageous for immortalization of cells harbouring less oncogenic 
HPV types. Methylation of hTERT has previously been described to result in gene 
activation and increased hTERT expression is associated with immortalization [18, 
21-23]. 
This phenomenon could be confirmed in present study, in which upregulated 
hTERT mRNA expression, as previously demonstrated in all HPV-immortalized cell 
lines [8], was associated with increased hTERT methylation when compared to 
hTERT mRNA negative primary cells. However, the CpGs around the transcription 
start site (region S2) remained largely unmethylated (Figure 3), which was also 
described by Renaud et al. [25] and Jiang et al. [46]. This finding suggests that the 
core promoter needs to remain unmethylated to allow hTERT activation. 
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Methylation of other regions of the hTERT CpG island has often been associated 
with elevated hTERT expression [18, 21, 22, 25]. Two of those regions within the 
gene contain CTCF binding sites of which methylation is known to hinder CTCF 
binding [25]. It has therefore been suggested that hTERT activation is due to 
hypermethylation of the CTCF binding sites located at S2 (CpG 2-7) and S4 (CpG 54-
56) [25]. Except for a few CpGs in HPV45- and HPV66-immortalized cells, frequent 
methylation within the CTCF binding sites was not observed, in contrast to the 
flanking CpGs, which is in line with our previous findings [18].  
It is therefore unlikely that in the studied cell lines hTERT expression is preceded by 
methylation-mediated inhibition of CTCF binding to established binding sites. 
Recently, a CTCF-regulated enhancer element 4.5 kb upstream of hTERT, as well as 
a number of novel candidate CTCF binding sites and non-CTCF repressive elements 
in the proximal exonic region have been identified, each of which may be affected 
by DNA methylation [47, 48]. Moreover, accumulating evidence indicates that the 
HPV-encoded E6 protein plays a prominent role in hTERT gene activation by binding 
to c-Myc or E6AP [29, 31, 32, 49]. More recently, E6 was shown to inhibit the 
binding of MAZ, a novel hTERT repressor, which correspondingly increased SP1 
binding and gene activation [50]. The E6 proteins of different HPV types have 
different capacities to transactivate hTERT. The E6 proteins of HPV16, 18, 31, 33, 
35, 51, 52 and 58 showed highest hTERT promoter activation capacity, whereas E6 
of HPV66 and 70 displayed lower activity [51].  
In present study least methylation was detected in HPV16-immortalized cells, 
suggesting that amongst the hrHPV types tested, methylation-mediated hTERT 
activation may be less essential in case of HPV16E6/E7, expression. Except for 
HPV16, no difference in frequency of hTERT methylation between the strongest 
(HPV18, 31, and 33) and weakest hTERT activators (HPV66 and 70), as described by 
Van Doorslaer et al. [51], was seen. Therefore, next to differences in E6 activation 
capacities, site-dependent methylation patterns or other mechanisms may 
contribute to hTERT gene activation. Although controversial, HPV16 E6-mediated 
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hTERT activation has previously been suggested to rely (in part) on the proximal E-
box [32]. Except for methylation of a few CpGs in the distal E-box in HPV18- and 45-
immortalized cells, the E-boxes were unmethylated in most immortalized cells.  
In conclusion, passaging of HPV16-, 18-, 31-, 33-, 45-, 66- and 70-transduced human 
keratinocytes is correlated with a progressive increase in DNA methylation of 
selected host cell genes. The timing of the methylation events differed between 
genes. hTERT, miR124-2 and PRDM14, were the first genes that became 
methylated, even prior to immortalization (stage 1). Following immortalization, 
ROBO3 methylation (stage 2) preceded CYGB methylation (stage 3) followed by 
CADM1, FAM19A4, MAL, PHACTR3 and SFRP2 methylation. Early onset of selected 
epigenetic host cell alterations during HPV-induced HFK immortalization was 
mostly independent on the viral oncogenic capacity. The onset of hTERT 
methylation was inversely related to the immortalization capacity of the HPV types 
tested, though diminished with passaging. More detailed analysis of the hTERT 
regulatory sequences indicated that reactivation of hTERT expression in immortal 
cells is most likely not due to severe methylation of known repressor sites.  
 
MATERIALS AND METHODS 
Cells and cell lines 
HFKs were isolated from foreskins of independent donors as described before [52]. 
Cell cultures containing low-risk HPV11, hrHPV16, 18, 31, 33, 45 and probable 
hrHPV66 and 70 were established by retroviral transduction of HFKs with the E6/E7 
open reading frames of the respective HPV type as described before [8]. 
Untransduced HFKs and empty vector (LZRS) transduced HFKs served as controls. 
HFKs of donor I were transduced with all HPV types. Donor II was transduced with 
all HPV types except HPV33 and donor III was transduced with HPV16, 33, 45 and 
70. Transductants were grown in defined keratinocyte serum-free medium (SFM) 
(Life Technologies 17005-075) containing 5ng/ml EGF and 50ng/ml bovine pituitary 
extract, 100 U/mL natrium-penicillin G (Astellas Pharma B.V. 117837/ 315932), 100 
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μg/mL streptomycin (Life Technologies 11860038), and 2 mmol/L l-glutamine (Life 
Technologies 25030024) and 80μg/ml geneticin (Sigma-Aldrich G8168) selection. 
The cervical cancer cell lines SiHa (HPV16) and CaSki (HPV16) and the lung cancer 
cell line A549 (HPV-negative) were obtained from the American Type Culture 
Collection (Manassas, VA, USA). Culture conditions were described previously [52, 
53]. All cells were grown at 37°C and 5% CO2.  
 
DNA isolation and bisulfite modification 
Genomic DNA was isolated from cell pellets by proteinase K digestion followed by 
UltraPure
TM
 Phenol:Chloroform:Isoamyl Alcohol (Life Technologies 15593049) 
extraction as described previously [54]. 
Sodium bisulfite modification was performed on 1μg DNA using the EZ DNA 
Methylation
TM
 Kit (Zymo Research D5002) according to the manufacturer’s 
protocol, which induces chemical conversion of unmethylated cytosines into uracils 
while leaving methylated cytosines unchanged. 
 
Quantitative methylation specific PCR (qMSP) 
DNA methylation of the promoter regions of 14 host cell genes (i.e. APC, CADM1, 
CYGB, FAM19A4, hTERT, miR124-1, miR124-2, miR124-3, MAL, PHACTR3, PRDM14, 
RASSF1A, ROBO3 and SFRP2) was determined by qMSP. For hTERT two different 
regions were analyzed, located in the promoter (M1) and proximal exonic region 
(M2) [18]. MiR124-1, -2 and -3 are located at different chromosomal regions and 
regulated by distinct promoter regions, but all encode the same mature miRNA 
[15]. 
QMSPs of single (Table 2) and multiple targets (Table 3) were performed in a 12 μl 
reaction volume containing 50 ng of bisulfite treated DNA. For single target qMSP 
QuantiTect Probe PCR Kit (Qiagen 204345) was used and for multiplex qMSP 
Quantitect Multiplex PCR Kit (Qiagen 204545) [55]. qMSPs were run on the ABI 
7500 and/or ABI 7900 Fast Real-Time PCR System (Applied Biosystems). 
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Table 2: Primer and probe sequences for single target qMSP. 
Gene Forward primer Reverse primer probe (bp) 
hTERT 
M1  
GAGTAGCGTAGGCG
ATTTAGGGCGT 
GTCCAACAACGCGAAACC
GAA 
CGCACAACCTCTACAACACTCG
AACCACCAACTC 
75 
hTERT 
M2 
TAGATTTTCGGGTTC
GTTCG 
TCTATACCCGCGAATCCAC
T 
CGACCTAACCCCGACAACGCA
ACTA  
132 
MAL  TTAGGTTATTGGGTT
TCGCG 
GTACTAACGTCGACCTTAA
AACGA 
TCCGCGCAAACCTCTCGCTAAC 86 
miR124-
1 
CGGCGGGGAGGATG
TT 
ATAAAAAACGACGCGTAT
ACGTACG 
CGGCGTTTTTTATTTTT 94 
mir124-3 ACGCGGCGAAGACG
TTT 
CGAACGACGAACGTCGAA
A 
AAAATCCTCGCCCGAAAAACG
CGA 
95 
ROBO3  AGGAGGAGGGTACG
AAGAGGTATC 
AAAACCCGTAAACTAAAA
ACCGTAAAC 
CCGCTCTCCTACCGATACGCCT
AAATACGAT 
120 
ACTB  TGGTGATGGAGGAG
GTTTAGTAAGT 
AACCAATAAAACCTACTCC
TCCCTTAAA 
ACCACCACCCAACACACAATAA
CAAACACA 
 
CpGs are indicated in bold 
 
Methylation levels were normalized to the housekeeping gene MYOD1 (in case of 
APC, CYGB and RASSF1A) or ACTB (in case of all other qMSP targets). DNA isolated 
from cancer cell lines SiHa and A549 served as reference and positive control in the 
individual qMSPs and were set to 100. SiHa DNA was used as a reference for qMSPs 
of CADM1, FAM19A4, hTERT, miR124-1, miR124-2, miR124-3, MAL, PHACTR3, 
PRDM14, ROBO3 and SFRP2 and A549 DNA for APC, CYGB and RASSF1A qMSPs. 
Methylation levels were determined using the 2
-ΔΔCT
 method [56], resulting in a 
quantification of DNA methylation in the HPV-transduced cells relative to the 
positive controls SiHa or A549. All samples had a ACTB Ct-value <32, indicating 
sufficient DNA quality.  
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Table 3: Primer and probe sequences for multiplex qMSP. 
Gene Forward primer Reverse primer probe (bp) 
APC GAACCAAAACGCTCCCCAT TTATATGTCGGTTACGTGC
GTTTATAT 
CCCGTCGAAAACCCGCCCG
ATTA 
74 
CAD
M1  
CGTATGTTATTAGTATTTTA
TTAGTTGTTCGTTC 
CGCTCGACAACACTACACT
CG 
ACCTACCTCAAACTAACGA
CGTTAACTACCTCCGA 
106 
CYGB  CGAGGTCGATCGTTAGTTC
GTTC 
CCAACGACTAACTCGAAAA
CGCG 
CGGCGGTCGTCGTGGATTT
AG 
117 
FAM1
9A4  
AGTCGGGCGGTTCGGTTA CCAAAACGACGCGCAACTA CCCAACTAACGCGCTAA 106 
miR1
24-2 
GGGTAATTAATTTGGATTTA
CGTCGTTAT 
CGTAAAAATATAAACGATA
CGTATACCTACGT 
TTTACAACACACGCCTAAA 138 
MYO
D1 
CCAACTCCAAATCCCCTCTC
TAT 
TGATTAATTTAGATTGGGT
TTAGAGAAGGA 
TCCCTTCCTATTCCTAAATC
CAACCTAAATACCTCC 
162 
PHAC
TR3 
GGTTATTTTGCGAGCGGTTT
C 
CGAATACTCTAATTCCACG
CGACT 
AACCGCGTCGAAAAACGA
AAACGACTAC 
114 
PRD
M14  
TTACGTGTTATTGTCGGGG
ATTC 
ATATCTATTCCTAATACCTA
AAAACGAAACG 
AAACGCCTTAAACGCTAAA
AAACTTCGCCTC 
88 
RASS
F1A  
GCGTTGAAGTCGGGGTTC CCCGTACTTCGCTAACTTTA
AACG 
ACAAACGCGAACCGAACG
AAACCA 
75 
SFRP
2  
GAGTAGCGTAGGCGATTTA
GGGCGT 
TCCCGAACCCGCTCTCTT CGCTAAATACGACTCGAAA
CCCCGAA 
69 
CpGs are indicated in bold 
 
Bisulfite sequencing 
For hTERT methylation analysis by bisulfite sequencing methylation independent 
PCR (MIP) was performed using 4 primer sets (Table 4) spanning the hTERT 
promoter and first exon from the coding sequence from -476 to +600 bp relative to 
the ATG. MIP, cloning and sequencing was performed as described before [18]. 
Shortly, purified MIP-products were cloned in pGEM-T using pGEM®-T Easy Vector 
System (Promega A1360) or into the Zero pCR-Blunt II-TOPO vector (Life 
Technologies K282020). Approximately ten cloned PCR-fragments of every region 
and cell line were sequenced using the BigDye Terminator v1.1 cycle sequencing kit 
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on an ABI Prism 3100 sequencer (Applied Biosystems). Sequences were analyzed 
using Chromas Lite version 2.01. 
 
Statistical analysis 
Statistical analysis was performed using SPSS (version 20). The average methylation 
level of all investigated genes as well as methylation levels per gene were 
compared between stages and between continuously growing cell lines and cell 
lineages that encountered a crisis period using the non-parametric Mann-Whitney 
U test. A two-sided p-value <0.05 was considered statistically significant. 
 
Table 4: Primer and probe sequences for bisulfite sequencing. 
Gene Forward primer Reverse primer length 
(bp) 
hTERT S1 GTTTTTAGGGTTTTTATATTATGG AAACTAAAAAATAAAAAAACAAAAC 292 
hTERT S2 GTTTTGTTTTTTTATTTTTTAGTTT AACCCTAAAACCCCAAA 305 
hTERT S3 TTGGGGTTTTAGGGTTG ACCAACTCCTTCAAACAAAA 248 
hTERT S4 GTAGGTGTTTTGTTTGAAGGA AACTAAAAACCACCAACACAA 281 
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Abstract  
High-risk human papillomavirus (hrHPV) types induce immortalization of primary 
human epithelial cells. Previously we demonstrated that immortalization of human 
foreskin keratinocytes (HFKs) is HPV type dependent, as reflected by the presence 
or absence of a crisis period before reaching immortality. This study determined 
how the immortalization capacity of ten hrHPV types relates to DNA damage 
induction and overall genomic instability in HFKs. Twenty five cell cultures obtained 
by transduction of ten hrHPV types (i.e. HPV16, 18, 31, 33, 35, 45, 51, 59, 66 and 70 
E6/E7) in two or three HFK donors each were studied. 
All hrHPV-transduced HFKs showed an increased number of double strand DNA 
breaks compared to controls, without exhibiting significant differences between 
types. However, immortal descendants of HPV-transduced HFKs that underwent a 
prior crisis period (HPV45-, 51-, 59-, 66- and 70-transduced HFKs) showed 
significantly more chromosomal aberrations compared to those without crisis 
(HPV16-, 18-, 31-, 33- and 35-transduced HFKs). Notably, the hTERT locus at 5p was 
exclusively gained in cells with a history of crisis and coincided with increased 
expression. Chromothripsis was detected in one cell line in which multiple 
rearrangements within chromosome 8 resulted in a gain of MYC. 
Together we demonstrated that upon HPV-induced immortalization, the number of 
chromosomal aberrations is inversely related to the viral immortalization capacity. 
We propose that hrHPV types with reduced immortalization capacity in vitro, 
reflected by a crisis period, require more genetic host cell aberrations to facilitate 
immortalization than types that can immortalize without crisis. This may in part 
explain the observed differences in HPV type prevalence in cervical cancers and 
emphasizes that changes in the host cell genome contribute to HPV-induced 
carcinogenesis. 
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INTRODUCTION  
A persistent infection with certain types of the human papillomavirus (HPV) has 
been causally associated with the development of cervical cancer, as well as a 
subset of other anogenital and head-and-neck cancers. Based on epidemiological 
data and functionally relevant genomic sequence differences, HPV types of the 
alpha-genus are classified as high-risk (hrHPV) (i.e. HPV 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58 and 59: IARC group 1, frequently found in cervical cancers), probable/ 
possible hrHPV (i.e. HPV 26, 53, 66, 67, 68, 70, 73 and 82: IARC group 2A/B, 
infrequently found in cervical cancers) and low-risk HPV (e.g. HPV6 and 11, 
associated with low-grade cervical lesions or condyloma) [1]. The oncogenic 
potential of the hrHPV types as well as possible and probable hrHPV types 
(hereafter collectively referred to as hrHPV) primarily resides in two viral genes, E6 
and E7, including their regulatory elements and splice sites, that function to 
deregulate apoptosis and the host cell cycle by their ability to amongst others 
degrade p53 and pRb, respectively [2]. Generally, HPV infections are transient and 
self-limiting, but persistent infections with deregulated expression of E6 and E7, so-
called transforming infections, can drive epigenetic and genetic aberrations and 
promote malignant progression [2].  
High-risk HPV types can induce immortalization of primary keratinocytes in vitro via 
a two-step process, that involves the bypass of two mortality phases (M1 and M2) 
(reviewed in [3]). M1, or senescence, can be overcome by hrHPV itself, resulting in 
an extended though still limited lifespan. In this phase hrHPV E6 and E7 induce DNA 
double strand breaks that are prevented from repair by virus-mediated impairment 
of cell cycle control [4, 5]. The accumulation of DNA double strand breaks as well as 
continued telomere shortening during extended cell division may result in a phase 
of extensive and lethal chromosomal instability, termed the second proliferative 
lifespan barrier (M2) or crisis period. Subsequent immortalization has been linked 
to (epi)genetic hits in host cell genes that give a pro-survival phenotype and the 
activation of the telomere lengthening enzyme telomerase via upregulation of its 
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catalytic subunit hTERT [6, 7]. Studies on (epi)genetic host cell aberrations 
associated with hrHPV-mediated immortalization have mostly focused on HPV16 
and HPV18 [8-11]. In these studies in vitro immortalization has been associated 
with chromosomal aberrations that largely overlap with those described in cervical 
carcinomas and its high-grade precursor lesions (cervical intraepithelial neoplasia 
grade 3; CIN3), such as gains at 1q and 3q (reviewed in [12, 13]).  
 
Despite the fact that HPV16 and HPV18 are the most common HPV types detected 
in cervical cancer, one third of cervical cancers can be attributed to other hrHPV 
types. To determine whether in vitro immortalization capacities and associated 
host cell aberrations differ amongst the various hrHPV types, we have recently 
established a large series of HPV type specific in vitro models. Primary human 
foreskin keratinocytes (HFKs) isolated from two to three independent donors were 
transduced with the viral oncogenes E6 and E7 of HPV16, 18, 31, 33, 35, 45, 51, 52, 
59, 66 and 70 [14]. When studying the immortalization capacities of the different 
HPV types, two main groups were distinguished based on their growth behavior in 
culture. One group, including HPV types 16, 18, 31, 33 and 35, showed the highest 
growth promoting activities and these HPV-transduced HFKs displayed a 
continuous growth in culture without an apparent crisis period. The second group 
consisted of HPV45, 51, 52, 59, 66 and 70 that efficiently induced an extended 
lifespan, but these HPV transduced HFKs encountered a severe crisis period, a 
period with strongly reduced cellular growth and widespread cell death. In the 
cases of HPV45 and HPV51 only one out of three transduced donors, and in the 
case of HPV59 two out of three donors became immortal. None of the HPV52-
transduced HFKs reached immortality, and this type was therefore not included in 
present study. These data showed that the immortalization capacities vary 
between hrHPV types, which may reflect a differential dependence on (epi)genetic 
aberrations in host cell genes. Previously, we did not observe a clear relationship 
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between DNA methylation of several tumor suppressor gene promoters, and 
growth behavior [15].  
This study aimed to determine whether HPV type dependent immortalization 
capacities were related to differential DNA damage induction and copy number 
aberrations in immortal descendants. To this end, we analyzed HPV16-, 18-, 31-, 
33-, 35-, 45-, 51-, 59-, 66- and 70-transduced HFKs, from two-to-three donors each, 
at distinct stages during immortalization, i.e. early passages representing pre-
immortal cells in their extended lifespan and later passages representing immortal 
cell lines. Immortalization was previously determined by detection of telomerase 
activity and upregulated hTERT expression [14]. In case of HPV45-, 51-, 59-, 66- and 
70-transduced cells these are the cells that escaped from crisis. Cells were analyzed 
for DNA damage using γ-H2AX staining, and DNA copy number aberrations using 
array comparative genomic hybridization (arrayCGH).  
 
RESULTS 
Different hrHPV types equally induce DNA double strand breaks  
The induction of DNA damage is a well-established feature of hrHPV types such as 
HPV16 and is known to contribute to HPV-induced cellular transformation 
(reviewed by [16]). Hence, the observed differential immortalization capacities of 
various hrHPV types in our established cell cultures of HPV-transduced HFKs may 
be explained by a type-dependent difference in the extent of DNA damage 
induction. To study this hypothesis early passages of HPV16-, 18-, 31-, 33-, 35-, 45-, 
51-, 59-, 66- and 70-transduced HFKs established in the same donor cells (donor I) 
were analyzed for the presence of phospho-histone H2A.X (γ-H2A.X), a marker for 
DNA-double strand breaks (DSBs). Untransduced HFKs and low-risk HPV11 
transduced HFKs were included as a control. Control cells showed low γ-H2A.X 
positive staining (average=17.5%; range 7.7-26.3%), whereas on average 65.8% 
(range 42.8-89.3%) of hrHPV-transduced cells stained positive for γ-H2A.X (Figure 
1A, 1B). Comparison of the number of γ-H2A.X positive cells between cultures 
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showing continuous growth (HPV16-, 18-, 31-, 33- and 35-transduced HFKs) and 
cultures encountering a crisis period (HPV45-, 51-, 59-, 66- and 70-transduced 
HFKs) upon immortalization revealed no significant differences (p= 0.754) 
suggesting that differences in growth behavior between HFKs transduced with the 
various HPV types are not associated with differential induction of DNA double-
strand breaks.  
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Figure 1. HPV11, 16, 18, 31, 33, 35, 45, 51, 59, 66 and 70 E6/E7 induced DNA-double strand breaks. A 
Representative stainings of the nuclei (DAPI) and DNA-double strand breaks (γ-H2A.X) of donor cells 
(HFK), HPV18- (without crisis) and HPV70- (with crisis) containing HFKs. B Boxplot of γ-H2A.X positive 
cells (percentage) in controls (including HFKs and lrHPV11), pre-immortal cell lines that did not 
encounter a crisis prior to immortalization (no crisis, including HPV16, 18, 31, 33 and HPV35) and pre-
immortal cell lineages with a crisis period (including HPV45, 51, 59, 66 and 70). The upper and lower 
boundaries of the boxes represent the 75th and 25th percentiles, respectively. The black line within the 
box represents the median, the whiskers represent the minimum and maximum values that lie within 
1.5 inter quartile range from the end of the box. The experiment was performed in duplicate. 
 
Immortal descendants that underwent a crisis period have significantly 
more DNA copy number aberrations (CNA) 
Illegitimate repair of DSBs can lead to CNAs, which could explain the observed 
differences in growth behavior between the HPV types. We therefore compared 
the genome-wide chromosomal copy number aberrations observed in pre-
immortal and immortal passages (Figure 2A,B). A total of 19 pre-immortal and 20 
immortal cell cultures (donor I-III, transduced with E6 and E7 from HPV16, 18, 31, 
33, 35, 45, 51, 59, 66 and/or 70; see Supplementary Table 1) were analyzed on a 
105K arrayCGH platform. The CNAs observed in pre-immortal cells were conserved 
in their corresponding immortal descendants, which had accumulated more 
alterations. To enable a comparison of the extent of CNA among different cell lines 
we determined the percentage of probes on the array deviating from the normal 
state, hereafter referred to as the percentage of aberrations. Immortal cells 
showed significantly higher percentages of both gains and losses of copy numbers 
as compared to pre-immortal passages (p<0.001) (Figure 3A-C).  
In pre-immortal passages, no difference was observed in the percentage of 
aberrations between cell lines that were to undergo crisis before immortalization 
and cell lines that were to immortalize without an apparent crisis period (data not 
shown). However, upon comparison between immortal cells that emerged from 
continuous growing ancestors and immortal cells that escaped from crisis, 
significantly more CNA were detected in the post-crisis cells (Figure 3D), which was 
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mainly attributable to a strong increase in the percentage of gains (Figure 3E), 
rather than losses (Figure 3F). 
 
 
A 
B 
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Figure 2. Chromosomal profiles in pre-immortal and immortal cell lines. A Frequency plot of pre-
immortal cell lines (dark red and blue) (n=19) and immortal cell lines (light red and blue) (n=20). B 
Matched pre-immortal and immortal passages of the individual cell lines were shown followed by cell 
lines of which only one passage was present. Red indicates a gain and blue a loss. 
 
 
 
 
Figure 3. Boxplots showing the percentage of total aberrations, gains and losses. Pre-immortal and 
immortal cells are compared for A percentage of total aberrations, B percentage of gains and C 
percentage of losses. Cells with and without crisis were compared for percentage of total aberrations, 
gains and losses in immortal (D-F) passages. The upper and lower boundaries of the boxes represent the 
75th and 25th percentiles, respectively. The black line within the box represents the median, the whiskers 
represent the minimum and maximum values that lie within 1.5 inter quartile range from the end of the 
box. 
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Regions on chromosome 5p, 8 and 9q are specifically altered in immortal 
cells that underwent crisis 
A frequency plot for immortal cell lines with (n=9) and without (n=11) a preceding 
crisis period is shown in Figure 4. Overall, gains of regions on chromosome 20q and 
losses at chromosome 3p and 22q were observed in more than 70% of cell lines. An 
overview of all smallest regions of overlap occurring in at least 30% of cell lines is 
summarized in Table 1.  
 
 
 
Figure 4. Frequency plot of DNA copy number aberrations in immortal cell lines. Cell lineages without 
crisis including HPV16, 18, 31, 33 and 35 (n=11) are shown in dark red and blue, and cell lines with a 
crisis prior to immortalization including HPV45, 51, 59, 66 and 70 (n=9) are shown in light red and blue. 
Red indicates a gain and blue a loss.  
 
To determine whether specific chromosomal aberrations could potentially 
contribute to the outgrowth of immortal cells during crisis, we compared the 
chromosomal profiles of immortal descendants of cell lines with (n=9) and without 
(n=11) crisis. Gains of two regions in chromosome 5p, 3 regions on 8q and a region 
on 9q as well as loss of two regions on chromosome 8p were observed significantly 
(χ
2
 test, FDR<0.10) more often in immortal cells that underwent crisis, whereas loss 
of a region on chromosome 4p was significantly (χ
 2
 test, FDR<0.10) more frequent 
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in immortal cells showing continuous growth without an apparent crisis period 
(Table 2). 
Interestingly, the gains at 5p13.3-p11 and 5p15.33-p14.1, which were only 
observed in immortalized cells with crisis, contain the DROSHA and hTERT gene, 
respectively. Detectable hTERT mRNA expression, as determined in our previous 
study [14], coincided with occurrence of the 5p copy number gain in these cells. 
Conversely, in cells without crisis hTERT expression was detectable at earlier 
passages and these cells did not acquire the 5p gain (see Supplementary Table 1). 
In addition, gains more frequently observed in immortalized cells with crisis 
compared to those without crisis also affected well-known oncogenes MYC 
(8q24.21) and CCND1 (11q13.3). Low level amplifications of hTERT, DROSHA, MYC 
and CCND1 have been implicated in cervical carcinogenesis before [17-19]. An 
overview of all genes located in the differentially altered regions between immortal 
cells with and without crisis is given in Supplementary Table 2. 
Together, these results suggest that the increased number of chromosomal 
aberrations, and in particular chromosomal gains, in cells that underwent a crisis 
period may have contributed to the acquisition of an immortal phenotype. 
 
Chromothripsis in HPV16-immortalized cells resulted in a gain of the 
oncogene MYC  
One cell line (immortal cell line of donor I containing HPV16, no crisis, passage 40) 
showed relatively few CNA genome-wide except for chromosome 8, with a 
strikingly high number of clustered breaks. Analysis after long-range paired-end 
sequencing revealed high number of intrachromosomal rearrangements on 
chromosome 8 and a single translocation connecting chromosome 4 with 
chromosome 8 (Figure 5A). Interestingly, the highest peak was situated at 8q24.21, 
the region encoding the oncogene MYC (Figure 5B). Such localized massive 
genomic rearrangement is compatible with “chromothripsis”, in which shattering of 
several genomic regions is hypothesized to occur during a single catastrophic event 
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[20]. Chromothripsis was neither evident in pre-immortal cells (passage 15 cells; 
arrayCGH results), nor in cells at passage 20 and passage 30 (low-coverage 
sequencing results), but was retained in late immortal cells (passage 100; array 
CGH results) (Figure 5C). To the best of our knowledge, this is the first cell line with 
chromothripsis that is established in vitro and that exhibits an immortal, but non-
transformed phenotype (unable to grow anchorage independent/ data not shown) 
and represents a precancerous lesion when cultured on organotypic rafts [14].  
 
 
 
Figure 5. Cell line with Chromothripsis. A Circos plot of a single cell line (donor I, HPV16, passage 40) 
showing the interchromosomal translocations (orange), inversions (grey) and intrachromosomal 
translocations (green). B Chromothripsis on the q-arm of chromosome 8. C DNA copy number profiles of 
chromosome 8 over 5 passages of the cell line presented with chromothripsis, either assessed with 
arrayCGH or low-coverage, whole genome sequencing (LC-WGS). 
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DISCUSSION 
In the present study we showed a progressive increase in chromosomal aberrations 
during hrHPV-mediated immortalization. Interestingly, we found that the 
frequency of aberrations was inversely related to the immortalization capacity of 
the ten hrHPV types analyzed. Cell lines immortalized by HPV types with a higher 
immortalization capacity, including HPV16, 18, 31, 33 and 35, showed significantly 
fewer CNA compared to the cell lines immortalized by HPV types with a lower 
immortalization capacity (i.e. HPV45, 51, 59, 66 and 70), in which immortalization 
was preceded by a crisis period. The increased number of CNA in cells that 
encountered a crisis period was not linked to a differential induction of DNA double 
strand breaks, as determined by γ-H2A.X staining, between HPV types with low and 
high immortalization capacities.  
In all hrHPV-transduced HFKs a significant increase in DNA-double strand breaks (γ-
H2A.X positive cells) compared to controls was observed, with most cells being 
tested at early passage. Yet, most CNA became apparent at later passages following 
immortalization. This observation is in line with a previous report by Bester et al. in 
which DNA damage was immediately induced following expression of HPVE6 and 
E7 due to forced entry into S-phase without concomitant up-regulation of 
deoxyribonucleoside triphosphate synthesis, whereas loss of heterozygosity and 
copy number variations became evident after 100-250 population doublings [21]. 
Since in the context of full length HPV the early genes E1 and E2 are also known to 
contribute to DNA damage induction upon HPV infection or during transformation 
[22, 23], the DNA damage and genomic instability observed upon ectopic 
expression of E6 and E7 only may be an underestimation of the natural process,  
Cell lines without a crisis period and relatively few CNA were previously shown to 
express hTERT at early passages and to more efficiently degrade p53, indicating 
that the respective E6 proteins are more oncogenic than the E6 proteins of HPV 
types with reduced immortalization capacity [14]. This suggests that earlier 
activation of telomerase upon hTERT upregulation mediated by oncogenic E6 
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activity [7, 24], reduces genomic instability by maintaining telomere function and 
suppression of chromosome fusions after chromosome breakage [25]. Accordingly, 
less oncogenic HPV types, which did not induce an early upregulation of hTERT 
[14], most likely require more CNA to induce telomerase and to enable a subset of 
cells with a genetic profile permissive for proliferation to emerge from crisis. 
Interestingly, regions on chromosome 5p, where the hTERT and DROSHA gene are 
located, were exclusively gained in the majority of cell lines that encountered a 
crisis and not in cell lines that showed a continuous growth (Figure 4). In fact, 
upregulation of hTERT expression coincided with the detection of a 5p gain in the 
immortal cells that underwent crisis. This suggests that a 5p gain resulting in 
increased hTERT expression may have facilitated immortalization. Although a gain 
of the hTERT locus is a common feature in cervical cancer [26, 27], it is unknown 
whether this is type dependent. Similarly, increased expression of DROSHA related 
to a copy number gain was described before in cervical cancer and was shown to 
result in altered miRNA expression profiles [17]. 
Regions on chromosomes 8q and 9q were more often gained in cell lines with a 
crisis period and may harbor (putative) oncogenes that provide a growth advantage 
in cells infected with less carcinogenic virus types during crisis. The lost region on 
chromosome 4p was significantly more frequent in cells that showed a continuous 
growth. Loss of heterozygosity at this region has been demonstrated in cervical 
carcinomas [28].  
Overall, gain of chromosome 20q and loss of chromosome 3p and 22 represented 
the most frequent events in the HPV-immortalized cell lines [29]. A gain at 
chromosome 20q has previously been described to be essential for HPV-induced 
immortalization [29-31] and to be associated with HPV16 E7 induced inactivation of 
the pRB pathway [32]. Loss of chromosome 3p, particularly at position 3p12-14, has 
been recognized as one of the most common events in cervical squamous cell 
carcinoma [13, 33]. CNA at chromosome 22 are uncommon in HPV-associated 
lesions, though breakage-fusion translocations involving chromosome 22 have 
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been described in HeLa cells [34]. Frequent CNA at chromosome 22 as detected in 
present study were also found in other in vitro transformed HPV-containing cell 
lines and may represent an effect of in vitro culturing [9, 35, 36].  
Interestingly and to the best of our knowledge, we are the first to report an in vitro 
generated HPV-immortalized cell line with chromothripsis. Chromothripsis is 
characterized by massive rearrangements involving one or a few chromosomes and 
is a rare event that has been observed in 2 to 3% of all cancers [20]. In one of our 
HPV16-immortalized cell lines we observed chromothripsis at passage 40. No 
chromothripsis was observed at earlier passages, i.e. passages 15, 20 and 30. This 
supports the notion that chromothripsis results from a single catastrophic event 
that either occurred after passage 30 or remained undetectable until passage 40. 
High level intrachromosomal rearrangements occurred in chromosome 8, and 
resulted in amplification of the oncogene MYC. Since MYC amplification was only 
detected at passage 40, which is approximately 20 passages after immortalization, 
the biological advantage remains to be determined. Activation of MYC as a result of 
viral integration at the MYC locus has been recognized as a potential mechanism of 
HPV-induced carcinogenesis [37]. Current data indicate that activation of MYC as a 
result of chromothripsis or CNA may represent an alternative mechanism 
contributing to HPV-induced carcinogenesis. Given the fact that these HPV-
immortalized cell lines resemble precancerous lesions of the cervix upon growth in 
three-dimensional organic raft cultures [14], these data indicate that 
chromothripsis may represent an early event already occurring in precancerous 
lesions.  
Our preliminary data on mutation analysis of 48 cancer-related genes (TruSeq 
Amplicon panel Illumina) indicate that somatic mutations are extremely rare in 
HPV-immortalized cells. Only one mutation in GNAQ was found in one cell line. 
Furthermore, previous DNA methylation analysis of 15 genes in HPV16-, 18-, 31-, 
33-, 45-, 66- and 70-immortalized cells showed no major differences in methylation 
patterns between the various HPV-immortalized cell lines [15]. Apparently, the HPV 
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type dependent immortalization capacity, as reflected by different growth 
behaviors of HPV transduced HFKs, is particularly associated with variability in copy 
number aberrations, including those associated with gains, and deletions that may 
affect expression levels of the associated driver proteins. This suggests that the 
CNA as described in this study are likely to provide a growth advantage and enable 
the bypass of crisis.  
In conclusion, analysis of HPV-immortalized HFK cell lines transduced with ten 
different HPV types revealed that the induction of DNA-double strand breaks 
(phospho-histone H2A.X induction) is HPV type independent. Conversely, the 
extent of CNA in immortal cells appeared to be HPV type dependent. The 
percentage of CNA was found to be inversely related to the immortalization 
capacity of the virus type present. In particular the number of chromosomal gains 
was significantly increased in HPV-immortalized cells that underwent a crisis period 
compared to HPV-immortalized cells that grew continuously. 
The reduced in vitro immortalization capacity and apparent requirement of more 
genetic host cell aberrations to support an unlimited lifespan of HPV types 45, 51, 
59, 66 and 70, compared to HPV types 16, 18, 31, 33 and 35, may in part explain 
their mostly lower prevalence in cervical cancers and precursor lesions. 
 
MATERIALS AND METHODS 
Cell culture and DNA isolation 
Cell lines were retrieved and cultured as described before [14]. Briefly, HFKs were 
isolated from the foreskins of three independent donors as described previously 
[6]. After two initial passages, HFKs were transduced with amphotropic retroviruses 
expressing the E6/E7 open reading frame of HPV types 16, 18, 31, 33, 35, 45, 51, 
59, 66 and 70. Geneticin (Life Technologies, Breda, The Netherlands) selection was 
performed 48 h after transduction. All cell lines were cultured in defined 
keratinocyte serum-free medium (SFM) (Life Technologies, Breda, The Netherlands) 
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containing 5ng/ml EGF and 50ng/ml bovine pituitary extract, 100 U/mL penicillin, 
100 μg/mL streptomycin, 2 mmol/L L-glutamine (Life Technologies) and 80 μg/ml 
geneticin (Life Technologies) at 37°C and 5% CO2. Splitting dates and dilutions were 
noted to determine proliferation characteristics. Exponentially growing cells were 
harvested by trypsinization. Genomic DNA was isolated from cell pellets by 
proteinase K digestion followed by UltraPure
TM
 Phenol:Chloroform:Isoamyl Alcohol 
(Life Technologies) extraction as described previously [38].  
An overview of the various cell lines and passages used in the different experiments 
is given in Supplementary Table 1. 
 
Phospho-histone H2A.X (γ-H2A.X) immunofluorescence staining  
Cells were grown in chamber slides (Nunc), washed with PBS and pre-
permeabilized with 0.25% Triton X-100 in PBS (1 min on ice). Cells were fixed with 
4% paraformaldehyde/PBS (15 min at room temperature) and permeabilized with 
0.5% Triton X-100 in PBS (10–20 min at room temperature). Unspecific binding sites 
were blocked with 10% BSA/PBS for 1 h at room temperature. Slides were 
incubated for 2 h at room temperature with anti-phospho-Histone H2A.X 
(Millipore, clone JBW301, 1:1000) in blocking buffer and excess antibody was 
removed by four washing steps with 0.2% Triton X-100/PBS. Slides were then 
incubated with secondary antibody labeled with Alexa 488 (Invitrogen, 1:1000) and 
DAPI (1:1000) for 1 h at room temperature. Finally, slides were washed four times 
with 0.2% Triton X-100/PBS and embedded in vectashield (Vector laboratories, UK). 
Slides were analyzed with a fluorescent microscope (DM5000, Leica). Experiments 
were performed in duplicate and the percentage of phospho-histone H2A.X 
positive cells was scored from digitized images using constant light intensities. 
Approximately, 100-200 cells per duplicate were counted and scored for γ-H2A.X 
positivity. 
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ArrayCGH analysis and pre-processing 
Labeling and hybridization to the 2x105K arrayCGH platform (Agilent Technologies, 
Palo Alto, USA) was performed as described previously [29]. Downstream analysis 
was performed and plots were made using the statistical programming language R 
version 3.0.1. Log2-ratios of signal intensities between sample and reference for 
every probe were median-normalized and post-segmentation mode normalization 
was performed [39]. The arrayCGH data has been made available through the Gene 
Expression Omnibus (GEO;http://www.ncbi.nlm.nih.gov/projects/geo/) through 
series accession number GSE72063 
 
Paired-end and Mate-pair sequencing and Structural Variant detection 
Whole genome low-coverage short insert size library preparation was performed 
using the NEBNext Ultra DNA Library Prep Kit (New England Biolabs) and long-range 
(4422 bp insert size) mate-pair library preparation was done using the Nextera 
Mate Pair Sample Prep Kit (Illumina Inc.), both according to the manufacturer’s 
protocol. Sequencing was performed on Illumina HiSeq instruments to an average 
3x spanning coverage for short insert size paired-end and 38x spanning coverage 
for mate-pair, with the raw length of the reads displaying a median of 101bp. 
Structural variants larger than 5,000 bp were detected using the DELLY tool [40], as 
previously described [41]. DNA copy number analysis was performed using 
qDNAseq [42]. The sequencing data has been made available through the European 
Nucleotide Archive (ENA; http://www.ebi.ac.uk/ena; dataset ID: PRJEB9176.) 
 
Statistical analysis 
The χ
2
-test as available in the R-package CGHtest was used to determine possible 
differences between chromosomal profiles of cell lines with a high immortalization 
capacity and cell lines with a low immortalization capacity [43]. The test includes a 
permutation-based false discovery rate (FDR) correction for multiple testing. 
Differences were considered to be significant if the FDR was <0.10. 
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Supplementary Table 1. Overview of HPV-transduced cell lines and passages used 
for γ-H2A.X staining and arrayCGH, presence of 5p gain and onset of hTERT mRNA 
expression 
Donor 
HPV 
type 
crisis 
yH2Ax 
(passage 
number) 
arrayCGH 
mortal 
(passage 
number) 
Array CGH 
immortal 
5p gain in 
immortal 
cells 
Onset 
hTERT 
mRNA 
expression* 
I 16 NO p16 p15 p40 NO Early 
 18 NO p20 p17 p45 NO Early 
 31 NO p27 p16 p45 NO Early 
 33 NO p21 p17 p46 NO Early 
 35 NO p18 p15 p45 NO Late 
 45 YES p19 p25 p45 YES Late 
 51 YES p13 p15 p46 YES Late 
 59 YES p18 p17    
 66 YES p34 p12 p45 NO Late 
 70 YES p12 p15 p45 NO Middle 
(p15) 
II 16 NO   p45 NO Early 
 18 NO   p45 NO  
 31 NO   p40 NO Late 
 35 NO   p45 NO Early 
 45 YES
†
  p20    
 51 YES
†
  p14    
 59 YES  p15 p45 YES Early 
 66 YES  p13 p45 YES Late 
 70  YES  p15 p45 YES Late 
III 33 NO   p45 NO Early 
 35 NO   p45 NO Late 
 45 YES
†
  p19    
 51 YES
†
  p15    
 59 YES  p15 p45 NO Early 
 70 YES  p14 p45 YES Late 
† no immortalization 
*Early:passage 7-10; Late: passage ≥25 
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SUMMARY AND GENERAL DISCUSSION  
A persistent infection with certain types of the human papillomavirus (HPV) has 
been causally associated with the development of cervical cancer, as well as a 
subset of other anogenital and head-and-neck cancers [1]. So far, more than 150 
HPV types have been discovered that either infect the skin or mucosa and can 
cause warts, condylomas or cancer. Based on epidemiological data HPV types of 
the alpha genus (HPV types that infect the mucosa) are classified as high-risk 
(hrHPV) (i.e. HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59: IARC group 1, 
frequently found in cervical cancers), probable/ possible hrHPV (i.e. HPV 26, 53, 66, 
67, 68, 70, 73 and 82: IARC group 2A/B, infrequently found in cervical cancers) and 
low-risk HPV (e.g. HPV6 and 11, associated with low-grade cervical lesions or 
condyloma) [2].  
At present HPV type specific cancer risks and precancer risks (i.e. high grade 
cervical intraepithelial neoplasia; CIN2/3) have been assessed based on 
epidemiologic data [2]. However, the actual oncogenic risk of low prevalent types is 
still undefined and the precise mechanisms underlying HPV-induced carcinogenesis 
are still not fully understood. Research on the most prevalent types HPV16 and 
HPV18 has revealed that deregulated expression of the viral oncogenes E6 and E7 
in the dividing basal cells of the epithelium is a main driver of malignant 
transformation. However, the mechanisms underlying E6 and E7 deregulation are 
still unclear, and may involve DNA methylation of viral regulatory sequences as is 
subject of Chapter 2. Next to altered viral oncogene expression, additional 
alterations in the host cell genome are required to develop invasive cervical cancer. 
To what extent viral oncogenicity and the required additive host cell alterations are 
HPV type dependent is currently largely unknown.  
To study the temporality and accumulation of such host cell alterations the use of 
in vitro models has proven to be very useful [3-5]. Most studies focused on HPV16 
and 18, and limited data exists on other hrHPV types, in particular the 
probable/possible hrHPV types. Therefore, as part of this thesis in vitro models 
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containing common hrHPV and less prevalent probable/possible hrHPV were 
generated to study their immortalization capacity and the epigenetic and genetic 
aberrations that contribute to the immortalization process (Chapters 3 to 5).  
 
Deregulated expression of E6 and E7 in the dividing basal cells marks the onset of 
malignant transformation. Expression of E6 and E7 is regulated through an 
upstream promoter and enhancer region, known as long control region (LCR). 
During the normal course of viral infection the E2 gene regulates E6 and E7 
expression. E2 can bind to four E2 binding sites (E2BS) that reside in the LCR, which 
results in E6 and E7 repression [6, 7]. Consequently, upon inactivation of the E2 
gene, expression of E6 and E7 is altered. Inactivation of E2 can either occur by 
disruption of E2 upon integration of the viral genome into the host cell genome [8], 
by inhibition of E2 binding to E2 binding sites (E2BS) upon DNA methylation of CpG 
dinucleotides within the E2BS [9, 10] or by deregulated transcription factor binding 
and activity [11].  
In Chapter 2 we developed a novel methylation detection method based on 
Methylation-independent PCR (MIP) in combination with the Luminex® xMAP™ 
system to determine the frequency of E2BS methylation in HPV16-positive high-
grade CIN lesions (CIN3) and squamous cell carcinoma (SCC). With the use of MIP, 
DNA was amplified independent of its methylation status. Subsequently, the 
Luminex® xMAP™ system was used to distinguish methylated and unmethylated 
CpGs in E2BS1, E2BS3 and E2BS4. The Luminex® xMAP™ system was very sensitive 
with a limit of detection of 0,5- 1% methylated DNA in a background of 
unmethylated DNA. We found that the frequency of E2BS methylation was 
significantly higher in SCC compared to CIN3 and normal controls. When combining 
methylation results of E2BS1, E2BS3 and E2BS4 all SCC (100%) were methylation 
positive, compared to 58% of the CIN3 and 24% of the controls. Of the three E2BSs 
analyzed, particularly methylation of E2BS3 occurred proportional to severity of 
cervical disease and provided the best distinction between controls (6% positive), 
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CIN3 (47% positive) and SCC (90% positive), and may provide a good indicator of 
disease progression. Interestingly, whereas the far majority of CIN3 lesions show 
diffuse p16INK4A staining [12], reflecting a transforming HPV infection (i.e. 
deregulated E6 and E7 expression in dividing cells) and onset of malignant 
transformation [1], E2BS methylation was detected in only half of CIN3 lesions. This 
indicates that next to DNA methylation of E2BS, also other mechanisms may 
contribute to E6/E7 mRNA expression deregulation (see Discussion below).  
 
Following a transforming HPV infection, the acquisition of an immortal phenotype 
represents a key oncogenic event driving subsequent malignant transformation, 
HPV16- and 18-induced immortalization is characterized by the activation of 
telomerase upon upregulation of its catalytic subunit hTERT. These markers of 
immortalization have been detected in a subset of CIN3 lesions and the far majority 
of cervical carcinomas, underlining its importance in cervical carcinogenesis [13]. 
To study the immortalization capacity of various high-risk as well as 
probable/possible hrHPV types and to unravel the accompanying host cell 
alterations novel longitudinal in vitro models have been developed in Chapter 3. To 
this end, retroviral constructs containing two possible/probable high-risk (HPV66 
and 70) and nine hrHPV types (HPV16, 18, 31, 33, 35, 45, 51, 52 and 59) E6/E7 open 
reading frames were transduced to primary human foreskin keratinocytes (HFK) 
isolated from two to three independent donors. Cells were monitored for their 
growth behavior in culture, their capability to degrade the tumor suppressors p53 
and pRb, their ability to activate telomerase and to differentiate on organotypic 
raft-cultures. One low-risk HPV type (HPV11) and the empty vector were included 
as controls. Differential immortalization capacities between the HPV types were 
observed in which closely related types (HPV16, 31, 33 and 35 and to a lesser 
extent HPV18) showed the highest growth promoting activities early during the 
immortalization process. HPV45, 51, 59, 66 and 70 were less efficient in inducing 
immortalization by showing a strong crisis period prior to immortalization. HPV52 
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invariably induced an extended lifespan, but failed to induce immortalization. The 
differential immortalization capacities were associated with an early onset of 
hTERT expression in the cell lines transduced with the more efficient HPV types and 
better degradation of p53 by E6 compared to the less efficient HPV types. The 
observation that p53 degradation was less prominent in HPV51, 52, 66 and 70 cell 
lines may indicate that p53 can still be activated in response to DNA damage and 
other cellular stresses and thereby contribute to the induction of crisis [14].  
 
The observed crisis period prior to immortalization in HPV45-, 51-, 59-, 66- and 70-
transduced cells may suggest that these cells require more additional (epi)genetic 
hits in host cell genes to acquire an immortal phenotype. Alternatively, the timing 
of these events may differ between cells transduced with HPV16, 18, 31, 33 and 35 
versus cells transduced with HPV 45, 51, 59, 66 and 70, thereby evading a crisis 
period upon E6/E7 expression of the more oncogenic types. To study these 
hypotheses epigenetic and genetic events during immortalization were studied in 
Chapter 4 and Chapter 5, respectively. 
Epigenetic events associated with HPV-induced cervical carcinogenesis include 
promoter DNA methylation of various host cell genes, that often result in silencing 
of the respective genes. Frequently methylated genes in cervical cancer include 
APC, CADM1, CYGB, FAM19A4, hTERT, miR124-1, miR124-2, miR124-3, MAL, 
PHACTR3, PRDM14, RASSF1A, ROBO3, and SFRP2 (for reviews see refs. [1, 15-17]). 
For CADM1, hTERT, MAL, miR124, PRDM14 and SFRP2 a functional role of 
methylation-mediated gene silencing in HPV-induced transformation could be 
demonstrated [18-23]. In Chapter 4 we investigated HPV16, 18, 31, 33, 45, 66 and 
70 containing cell lines for the onset of DNA methylation of 14 (tumor suppressor) 
genes (APC, CADM1, CYGB, FAM19A4, hTERT, miR124-1, miR124-2, miR124-3, MAL, 
PHACTR3, PRDM14, RASSF1A, ROBO3, and SFRP2) during immortalization. Various 
passages (from pre-immortal to late immortal passages; passages 15 to 80) were 
analyzed using quantitative methylation specific PCR (qMSP). It was found that the 
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onset of methylation occurs at early passages and both methylation levels and 
number of genes targeted by methylation increase with passaging. Methylation of 
hTERT, miR124-2 and PRDM14 was already evident at low levels in stage 1 (pre-
immortal) cells followed by ROBO3 in stage 2 (early immortal) cells and CYGB at 
stage 3 (middle immortal). In stage 4 (late immortal) cells FAM19A4, MAL, 
PHACTR3 and SFRP2 methylation became additively apparent. For most genes, the 
onset and level of methylation was not related to the growth behavior of the cell 
lines in culture. Only hTERT showed significantly increased methylation levels at 
stage 2 in cells that just escaped crisis (HPV 45, 66 and 70). HTERT has previously 
been shown to be activated by DNA methylation [19, 24-27]. Consequently, 
increased methylation of hTERT at stage 2 in cells immortalized by the less 
oncogenic types may have contributed to hTERT upregulation, resulting in 
telomerase activation and the acquisition of an immortal phenotype. The lower 
hTERT methylation levels at stage 2 in cells showing a continuous growth was 
associated with an early onset of hTERT expression (see Chapter 3) which may be 
initiated by the E6 genes itself, as has previously been shown by van Doorslaer et 
al. [28]. At stage 3 the difference in hTERT methylation between cells with and 
without a crisis leveled off. Bisulfite sequencing confirmed increased methylation in 
immortal cells compared to controls, with the transcription core and known 
repressor sites remaining largely unmethylated.  
 
In Chapter 5 we investigated the chromosomal aberrations in relation to the 
differential immortalization capacities. Chromosomal profiling using array 
comparative genomic hybridization (arrayCGH) of our in vitro models showed an 
increase in the number of chromosomal aberrations with progression from the 
mortal to the immortal stage. Interestingly, immortal cells of cell lines that 
encountered a crisis period (HPV45, 51, 59, 66 and 70-immortalized cells) showed a 
significantly higher number of chromosomal gains compared to cell lines that 
showed a continuous growth (HPV16, 18, 31, 33, 35-immortalized cells). Thus, the 
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higher immortalization capacities of HPV16, 18, 31, 33 and 35 are not related to 
increased numbers of chromosomal abnormalities. Instead, if functionally essential, 
increased numbers of chromosomal aberrations are likely to be required to induce 
immortalization by less oncogenic types. Such a HPV type dependent number of 
chromosomal aberration has also previously been described in high-grade CIN 
lesions [29]. Chromosomal aberrations leading to a gain of an oncogene or a loss of 
a tumor suppressor gene, may provide a growth advantage in culture and 
contribute to the immortalization process. One interesting observation in our cell 
line models was the detection of gains at 5p, encoding both the DROSHA and the 
hTERT genes, exclusively in cell lines that encountered a crisis period. Furthermore, 
the differential number of chromosomal abnormalities could not be explained by 
differential induction of DNA double strand breaks by E6 and E7 expression. 
Preliminary data on the mutation analysis of 48 cancer genes indicated that 
somatic mutations are extremely rare (data not shown). Therefore, we propose 
that HPV type dependent immortalization capacity, as reflected by differential 
growth behaviors of HPV-transduced HFKs, is particularly associated with variability 
in CNA, in which CNA aberrations are likely to provide a growth advantage and 
enable the bypass of crisis. 
 
Discussion and Future Perspectives 
As outlined above the results described in this thesis have largely enhanced our 
current understanding of HPV-mediated transformation, both with respect to DNA 
methylation-mediated regulation of viral gene expression as to HPV type-
dependent capacities and mechanisms of in vitro immortalization. A summary of 
the results obtained by the in vitro studies is shown in Figure 1.  
Deregulated viral oncogene expression drives HPV-induced transformation and 
constitutes a hallmark of many high-grade CIN lesions, also referred to as 
transforming CIN lesions. Aberrant E7 activity in dividing cells is characterized by 
diffuse p16INK4A staining and virtually all CIN3 lesions are p16INK4A positive [12]. 
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The findings described in Chapter 2 on E2BS methylation indicate that next to DNA 
methylation of E2BS, as was detected in 58% of CIN3 lesions, other mechanisms are 
likely to contribute to E6/E7 deregulation in CIN3 lesions. For the subset of 
transforming CIN3 lesions in which E2BS methylation seemingly did not contribute 
to E6/E7 deregulation altered transcription factor binding or activity and/or viral 
integration could be involved. With respect to the latter one, previous studies have 
shown that cervical specimens, including CIN3 and SCC, with episomal viral DNA 
generally show higher methylation levels compared to specimens that contain a 
single copy of integrated HPV DNA [30, 31]. In case of cancer cells with multiple 
integrated viral copies, as is seen in CaSki cells, E6/E7 expression is fine-tuned by 
high methylation levels resulting in non-actively transcribed copies [32]. With 
respect to our study it would be interesting to analyze whether in the CIN3 lesions 
with high E2BS3 and E2BS4 methylation levels viral DNA is present as an episome 
or as multiple copies integrated DNA. Lesions with relatively low methylation levels 
at both E2BSs may contain integrated HPV at single or low copy numbers.  
Concerning altered transcription factor binding and activity, previous studies have 
shown that the E2 protein can regulate E6/E7 expression by complex formation 
with multiple cellular proteins [11, 33]. These cellular proteins are required to 
maximize E2-mediated repression. Some of these proteins are known for their 
ability to remodel chromatin, suggesting that the chromatin microenvironment 
surrounding the LCR is important for E6/E7 regulation. Future studies may be 
directed towards samples without integrated viral DNA and in which methylation of 
the E2BSs is not detected to better characterize which alternative mechanisms may 
contribute to deregulated E6/E7 expression. Additionally, it may be interesting to 
compare LCR interacting factors in productive and transforming infections either or 
not in context of methylated E2BS. Recently, a still unknown protein has been 
detected that is able to bind to methylated E2BS1 and thereby results in a strong 
activation of the HPV promoter [34].  
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The new concept on cervical carcinomas arising from viral infection of embryonal 
squamo-columnar-junction (SCJ) cells may imply that in the absence of 
differentiation of this particular cell population, the need for viral promoter 
deregulation is circumvented and that these cells express E6/E7 at sufficiently high 
levels to induce transformation. In fact, expression of viral oncogenes in these SCJ 
has recently been described [35]. In line with these findings it would be of major 
interest to study viral promoter regulation in cuboidal embryonal SCJ cells versus 
metaplastic cells of the transformation zone.  
The data presented in Chapters 3 to 5 was based on cell line models that were 
created by retroviral expression of the viral oncogenes E6 and E7. Consequently, 
the level of viral oncogene expression may be above physiological levels when 
regulated by the natural promoter. Therefore, we cannot exclude that the 
immortalization efficiencies observed may be somewhat overstated or that subtle 
differences between HPV types may not be noticed using this approach. Similarly, 
the potential contribution of other viral genes such as E2 and E5 to HPV-induced 
immortalization remains undetermined. E2 has recently been suggested to possess 
oncogenic functions [36] and E5 has been shown to interact with the epidermal 
growth factor receptor (EGFR), which leads to cell proliferation (reviewed by [37]).  
Furthermore, although no differences in immortalization efficiencies have 
previously been found for the HPV types 11, 16, 18 and 31 in different cell types 
like primary human cervical, tonsillar, and foreskin keratinocytes [38], this may still 
be the case for less oncogenic types and may in part explain the differences in HPV 
type distributions amongst cancers at the various sites [2]. Our cell line models 
were created by transduction of human foreskin keratinocytes, rather than cervical 
epithelial cells. Given the new concept that infection of squamous columnar 
junction (SCJ) cells in the cervix is most likely to give rise to cervical carcinomas, 
future studies should draw attention to the analysis of HPV-induced 
immortalization in these cells. However, the low number of SJC cells in normal 
cervical tissue biopsies implies that this may be a technically demanding effort.  
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The data presented in Chapter 3 to 5 from our cell line models provides an 
excellent basis for future studies to better understand HPV type specific cervical 
carcinogenesis. Moreover, the cell line models may contribute to the discovery of 
markers for the early detection of cervical cancer or the development of an HPV 
type specific therapy. In Chapter 4 we studied the onset of DNA methylation of 
candidate tumor suppressor genes. For most genes methylation of their promoter 
region in cervical carcinomas and CIN3 lesions has been well established (reviewed 
by [1]), however little to no data exist for ROBO3 and CYGB. The results described 
in Chapter 4, showed that methylation of both ROBO3 and CYGB are common 
events that occur early in the transformation process. In follow up of these findings 
we determined their methylation patterns in cervical tissue specimens (W. Verlaat, 
unpublished results). For both genes methylation levels increased with progression 
of disease, with ROBO3 and CYGB methylation being detected in respectively 81% 
and 38% of cervical squamous cell carcinoma (SCC). This data shows that the newly 
created cell line models may offer valuable tools to define epigenetic changes 
associated with HPV-induced carcinogenesis that may applied for early detection of 
HPV-induced cancers. 
Furthermore, our data presented in Chapter 5 opens the door for further 
functional analysis. Regions found to be more often altered in cell lines that 
encountered a crisis period may harbor putative tumor suppressor genes or 
oncogenes, including both protein encoding genes and miRNAs, that are involved in 
HPV-induced immortalization. Candidate cancer genes, such as hTERT and DROSHA, 
located at the 5p locus that is frequently gained in cells that encountered a crisis 
period, may be studied by gene or epigenetic editing techniques and thereby reveal 
their (potentially yet unknown) role in HPV-mediated transformation. Recent 
studies have for example shown that hTERT has extra-telomeric functions that 
contribute to immortalization [39]. 
In addition, these model systems enable the analysis of viral-host interactions that 
either or not may be HPV type specific. Previous studies by Rozenblatt-Rozen et al. 
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[40] and White et al. [41, 42] showed that next to common viral E6/E7-host protein 
interactions also HPV type specific or genus-specific viral-host protein interactions 
exist (reviewed in [43]).  
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Figure 1: Schematic representation of the novel insights obtained in this thesis from our comparative 
analysis of primary human foreskin keratinocytes (HFK) of two to three donors transduced with eleven 
(probable/possible) hrHPV types. Four groups could be discerned based on their immortalization 
characteristics; 1) the control cell lines (untransduced HFK, empty vector/LZRS and low-risk HPV11) that 
senesced at the first proliferative lifespan barrier and, showed no degradation of the tumor suppressors 
p53 and pRB, had no hTERT expression, no substantial DNA methylation, no chromosomal aberrations 
(CNA) and only few cells stained positive for γH2AX, a marker of DNA-double strand breaks. 2) HFKs 
transduced with HPV52 that entered an extended lifespan, but did not become immortal. These cell 
lines showed slight p53 and pRB degradation, no hTERT expression, increased γH2AX staining and some 
CNA at the pre-immortal stage. 3) HFKs transduced with HPV45, 51, 59, 66 and 70, that became 
immortal following a long and strong crisis period. At early passage all cells showed a high number of 
DNA double stand breaks. With exception of HPV59 these cell lines showed some p53 degradation and 
more pRB degradation, and hTERT expression was evident following immortalization. In these cells 
hTERT methylation was already evident in pre-immortal cells, but increased in immortal cells and was 
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accompanied by a high number of CNA in immortal cell lines. 4) HPV16-, 18-, 31-, 33- and 35-transduced 
HFKs. These cell lines were characterized a high number of DNA double strand breaks (similar to group 
3) and by more p53 degradation compared to pRB degradation and low hTERT expression in pre-
immortal cells. In immortal cells hTERT expression was increased and accompanied by hTERT 
methylation. Compared to group 3 cells the frequency of CNA in immortal cells was still relatively low.  
In both group 3 and group 4 DNA methylation of the 14 evaluated genes increased with passaging, but 
except for hTERT methylation at early immortal passages (stage 2; see Chapter 4), no significant 
differences were observed between both groups. 
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Hoe epitheelcellen onsterfelijkheid worden: Moleculaire karakterisering van 
in vitro immortalisatie door verschillende HPV types 
Baarmoederhalskanker, alsook een deel van de andere anogenitale en hoofd-hals 
tumoren, wordt veroorzaakt door infectie met het humaan papillomavirus (HPV). 
Tot op heden zijn er meer dan 150 verschillende HPV types ontdekt. HPV infecteert 
epitheelcellen van de slijmvliezen of de huid en afhankelijk van het HPV type kan 
dit leiden tot de ontwikkeling van (genitale) wratten of kanker. Van de HPV types 
die met baarmoederhalskanker geassocieerd zijn, is bekend dat ze niet allemaal 
hetzelfde risico voor het ontstaan van kanker met zich meebrengen. HPV types die 
vaak in baarmoederhalskanker worden gevonden, zoals HPV16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58 en 59, worden als hoog-risico types (hrHPV) geclassificeerd. 
Andere types zoals HPV 26, 69, 82, 30, 53, 66, 68, 70, 73, 85, 97 en 67 worden 
minder vaak of zeer zelden in baarmoederhalskanker aangetroffen, maar komen 
wel vaker voor in voorloperlaesies van kanker. Van deze types is het risico om 
kanker te ontwikkelen niet duidelijk, en daarom worden deze HPV types als 
mogelijk hoog-risico types geclassificeerd. HPV types die alleen met genitale 
wratten zijn geassocieerd, zoals HPV6 en 11, worden als laag-risico types 
beschouwd. 
Bij de meeste infecties wordt het virus vanzelf door het immuunsysteem geklaard, 
zonder enige nadelige consequenties. Als een infectie echter persisteert kan er na 
een periode van wel 10 tot 30 jaar baarmoederhalskanker ontstaan. De 
ontwikkeling van baarmoederhalskanker verloopt via voorloperlaesies, de 
zogeheten cervicale intra-epitheliale neoplasieën (CIN). Deze worden op basis van 
de ernst van de afwijking in drie gradaties ingedeeld, waarbij CIN1 als een 
laaggradige en CIN2 en CIN3 als hooggradige afwijkingen gezien worden. Tot op 
heden is het risico dat individuele HPV types geven op de ontwikkeling van 
baarmoederhalskanker en hooggradige voorloperlaesies (CIN2/3) alleen op basis 
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van epidemiologische data bekend. Het kanker-risico van minder vaak 
voorkomende HPV types is daardoor nog steeds onduidelijk en ook is onbekend 
hoe deze HPV types kanker veroorzaken. De meeste studies naar het ontstaan van 
baarmoederhalskanker door HPV zijn gebaseerd op de twee meest voorkomende 
types in baarmoederhalskanker, HPV16 en 18. Uit deze studies is gebleken dat 
wanneer de expressie van de zogenaamde virale oncogenen (kanker-inducerende 
genen) E6 en E7 ontregeld is en E6 en E7 in delende cellen tot expressie komen de 
celdeling verstoord raakt. Deze ontregelde expressie kan leiden tot de ontwikkeling 
van hooggradige voorloperlaesies en in zeldzamere gevallen tot kanker. Waarom 
E6 en E7 in deze gevallen in delende cellen tot expressie komt is nog deels 
onbekend en is daarom in hoofdstuk 2 onderzocht. Voor het ontstaan van 
baarmoederhalskanker zijn naast ontregeling van virale oncogenen ook 
veranderingen in het genoom van de geïnfecteerde cel noodzakelijk. Tot op heden 
is het nog onbekend in hoeverre de genomische veranderingen die in tumoren 
worden gevonden afhankelijk zijn het specifieke HPV type dat aanwezig is. 
Om dit te onderzoeken kan gebruik gemaakt worden van in vitro cellijn-modellen. 
Voor het onderzoek beschreven in dit proefschrift zijn cellijnen ontwikkeld die de 
virale oncogenen E6 en E7 van verschillende hoog-risico (hr) en mogelijk hrHPV 
types bevatten. Wij hebben onderzocht of deze cellen het vermogen krijgen om 
oneindig te delen (onsterfelijk of immortaal worden) en of dit samenhangt met 
veranderingen in bepaalde genen van de cel zelf (hoofdstuk 3). In hoofdstuk 4 en 5 
zijn de veranderingen in het genoom van de cellen onderzocht.  
De E2 bindingssequenties (E2BS) van HPV16 zijn vaak gemethyleerd in 
baarmoederhalskanker  
In eerste instantie hebben wij onderzocht waardoor de expressie van de virale 
genen E6 en E7 gedereguleerd raakt. Het was reeds bekend dat het uitschakelen 
van het virale eiwit E2 hier een rol bij speelt. E2 kan op twee verschillende 
manieren uitgeschakeld worden: 1) door integratie van het virale genoom in het 
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humane genoom, en 2) door methylering van bepaalde locaties in het hrHPV 
genoom (zogenaamde E2 bindingssequenties (E2BS)). Bij dit proces wordt er een 
methylgroep (-CH3) aan één van de bouwstenen van het DNA gekoppeld (CpG), 
waardoor de DNA structuur verandert.  
 In hoofdstuk 2 hebben wij DNA methylering van drie E2BS in het HPV16 genoom 
bepaald in zowel weefselbiopten als uitstrijkjes. Hiervoor hebben wij een nieuwe 
techniek ontwikkeld die gebaseerd is op een combinatie van een Methylering-
Specifieke Independent PCR (MIP) en het Luminex xMAP
TM
 systeem. Wij hebben 
aangetoond dat deze techniek uiterst gevoelig is en 0,5-1% gemethyleerd DNA in 
een achtergrond van niet gemethyleerd DNA kan detecteren. Alle onderzochte 
tumoren waren positief voor methylering van tenminste één van de drie 
onderzochte E2BS, tegenover 58% van de hooggradige voorloperlaesies en 24% van 
de controles. Onze resultaten geven aan dat methylering van de E2BS relatief laat 
optreedt tijdens het ontstaan van baarmoederhalskanker en dus waarschijnlijk niet 
de oorzaak is van E6 en E7 deregulatie. Desondanks zou methylering van de E2BS 
wel als biomarker voor de vroegdetectie van baarmoederhalskanker gebruikt 
kunnen worden. Hierbij is E2BS3 het meest veelbelovend, aangezien slechts 6% van 
de normale controles methylering liet zien op deze locatie, tegenover 47% van de 
hooggradige voorloperlaesies en 90% van de tumoren.  
Immortalisatie van epitheelcellen is HPV type afhankelijk 
Bij het ontstaan van kanker na een infectie met HPV is het onsterfelijk (immortaal) 
worden van epitheelcellen een hele belangrijke eerste stap. Gezonde cellen hebben 
een beperkte levensduur doordat bij elke celdeling de chromosoomuiteinden 
(telomeren) korter worden. Te korte telomeren leiden ertoe dat de cel stopt met 
delen en er een proces van zelfdoding geactiveerd wordt. Kanker cellen zijn 
onsterfelijk doordat het enzym telomerase actief is, waardoor de telomeren weer 
verlengen en de cellen kunnen blijven delen. Telomerase wordt geactiveerd door 
verhoogde expressie van het hTERT gen.  
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In hoofdstuk 3 hebben wij cellijnmodellen ontwikkeld, om het vermogen te 
onderzoeken van verschillende hoog-risico en mogelijk hoog-risico HPV types om 
immortalisatie te induceren in gezonde cellen. Hiervoor hebben wij de virale 
oncogenen E6 en E7 van twee mogelijk hrHPV types (HPV66 en HPV70) en negen 
hrHPV types ( 16, 18, 31, 33, 35, 45, 51, 52 en 59) in gezonde voorhuidcellen 
ingebracht. Om persoons afhankelijke invloeden uit te sluiten, zijn er cellen van 
twee tot drie verschillende donoren gebruikt. Na het inbrengen van de virale 
oncogenen hebben wij het groeipatroon van de cellen geanalyseerd. Daarnaast is 
ook het vermogen van de virale genen E6 en E7 om de tumorsuppressorgenen p53 
en pRb, die normale celgroei controleren, uit te schakelen. Verder zijn de 
hierboven beschreven kenmerken van immortalisatie, te weten hTERT opregulatie 
en telomerase activatie onderzocht. Een laag-risico HPV type (HPV-11) en de lege 
vector zijn meegenomen als negatieve controles. De verschillende cellijnen lieten 
verschillen in groei zien, waarbij cellen met HPV16, 31, 33, 35 en HPV18 in iets 
mindere mate, constant door bleven groeien. Cellen met HPV45, 51, 52, 59, 66 en 
70 kwamen na een fase van verlengde groei in een fase terecht met veel celdood 
en weinig groei, de zogenaamde crisis fase. Na deze fase groeiden in de meeste 
gevallen immortale cellen uit. Uitzonderingen, waarbij geen immortalisatie 
plaatvond, waren twee van de drie HPV45-bevattende cellijnen, een van de drie 
HPV51-bevattende cellijnen en alle drie de HPV52-bevattende cellijnen. De 
verschillen in immortalisatie capaciteit bleken geassocieerd met een vroege 
opregulatie van hTERT expressie en een betere afbraak van p53 door E6 in de 
cellijnen die geen crisis ondergingen (cellen met HPV16, 18, 31, 33, en 35).  
Samenvattend heeft deze studie aangetoond, dat de geteste HPV types verschillen 
in hun vermogen om epitheelcellen te immortaliseren. Teven is aangetoond, dat de 
mogelijk hoog-risico HPV types 66 en 70 wel degelijk de potentie hebben om 
kanker te veroorzaken. 
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HPV type specifieke immortalisatie is onafhankelijk van DNA methylering 
Het feit dat er ondanks een lange crisisperiode immortale cellen uitgroeiden bij de 
HPV types 45, 51, 59, 66 en 70 geïnfecteerde cellen, suggereert dat in deze cellen 
additionele (epi)genetische veranderingen betrokken zijn bij immortalisatie. 
Anderzijds kan het moment waarop deze DNA veranderingen optreden variëren 
tussen cellen zonder crisis (met HPV16, 18, 31, 33 en 35) en cellen met crisis (met 
HPV 45, 51, 59, 66 en 70). Hierdoor zou bijvoorbeeld een crisisperiode bij infectie 
met meer oncogene HPV types (i.e. HPV16, 18, 31, 33 en 35) voorkomen kunnen 
worden. In hoofdstuk 4 is onderzocht in hoeverre epigenetische veranderingen, 
zoals DNA methylering van humane genen, betrokken is bij immortalisatie door de 
verschillende HPV types. Hiervoor zijn als uitgangspunt genen onderzocht die vaak 
in baarmoederhalskanker gemethyleerd zijn, namelijk APC, CADM1, CYGB, 
FAM19A4, hTERT, miR124-1, miR124-2, miR124-3, MAL, PHACTR3, PRDM14, 
RASSF1A, ROBO3, en SFRP2. Van deze genen is voor CADM1, hTERT, MAL, miR124, 
PRDM14 en SFRP2 aangetoond dat ze een directe rol spelen bij het ontstaan van 
baarmoederhalskanker. De verschillende cellijnen zijn op vier verschillende stadia 
(mortaal tot laat immortaal) tijdens hun immortalisatie-proces onderzocht op 
methylering. Over het algemeen bleek dat methylering al vroeg optrad en er een 
progressieve toename was van zowel de hoogte van methylering als van het aantal 
gemethyleerde genen. In mortale cellen (stadium 1) waren de genen hTERT, mirR-
124-2 en PRDM14 al verhoogd gemethyleerd in vergelijking met HPV-negatieve 
controles. Dit werd gevolgd door methylering van ROBO3 in vroege immortale 
cellen (stadium 2 cellen) en CYGB in middel immortale cellen (stadium 3). In late 
immortale cellen (stadium 4) namen wij ook verhoogde methylering waar van 
FAM19A4, MAL, PHACTR3 en SFRP2. Over het algemeen was er geen relatie tussen 
het groeipatroon (met of zonder crisis) van de HPV-geïnfecteerde cellen en het 
methyleringspatroon. Alleen hTERT liet een significant hogere methylering zien in 
stadium 2 (vroeg immortale) cellen die een crisisperiode hadden ondergaan. DNA 
methylering van hTERT leidt tot activatie van het gen en daarmee van telomerase. 
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Dit duidt erop dat methylering van hTERT in de cellijnen met minder oncogene HPV 
types (i.e. HPV 45, 51, 59, 66 en 70) heeft bijgedragen aan de immortalisatie van 
deze cellen. In de cellen die geen crisis hadden ondervonden was hTERT ook 
geactiveerd in stadium 2 cellen terwijl we weinig tot geen hTERT methylering 
vonden, wat suggereert dat in deze cellen hTERT direct door E6 geactiveerd zou 
kunnen zijn.  
De methylering van het hTERT gen in stadium 3 cellen is nog verder onderzocht 
met behulp van een specifieke sequencingtechniek (bisulfiet sequencing), die de 
methyleringsstatus van individuele CpG’s kan bepalen. Hiermee konden wij 
bevestigen dat er meer hTERT methylering is in HPV geïnfecteerde cellen 
vergeleken met de controles en ook dat de promoterregio die de expressie direct 
reguleert ongemethyleerd bleef. 
HPV-specifieke immortalisatie is afhankelijk van het aantal chromosomale 
afwijkingen  
In hoofdstuk 5 is de rol van genetische veranderingen bij HPV-geïnduceerde 
immortalisatie onderzocht. Genetische veranderingen betreffen onder andere 
mutaties, waarbij de genetische code verandert, of chromosomale afwijkingen, 
waarbij de hoeveelheid van het genetische materiaal (chromosomen) verandert. 
Met behulp van een zogenaamde hoog-resolutie chromosoom array (high-
resolution array comparative genomic hybridisation (arrayCGH)) zijn chromosomale 
afwijkingen onderzocht in mortale en immortale passages van de verschillende 
HPV-bevattende cellijnen. De immortale cellijnen vertoonden meer chromosomale 
afwijkingen dan de mortale voorlopercellen. Het was zeer interessant om te zien 
dat immortale cellen, die eerder een crisisperiode hebben gehad, meer 
chromosomale afwijkingen lieten zien dan de cellijnen zonder crisis. Hieruit blijkt 
dat de hogere immortalisatie capaciteit van HPV16, 18, 31, 33 en 35 niet 
geassocieerd is met meer chromosomale veranderingen. In plaats daarvan bleken 
chromosomale veranderingen juist nodig om immortalisatie te bewerkstellingen in 
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cellijnen die geïnfecteerd waren met minder oncogene HPV types. Dit impliceert 
dat de chromosomale veranderingen gebieden betreffen waar genen liggen die 
bijdragen aan de ontwikkeling van kanker (activatie van oncogenen) of die 
kankerontwikkeling remmen (uitschakelen van tumorsuppressorgenen). De 
chromosomale veranderingen leiden hierdoor tot een groeivoordeel en dragen 
daarmee bij aan het immortalisatieproces. Ook interessant was de observatie dat 
een toename van chromosoom 5 op de regio waar het hTERT gen ligt, alleen 
voorkwam in cellijnen die een crisis hadden ondergaan. De verschillen in 
chromosomale veranderingen tussen cellen met en zonder een crisis waren 
overigens niet het gevolg van een verschil in DNA breuken die direct door het virus 
worden veroorzaakt. Ook laten onze voorlopige onderzoeken zien dat mutaties in 
bekende kanker genen niet optreden tijdens immortalisatie.  
Hoofdstuk 6 beschrijft naast een samenvatting van voorgaande hoofdstukken ook 
een algemene discussie over de resultaten beschreven in het proefschrift en de 
mogelijkheden voor toekomstige studies en toepassingen. 
Samenvattend hebben de resultaten zoals beschreven in dit proefschrift tot nieuwe 
inzichten geleid in het ontstaan van baarmoederhalskanker door verschillende HPV 
types. Dit betreft met name de regulatie van de virale genexpressie door DNA 
methylering als ook HPV type afhankelijke mechanismen die bijdragen aan in vitro 
immortalisatie.  
Een ontregelde expressie van de virale oncogenen E6 en E7 is een eerste 
belangrijke stap voor het ontstaan van kanker en wordt al gezien in hooggradige 
voorloperlaesies. In hoofdstuk 2 toonden wij aan dat niet in alle hooggradige 
voorloperlaesies met ontregelde E6 en E7 expressie, deze verklaard kan worden 
door methylering van de onderzochte E2 bindingssequenties. In deze gevallen zou 
de ontregelde expressie van E6 en E7 mogelijk verklaard kunnen worden door 
andere mechanismen, zoals veranderde transcriptiefactorbinding en/of virale 
integratie. Methylering van de E2 bindingssequenties werd overigens wel gevonden 
in alle tumoren en lijkt dus belangrijk voor het ontstaan van kanker.  
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De resultaten beschreven in hoofdstuk 3 t/m 5 laten zien dat HPV types verschillen 
in hun capaciteit om epitheelcellen te immortaliseren. Dit uit zich in een groei met 
of zonder crisis, waarbij de cellen met een crisis meer chromosomale 
veranderingen laten zien. Deze chromosomale veranderingen leiden tot een 
groeivoordeel waardoor een deel van de cellen de crisis kunnen overwinnen. 
Andere DNA veranderingen zoals DNA methylering en DNA mutaties blijken niet 
geassocieerd te zijn met de verschillen in virale immortalisatie capaciteit. Al onze 
bevindingen zijn gebaseerd op cellijnmodellen waarbij de virale oncogenen E6 en 
E7 via een retrovirus tot expressie zijn gebracht. Hierdoor is de expressie van E6 en 
E7 mogelijk hoger dan in een natuurlijke situatie en wordt de immortalisatie 
capaciteit mogelijk overschat of worden subtiele verschillen uitgevaagd. Bovendien 
is in onze studies de mogelijke rol van andere virale genen niet onderzocht. Voor 
een meer fysiologische aanpak zouden in de toekomst primaire cellen met het hele 
HPV genoom geïnfecteerd kunnen worden. Ook is het interessant om naast de 
voorhuid epitheel cellen die nu gebruikt zijn, ook andere epitheel cellen zoals die 
van de baarmoederhals of het hoofd-hals gebied te testen. 
De hier ontwikkelde cellijnmodellen bieden een uitstekende basis voor 
toekomstige studies om beter inzicht in de ontwikkeling van 
baarmoederhalskanker door verschillende HPV types te verkrijgen. Bovendien 
kunnen de cellijnmodellen bijdragen tot de ontdekking van biomarkers voor de 
vroege opsporing van baarmoederhalskanker of de ontwikkeling van een HPV type-
specifieke therapie.  
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DANKWOORD 
Iedereen die mij kent, weet dat ik het liefst een dankwoord heel kort zou willen 
houden zoals met de woorden: Graag wil ik iedereen hartelijk bedanken voor de 
inzet om de promotie succesvol af te ronden en diegenen die van deze periode een 
onvergetelijk tijd hebben gemaakt! 
Desondanks zou ik toch een paar dankwoorden willen uitspreken. Maar zou ik toch 
iemand vergeten zijn bij naam te noemen, voel je alstublieft niet vergeten, want ik 
ben je zeker dankbaar voor de bijdrage en de kans je te hebben leren kennen. 
De meeste dank ben ik verschuldigd aan mijn copromotor, Renske. Je was tijdens 
mijn masterstages mijn begeleider. In mij zou het echt niet opgekomen zijn dat ik 
ooit zou promoveren, maar jij had er vertrouwen in en bood mij dit uitdagende 
project aan. Desondanks de provendusdip heb jij me met jouw entousiasme en 
optimisme ertoe kunnen zetten om toch hier mijn promotie te verdedigen. Net als 
mijn andere collega’s heb ik enorm veel respect en bewondering voor jou. Jij kan 
het drukke werk met je familie combineren. Naast sportverenigingen en 
oudercommissies kan jij nog rustig s’ avonds of op vakantie artikelen lezen en die 
van je promovendi corrigeren. Jij bent enthousiast als er goede resultaten worden 
behaald, maar je ziet ook positieve kanten aan minder mooie uitkomsten. Heel veel 
dank voor jouw interesse aan ook buiten werk gerelateerde aangelegenheden en 
alle hulp die je me tijdens het promotietraject hebt gegeven! 
Daarnaast wil ik mijn promotoren danken. Beste Chris, hartelijk bedankt dat ik 
onderzoek mocht uitvoeren op jouw afdeling. Bedankt dat ik de HumaVac 
vergaderingen bij mocht wonen, zodat ik wat meer klinische achtergrond op het 
gebied van cervixcarcinoom op kon doen. Eveneens bedankt ervoor dat ik aan de 
klinische HPV-015 studie mee kon werken. Wie had gedacht dat deze ervaring mij 
aan mijn huidige baan zou helpen. 
Peter, bedankt dat ik de kans heb gekregen om te promoveren. Met jou als 
promotor kwamen er altijd nog leuke discussies tijdens de werkbesprekingen. Ik 
dank jou ook voor je goede input om bij de stukken het puntje op de i te krijgen. 
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Ook mijn tweede co-promotor wil ik hartelijk danken. Gezien de fysieke afstand en 
de uiterst goede begeleiding door Renske heb ik niet erg veel beroep op jou hoeven 
te doen, maar ik wist dat je er voor mij zou zijn. 
Een hele grote dank gaat eveneens uit naar de leden van de leescommissie Jan, 
Bauke, Saskia, Tom, Leon en Ed. Bedankt voor de tijd en aandacht die jullie hebben 
besteed aan mijn proefschrift. Jan heel erg bedankt voor de kritische blik op het 
methyleingsstuk. Bauke, bedankt voor jouw kritische beoordeling van de 
introductie en het array-stuk. Saskia jou wil ik ontzettend bedanken voor jouw 
verfrissende input in al mijn stukken. Ik ben daarvan overtuigd, dat het 
methyleringsstuk hoofdzakelijk door jou mooie figuren meteen geaccepteerd werd. 
Ik wil natuurlijk ook de mensen van mijn groep bedanken voor alle gezelligheid. 
Leontien, mijn paranimf, jij was tijdens de hele promotie mijn rechter hand. Een 
echt werkwonder. Jij kon zoveel werk verzetten en met jou ervaring kon ik alles aan 
je vragen. Je was volhoudend (telomerase trap) en altijd gezellig. Wat hebben wij 
veel tijd samen in de celkweek doorgebracht en zo werd ik altijd op de hoogte 
gehouden van de softbalavonturen. Wat mis ik toch jou gezelligheid. Ik weet dat je 
met zwaar hart het CCA hebt verlaten, maar ik hoop dat jij een nieuwe leuke 
uitdaging in London hebt gevonden en jij je daar inmiddels goed thuis voelt. Heel 
veel succes met je verdere loopbaan.   
Suzanne, mijn ander paranimfje, jij bent samen met Jasmijn een maand later dan ik 
met je promotie begonnen. Je kwam naar Amsterdam en kende niemand, maar 
door jou open aard en omdat je er altijd voor iets in was om te doen, heb jij snel 
heel veel vrienden gevonden. Ik heb erg van de gemeenschappelijke tijd (Berlijn, 
Lausanne, Apenheul, E2BS project, CCA1.19 en alle uitjes en 
beachvolleybaltoernooitjes, etc.)  genoten. Verder heb jij tijdens de vier jaar op het 
CCA zoveel mee gemaakt (Opa, zus, vader van Bart) dat ik alleen maar kan zeggen, 
petje af, want je hebt je goed gehouden en je promotie desondanks erg snel 
afgerond. Gelukkig heb jij met Bart een ontzettende steun gevonden en hij in jou. 
Ik moet er nog steeds aan denken, dat jij ontzettend graag naar Monacco wilde, 
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maar het niet durfde te zeggen. Voor mij was het idee voor zoveel mensen te 
moeten presenteren niet fijn en ik durfde dus niet te zeggen dat jij moest gaan. 
Gelukkig was dat “probleem” heel snel opgelost, maar ik had zeker graag als 
ondersteuning in je koffer mee gegaan. Verder keek ik altijd naar je op, hoe jij even 
zo tussendoor aan je artikelen kon schrijven, je steeds even maar zo goed van de 
literatuur op de hoogde was en het nog alles bij elkaar kon voegen tot een geheel. 
Jij bent een ontzettend slimme meid en daarom wens ik je erg veel verder plezier 
en succes met je loopbaan samen met je familie. 
Andere mensen van de groep, die ik graag zou willen bedanken voor de hulp en 
gezelligheid zijn Annelieke (keratinocyten, miR en ook in de 30), Robert 
(reisgenootje in de metro, wat tof dat jij niet zomaar opgeeft en nog veel succes 
met de laatste lootjes van je promotie), Mariska (wat kan jij snel praten, maar jij 
bent er altijd voor een grapje, bedankt voor je hulp met de arrays), Floor (bedankt 
voor het inwerken in de celkweek en het kweken van de cellen tijdens mijn 
vakanties. Veel plezier met je familie), Jasmijn (introductie van de 
maandagmiddagdip, hmmm wat was dat altijd lekker), Sylvia (wij moeten nog 
steeds een keertje afspreken voor een motorritje en bedankt voor de tijd die jij erin 
hebt gestoken om de -80°C bakjes te digitaliseren), Debbie (bedankt voor het 
inwerken en de leuke praatjes op de 3
de
), Bart, Iris (kort erbij geweest, maar een 
soort gelijk project als ik), Lise (onze belgin), Wina (altijd gezellig), Annina, Clarissa, 
Barbara (Zaanstadler), Daniëlle H., Debby, Denira, Divera, Dorien, Duco (jouw eer 
voor de cellijnen), Fatih, Folkert (bedankt voor je pathologische view op mijn 
raftjes), Helma, Maaike D., Maarten vd S., Marije, Marinda, Marjolein B.-L., Martijn, 
Maryam, Murat, Muriël, Nathalie, Rene, Rick, Sonja, Viola, Dorien, Wendy, Douwe, 
Marta.  
Verder wil ik eveneens de studenten Leonie, Sabrina en Gaby voor hun inzet en 
bijdrage aan de artikelen bedanken.  
En er zijn echter nog meer mensen bij het VUmc die ik wil bedanken voor alle hulp 
en gezelligheid binnen en buiten werk! Anne, Annelies, Annemieke, Beatriz, 
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Begoña, Daniëlle I., Paul en Dirk (bedankt voor de hulp met de arrays), Eriënne, 
Eveline, Evert, François (het was zo gezellig met jou op kamer CCA1.29 en ik dank je 
zoveel voor je hulp met de arrays), Gerrit, Ilari (chipster ICT), Josien, Florence 
(CCA1.29 en carrierebeurs), Linda (veel plezier met je familie), Lisette (altijd 
gezellig), Marianne, Marjolein B., Meike, Oscar (ohhh die arrays. Hartelijk bedankt 
voor de mooie plaatjes voor het array stuk en jou inzet voor het stuk), Pien (altijd 
genoeg cellen in kweek), Remond, Rinus, Evert, Monique, Sander (raftjes en 
fibroblasten), Wil (inbedden en snijden van de raftjes), Mehrdad (exosomen), Ron 
en Jaap (foto’s en microscoop, buurman Ron). Dank ook aan Chantal, Martin en 
Johan de W.. 
Ook wil ik alle HumaVac heren en meiden bedanken. Door jullie kreeg ik naast mijn 
fundamenteel werk inzicht in de kliniek. Mariëlle en Jaqueline ik sta er nog steeds 
verstelt van hoe jullie al die vrouwen voor de HPV-015 studie konden includeren en 
wat jullie voor werk hebben verzet naast jullie promotie. Afra, Romy, Jacoline, 
Margot en Roosmarijn bedankt voor jullie inzet in de HPV-015 studie en de 
gezelligheid erbij. Ik wens jullie heel veel succes met de verdere opleiding en dat 
jullie goede gynaecologen worden. Hierbij wil ik eveneens de toenmalige monitor 
van GSK Marleen voor de leuke monitordagen bedanken.  
Een ding is zeker, zoveel gezellige collega’s te hebben was een geschenk. Er was 
altijd een reden voor koekjes, gebakjes en borreltjes. 
Naast mijn collega’s wil ik eveneens mijn vriend voor al zijn geduldige uren 
bedanken, al de tranen die ik op zijn schouder kon laten toen ik het even niet meer 
zag zitten. Ik dank je voor de ontzettend leuke tijd tijdens mijn afstudeerstage in 
Australië, waar je zomaar je baan voor hebt opgezegd om met mij mee te gaan. Dit 
is een ervaring waarnaar wij nog steeds vaak met plezier aan terug denken. Ik dank 
je voor al je werk, wat jij in ons huis gestoken hebt om er een kasteeltje van te 
maken en vooral dank ik je voor het mooiste geschenk, onze zonen Julian en 
Jayden. Ik hou van jou. 
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Einen großen Dank bin ich meinen Eltern verschuldet, die mich mein ganzes Leben 
unterstützt haben und die auch bei der Schulwahl das Beste aus mir herausholen 
wollten, die es mir ermöglichten zu Studieren sodass ich jetzt unerwarteter Weise 
meine Dissertation verteidigen kann. Nicht vergessen will ich eure neuen Partner, 
die mich gut aufgenommen haben. Arvid, du bist ein echter Kuschelbär und immer 
für einen Spaß zu haben. Daniel, genieße von deiner eigenen kleinen Familie. Iris, 
du fleißige Biene, musst auch mal an dich denken. Steffie, dir wünsche ich auch viel 
Freude mit deiner kleinen Familie.  
Een nieuw thuis heb ik eveneens bij mijn schoonfamilie gevonden en dat niet alleen 
in een spreekwoordelijke maar ook woordelijk zin. Jullie deur staat altijd open en 
zo ook tijdens de verbouwing van ons huis waardoor wij een half jaar bij jullie in 
mochten wonen. Jullie staan altijd voor ons en onze kleinen mannen klaar. Mijn 
enorme dank hiervoor. Jullie, ook jij Roy en Monique, hebben ontzettend veel 
interesse in mijn onderzoek getoond en volgens mij hebben jullie dit moeilijke 
onderwerp ook in grote lijnen begrepen. 
Annemieke en Remon. Annemiek, wij zijn er altijd voor om samen te sporten en 
hebben al het een ander samen gedaan beginnend van joggen (ja zelfs de Dam tot 
Dam), spinnen, workout, zumba, tennissen, prutracen (wat grappig om er een 
keertje maar zo echt vies te worden) en skiën. Ja wat skien betreft zo hebben wij al 
een paar gezellige wintersportvakanties met elkaar meegemaakt. Ik ben blij dat 
jullie kleine meid Nienke en Julian het heel goed met elkaar kunnen vinden en dank 
je voor al je fotoshop hulpjes en überhaupt alle gezellige tijd met elkaar. 
Dank gaat ook uit naar mijn vriendin, Franziska, met wie ik inmiddels alweer 23 jaar 
trouw door dik en dun ga. Hier geldt inderdaad, vrienden herken je daaraan dat het 
niet uitmaakt hoelang je elkaar niet ziet. Dat je toch op die ander kan vertrouwen 
en als je weer samen bent, je gemakkelijk met elkaar om kan gaan. Ich hab dich 
ganz doll lieb und glaub mir, es gibt zu viele Momente, dass ich lieber dicht bei dir 
sein würde. Ich danke dir für dein Vertrauen. 
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Verder wil ik mijn andere vrienden niet vergeten. Nicole en Simon (wat is het altijd 
gezellig met jullie en het off-roaden). David (jou heeft ook d 4x4 koorts gepakt) en 
Klaske (wat leuk om ook naast je eigen collega’s over promoties te kunnen praten. 
Veel succes nog met jouw laatste loodjes). 
Ik ben blij met mijn lieve en gezellige collega’s van het IKNL. Sophie en Wendy, 
jullie maken of hebben het promotieproject al meegemaakt, zodat het altijd fijn 
was om met jullie hierover te praten. 
